[
  {
    "id": "diabetes  of woman.pdf::chunk_0",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 0,
    "text": "WHO recommendations on\ncare for women with diabetes\nduring pregnancy\n\nWHO recommendations on\ncare for women with diabetes\nduring pregnancy\n\nWHO recommendations on care for women with diabetes during pregnancy\nISBN 978-92-4-011704-4 (electronic version)\nISBN 978-92-4-011705-1 (print version)\n© World Health Organization 2025\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-\nShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).\nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial\npurposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should\nbe no suggestion that WHO endorses any specific organization, p"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_1",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 1,
    "text": "he work for non-commercial\npurposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should\nbe no suggestion that WHO endorses any specific organization, products or services. The use of the WHO\nlogo is not permitted. If you adapt the work, then you must license your work under the same or equivalent\nCreative Commons licence. If you create a translation of this work, you should add the following disclaimer\nalong with the suggested citation: “This translation was not created by the World Health Organization (WHO).\nWHO is not responsible for the content or accuracy of this translation. The original English edition shall be\nthe binding and authentic edition”.\nAny mediation relating to disputes arising under the licence shall be conducted in accorda"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_2",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 2,
    "text": "nt or accuracy of this translation. The original English edition shall be\nthe binding and authentic edition”.\nAny mediation relating to disputes arising under the licence shall be conducted in accordance with the\nmediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/\nrules/).\nSuggested citation. WHO recommendations on care for women with diabetes during pregnancy. Geneva:\nWorld Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.\nCataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/.\nSales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-\norders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/\ncopyright.\nThird"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_3",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 3,
    "text": "g. To purchase WHO publications, see https://www.who.int/publications/book-\norders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/\ncopyright.\nThird-party materials. If you wish to reuse material from this work that is attributed to a third party, such\nas tables, figures or images, it is your responsibility to determine whether permission is needed for that\nreuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of\nany third-party-owned component in the work rests solely with the user.\nGeneral disclaimers. The designations employed and the presentation of the material in this publication\ndo not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status\nof"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_4",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 4,
    "text": "disclaimers. The designations employed and the presentation of the material in this publication\ndo not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status\nof any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or\nboundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not\nyet be full agreement.\nThe mention of specific companies or of certain manufacturers’ products does not imply that they are\nendorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors\nand omissions excepted, the names of proprietary products are distinguished by initial capital letters.\nAll reasonable precautions have been taken by WHO to"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_5",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 5,
    "text": "milar nature that are not mentioned. Errors\nand omissions excepted, the names of proprietary products are distinguished by initial capital letters.\nAll reasonable precautions have been taken by WHO to verify the information contained in this publication.\nHowever, the published material is being distributed without warranty of any kind, either expressed or\nimplied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall\nWHO be liable for damages arising from its use.\nDesign and DTP by Rizelle Stander Hartmeier\n\nContents\nForeword iv\nAcknowledgements v\nAcronyms and abbreviations vii\nExecutive Summary ix\nIntroduction ix\nTarget audience x\nGuideline development methods x\nPrinciples underpinning the recommendations x\nRecommendations xi\n1 Introduct"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_6",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 6,
    "text": "nts v\nAcronyms and abbreviations vii\nExecutive Summary ix\nIntroduction ix\nTarget audience x\nGuideline development methods x\nPrinciples underpinning the recommendations x\nRecommendations xi\n1 Introduction 1\n1.1 Background 1\n1.2 Rationale and objectives 2\n1.3 Target audience 3\n1.4 Scope of the recommendations 3\n1.5 Persons affected by the recommendations 3\n2 Methods 4\n2.1 Contributors to the guideline 4\n2.2 Evidence identification and retrieval 6\n2.3 Quality assessment and grading of the evidence 7\n2.4 Formulation of the recommendations 8\n2.5 Management of declaration of interests 9\n2.6 Decision making during the GDG meetings 10\n2.7 Document preparation and peer review 10\n3 Recommendations and supporting evidence 11\n3.1 Recommendations 11\n4 Dissemination and implementation of the guideline 3"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_7",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 7,
    "text": "making during the GDG meetings 10\n2.7 Document preparation and peer review 10\n3 Recommendations and supporting evidence 11\n3.1 Recommendations 11\n4 Dissemination and implementation of the guideline 36\n4.1 Dissemination and evaluation 36\n4.2 Implementation considerations 37\n4.3 Anticipated impact on the organization of care and resources 38\n4.4 Monitoring and evaluating guideline implementation 39\n5. Research implications 40\n5.1 Core practices in caring for women with diabetes during pregnancy 40\n5.2 Glucose monitoring 40\n5.3 Pharmacotherapy 41\n5.4 Additional monitoring and assessments 42\n6 Updating the recommendations 43\nReferences 44\nAnnex 1. Contributors to the guideline 48\nAnnex 2. Priority outcomes used in decision making 52\nAnnex 3. Summary and management of declared interests from G"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_8",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 8,
    "text": "dating the recommendations 43\nReferences 44\nAnnex 1. Contributors to the guideline 48\nAnnex 2. Priority outcomes used in decision making 52\nAnnex 3. Summary and management of declared interests from GDG members 54\nWeb annex A. Evidence-to-decision frameworks for non-pharmacological care 58\nWeb annex B. Evidence-to-decision frameworks for pharmacological care 58\n\nForeword\nNoncommunicable diseases, including diabetes, are among the leading health challenges of our time. Their\nimpact is especially profound during pregnancy, when the health of both mother and child is at stake. Each\nyear, millions of women experience pregnancies complicated by diabetes, with consequences that extend far\nbeyond the perinatal period – affecting lifelong health for mothers and their children.\nThis is an opportuni"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_9",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 9,
    "text": "of women experience pregnancies complicated by diabetes, with consequences that extend far\nbeyond the perinatal period – affecting lifelong health for mothers and their children.\nThis is an opportunity to change millions of lives for the better. Diagnosing and treating pre-existing conditions\nwill result in better outcomes for women and their children. High quality care in pregnancy is a clinical\nimperative and should be treated as a public health priority. Diabetes in pregnancy increases the risk of\nlife-threatening complications such as pre-eclampsia, stillbirth, birth injury, and long-term cardiometabolic\ndisorders for both women and their children. The burden is greatest in low- and middle-income countries,\nwhere access to specialized care and resources may be limited, yet the need is"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_10",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 10,
    "text": "cardiometabolic\ndisorders for both women and their children. The burden is greatest in low- and middle-income countries,\nwhere access to specialized care and resources may be limited, yet the need is most acute.\nThis guideline responds to the urgent need for evidence-based recommendations to improve care for women\nwith diabetes during pregnancy. Developed through a rigorous process involving global experts, patient\nrepresentatives, and key stakeholders, it provides practical guidance for healthcare providers, policy-makers,\nand programme managers across diverse settings.\niv\nBy integrating diabetes management with broader maternal and child health strategies, these\nrecommendations aim to:\n• reduce preventable complications and deaths\n• support individualized, respectful, and woman-centred"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_11",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 11,
    "text": "betes management with broader maternal and child health strategies, these\nrecommendations aim to:\n• reduce preventable complications and deaths\n• support individualized, respectful, and woman-centred care\n• empower health systems to address the growing burden of NCDs in pregnancy\n• promote health equity and improve outcomes for future generations.\nWe extend our deepest gratitude to all contributors whose expertise and dedication have shaped this\nguideline. Their commitment to advancing maternal and newborn health, and to tackling the challenges of\nNCDs in pregnancy, is reflected throughout this work.\nIt is our hope that this guideline will serve as a catalyst for action – supporting the implementation of best\npractices and fostering healthier futures for women, children, and communities wo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_12",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 12,
    "text": "s work.\nIt is our hope that this guideline will serve as a catalyst for action – supporting the implementation of best\npractices and fostering healthier futures for women, children, and communities worldwide.\nJeremy Farrar\nAssistant Director General\nHealth Promotion Disease Prevention and Care\n\nAcknowledgements\nWHO departments of Maternal, Newborn, Child and Adolescent Health and Ageing, Sexual and Reproductive\nHealth and Research, and Noncommunicable Diseases and Mental Health gratefully acknowledge the\ncontributions of many individuals and organizations to this guideline. Work on the guideline was initiated\nand coordinated by Doris Chou (Department of Sexual and Reproductive Health and Research) and Bianca\nHemmingsen (Department of Noncommunicable Diseases and Mental Health). Consultants"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_13",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 13,
    "text": "ne was initiated\nand coordinated by Doris Chou (Department of Sexual and Reproductive Health and Research) and Bianca\nHemmingsen (Department of Noncommunicable Diseases and Mental Health). Consultants to WHO, guideline\nmethodologists Jen Ramson and Myfanwy Williams, coordinated the evidence synthesis and technical\npreparatory activities.\nWHO extends its sincere thanks to Sumaiya Adam (University of Pretoria, South Africa), Amanda Adler\n(University of Oxford, United Kingdom of Great Britain and Northern Ireland), Fatima Al-Slail (Ministry of\nHealth, Saudi Arabia), Emmanuel Ameh (Ghana Health Service, Ghana), Shabina Ariff (Aga Khan University,\nPakistan), Stephen Colagiuri (University of Sydney, Australia), Margie Davenport (University of Alberta, Canada),\nMohamed Hassanein (Dubai Hospital,"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_14",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 14,
    "text": "rvice, Ghana), Shabina Ariff (Aga Khan University,\nPakistan), Stephen Colagiuri (University of Sydney, Australia), Margie Davenport (University of Alberta, Canada),\nMohamed Hassanein (Dubai Hospital, United Arab Emirates), Shane A. Norris (University of Southampton,\nUnited Kingdom of Great Britain and Northern Ireland), Rajalakshmi Ram Prakash (independent consultant on\nGender and Rights, India), João Filipe Raposo (Portuguese Society of Diabetology, Portugal), Sofia Saccone\n(Hospital de Clínicas Dr Manuel Quintela, Uruguay), Placxedes Sosa (patient representative, Zimbabwe), Nikhil\nv\nTandon (All India Institute of Medical Sciences, New Delhi, India), Hoang Thi Tran (University of Da Nang,\nViet Nam) and Kartik Venkatesh (The Ohio State University, United States of America) who served as me"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_15",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 15,
    "text": "All India Institute of Medical Sciences, New Delhi, India), Hoang Thi Tran (University of Da Nang,\nViet Nam) and Kartik Venkatesh (The Ohio State University, United States of America) who served as members\nof the Guideline Development Group (GDG).\nWHO acknowledges the important contribution of members of the WHO Steering Group, which included\nrepresentatives from the Department of Maternal, Newborn, Child and Adolescent Health and Ageing (Ulrika\nRehnström Loi); the Department of Noncommunicable Diseases and Mental Health (Daria Berlina, Alarcos\nCieza, Tea Collins, Ashish Krishna); the Department of Nutrition and Food Safety (María Nieves Garcia Casal,\nLisa Rogers); and the Department of Sexual and Reproductive Health and Research (Maria Barreix, Olufemi\nOladapo).\nSpecial thanks to the auth"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_16",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 16,
    "text": "nt of Nutrition and Food Safety (María Nieves Garcia Casal,\nLisa Rogers); and the Department of Sexual and Reproductive Health and Research (Maria Barreix, Olufemi\nOladapo).\nSpecial thanks to the authors of the systematic reviews used in this update for their assistance and\ncollaboration in updating them. Jessica Burk (University of Sydney, Australia), Soo Downe (University of\nCentral Lancashire, United Kingdom of Great Britain and Northern Ireland), Kenneth Finlayson (University\nof Central Lancashire, United Kingdom of Great Britain and Northern Ireland), Aoife Hurley (Burnet Institute,\nAustralia), Jenny Jung (Burnet Institute, Australia), Maureen Makama (Burnet Institute, Australia), Gill Moncrieff\n(University of Stirling, United Kingdom of Great Britain and Northern Ireland), Arianne Sw"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_17",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 17,
    "text": "alia), Jenny Jung (Burnet Institute, Australia), Maureen Makama (Burnet Institute, Australia), Gill Moncrieff\n(University of Stirling, United Kingdom of Great Britain and Northern Ireland), Arianne Sweeting (University\nof Sydney, Australia), Gemma Villanueva (Cochrane Response, United Kingdom of Great Britain and Northern\nIreland) and Joshua Vogel (Burnet Institute, Australia) were members of the Evidence Synthesis Group, who\nperformed synthesis and quality appraisal of the scientific evidence.\n\nJen Ramson and Myfanwy Williams drafted the evidence-to-decision frameworks and the final guideline\ndocument with substantial input from Doris Chou before the documents were reviewed by other members of\nthe WHO Steering Group and the GDG.\nThe External Review Group reviewed the final guideline prior"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_18",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 18,
    "text": "document with substantial input from Doris Chou before the documents were reviewed by other members of\nthe WHO Steering Group and the GDG.\nThe External Review Group reviewed the final guideline prior to publication clearance by WHO. We are\ngrateful for the contribution of Bosede Afolabi (University of Lagos, Nigeria), Hadil Ali-Masri Ministry of Health,\noccupied Palestinian territory, including east Jerusalem), Viswanathan Mohan (Madras Diabetes Research\nFoundation, India) and Jeremy Oats (University of Melbourne, Australia).\nWe acknowledge the following observers at the technical consultations, who represented various\norganizations: Howard Catton (International Council of Nurses), Elizabeth Franklin (International\nConfederation of Midwives), Hilary Hoey (International Paediatric Associat"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_19",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 19,
    "text": "ns, who represented various\norganizations: Howard Catton (International Council of Nurses), Elizabeth Franklin (International\nConfederation of Midwives), Hilary Hoey (International Paediatric Association), Liona Poon (International\nFederation of Gynecology and Obstetrics), Christopher Nolan (NCD Alliance), Beatriz Yáñez Jiménez\n(International Diabetes Foundation).\nWe also appreciate the support of staff at the WHO regional offices, including Adeniyi Aderoba, Carmen Antini,\nManjulaa Danansuriya, Rolando Enrique Domingo, Jill Farrington, Karima Gholbzouri, Rodolfo Gomez Ponce\nde León, Oleg Kuzmenko, Lamia Mahmoud, Pradeep Joshi, Delgermaa Vanya.\nWHO acknowledges the financial support for this work received from United Nations Development\nvi Programme/United Nations Population Fund/UNICEF/WHO"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_20",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 20,
    "text": "nko, Lamia Mahmoud, Pradeep Joshi, Delgermaa Vanya.\nWHO acknowledges the financial support for this work received from United Nations Development\nvi Programme/United Nations Population Fund/UNICEF/WHO/World Bank Special Programme of\nResearch, Development and Research Training in Human Reproduction Programme (HRP); The Global\nNoncommunicable Diseases Platform and The Leona M and Harry B Helmsley Charitable Trust. The views of\nthe funding bodies have not influenced the content of this guideline.\n\nAcronyms and abbreviations\nAR absolute risk\nCERQual Confidence in the Evidence from Reviews of Qualitative research\nCGM continuous glucose monitoring\nCI confidence interval\ndL decilitre\nDOI declaration of interest\neGFR estimated glomerular filtration rate\nESG Evidence Synthesis Group\nEtD evidence-to"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_21",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 21,
    "text": "tative research\nCGM continuous glucose monitoring\nCI confidence interval\ndL decilitre\nDOI declaration of interest\neGFR estimated glomerular filtration rate\nESG Evidence Synthesis Group\nEtD evidence-to-decision\nFPG fasting plasma glucose vii\ng gram\nGDG Guideline Development Group\nGDM gestational diabetes mellitus\nGLP-1RA glucagon-like peptide-1 receptor agonists\nGRADE Grading of Recommendations, Assessment, Development, and Evaluation\nHAPO Hyperglycemia and Adverse Pregnancy Outcome study\nHbA1c glycated haemoglobin\nHRP United Nations Development Programme/United Nations Population Fund/UNICEF/\nWHO/World Bank Special Programme of Research, Development and Research Training in\nHuman Reproduction Programme\nkg kilogram\nL litre\nMD mean difference\nmg milligram\n\nmmHg millimetres of mercury\nmmol mi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_22",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 22,
    "text": "WHO/World Bank Special Programme of Research, Development and Research Training in\nHuman Reproduction Programme\nkg kilogram\nL litre\nMD mean difference\nmg milligram\n\nmmHg millimetres of mercury\nmmol millimole\nmol mole\nNCDs noncommunicable diseases\nNPH neutral protamine Hagedorn\nPICO Population (P), Intervention (I), Comparison (C), Outcome (O)\nQES qualitative evidence synthesis\nRCT randomized controlled trial\nSGLT2 sodium-glucose transport protein 2\nSMBG self-monitoring of blood glucose\nWHO World Health Organization\nviii\n\nExecutive Summary\nIntroduction\nDiabetes mellitus, commonly known as diabetes, is one of the most prevalent noncommunicable diseases\n(NCDs), with 830 million adults living with diabetes in 2022 (1). The prevalence is rising more rapidly in low- and\nmiddle-income countries t"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_23",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 23,
    "text": "tes, is one of the most prevalent noncommunicable diseases\n(NCDs), with 830 million adults living with diabetes in 2022 (1). The prevalence is rising more rapidly in low- and\nmiddle-income countries than in high-income countries, with 85% of adults with diabetes living in low- and\nmiddle-income countries in 2022 (1). While more than 95% of people with diabetes have type 2 diabetes (2),\nin 2017, there were nine million people with type 1 diabetes (3), which is characterized by deficient insulin\nproduction and requires daily administration of insulin. It is estimated that around half of all people living with\ndiabetes are undiagnosed (4).\nAbout one in six live births (21 million per year) is affected by diabetes during pregnancy (5). Diabetes\nin pregnancy can be pre-existing (type 1 or type"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_24",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 24,
    "text": "le living with\ndiabetes are undiagnosed (4).\nAbout one in six live births (21 million per year) is affected by diabetes during pregnancy (5). Diabetes\nin pregnancy can be pre-existing (type 1 or type 2, also referred to as pre-gestational diabetes) or\nhyperglycaemia can be first detected during pregnancy, which is classified as either diabetes in pregnancy or\ngestational diabetes mellitus (GDM) (6). Women with a history of GDM have an increased risk of type 2 diabetes\nafter childbirth (7). The risks increase throughout the life span, with a cumulative incidence of type 2 diabetes\nof up to 70 percent 28 years after a pregnancy complicated by GDM (8).\nix\nThe management of type 1 and type 2 diabetes during pregnancy requires intensified treatment and\nmonitoring. In addition, any type of diabe"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_25",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 25,
    "text": "ercent 28 years after a pregnancy complicated by GDM (8).\nix\nThe management of type 1 and type 2 diabetes during pregnancy requires intensified treatment and\nmonitoring. In addition, any type of diabetes during pregnancy has effects on the fetus, birth process and\nlong-term cardiometabolic health outcomes across the lifespan for both the pregnant woman and the\nexposed child. Pregnancy-related complications of diabetes (including GDM), include pre-eclampsia and other\nhypertensive disorders of pregnancy for the woman; and stillbirth, macrosomia, hypoglycaemia, seizures,\nbirth injury and congenital anomalies for the developing baby. Children born after pregnancies complicated\nby diabetes have increased risks of obesity, cardiovascular disease, metabolic syndrome, type 2 diabetes,\nhypertension"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_26",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 26,
    "text": "al anomalies for the developing baby. Children born after pregnancies complicated\nby diabetes have increased risks of obesity, cardiovascular disease, metabolic syndrome, type 2 diabetes,\nhypertension, and fatty liver disease (9).\nClinical recommendations for the management of diabetes in pregnancy are essential to improve maternal\nand newborn health. In 2013, WHO published diagnostic criteria and classification of hyperglycaemia first\ndetected in pregnancy, but did not provide recommendations on diabetes management (6). The WHO 2016\nantenatal care guidelines identified this as a priority research area, particularly in low- and middle-income\ncountries (10). In a review of pregnancy-specific guidelines, 25 guidelines relating to diabetes in pregnancy\nwere found (25 addressed GDM and four ad"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_27",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 27,
    "text": "arch area, particularly in low- and middle-income\ncountries (10). In a review of pregnancy-specific guidelines, 25 guidelines relating to diabetes in pregnancy\nwere found (25 addressed GDM and four addressed type 1 and/or type 2 diabetes), of which 18 were from\nupper middle- or high-income countries, two were from low- and middle-income countries, and five were\nfrom international societies (11). Given that the disease burden of diabetes is global, with most cases in low-\nand middle-income countries, guidelines applicable to these environments are needed.\n\nTarget audience\nWHO maternal and perinatal health guidelines are relevant to those providing care and support during\npregnancy, labour, childbirth and postnatal periods, in any health-care setting.\nThe primary audience for this guideline"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_28",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 28,
    "text": "atal health guidelines are relevant to those providing care and support during\npregnancy, labour, childbirth and postnatal periods, in any health-care setting.\nThe primary audience for this guideline includes policy-makers or service providers who are responsible\nfor developing national and local health-care protocols and policies, as well as managers of maternal and\nchild health programmes. The guideline will also be useful to those directly providing care to women during\npregnancy, such as obstetricians, midwives, endocrinologists, nurses, general practitioners, dietitians and\ndiabetes educators. Finally, the information in this guideline will be useful for developing clinical tools for pre-\nand in-service training of health workers and health-system strengthening efforts to enhance thei"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_29",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 29,
    "text": "tors. Finally, the information in this guideline will be useful for developing clinical tools for pre-\nand in-service training of health workers and health-system strengthening efforts to enhance their delivery of\nclinical care.\nGuideline development methods\nThe development of this guideline was guided by the process described in the WHO handbook for guideline\ndevelopment (12). The guideline was developed using the following steps: (i) identification of priority questions\nand outcomes; (ii) retrieval of evidence; (iii) assessment and synthesis of evidence; (iv) formulation of the\nrecommendations; and (v) planning for the dissemination, implementation, impact evaluation and future\nx updating of the recommendations.\nDe novo systematic reviews were used to prepare evidence profiles for the pr"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_30",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 30,
    "text": "ns; and (v) planning for the dissemination, implementation, impact evaluation and future\nx updating of the recommendations.\nDe novo systematic reviews were used to prepare evidence profiles for the prioritized questions. The quality\nof identified scientific evidence underpinning the recommendations was appraised using the Grading of\nRecommendations Assessment, Development and Evaluation (GRADE) and the GRADE Confidence in the\nEvidence from Reviews of Qualitative research (GRADE-CERQual) approaches, for quantitative and qualitative\nevidence, respectively. The GRADE evidence-to-decision (EtD) framework – an evidence-to-decision tool\nthat includes intervention effects, values, resource use, equity and human rights, acceptability and feasibility\ncriteria – was used to guide the formulation of"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_31",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 31,
    "text": "amework – an evidence-to-decision tool\nthat includes intervention effects, values, resource use, equity and human rights, acceptability and feasibility\ncriteria – was used to guide the formulation of recommendations by the Guideline Development Group (GDG).\nThe GDG comprised an international group of experts who convened on 12–15 May 2025 for consideration of\nthe non-pharmacological management recommendations and on 29–31 July 2025 for consideration of the\npharmacological management recommendations.\nPrinciples underpinning the recommendations\n• WHO envisions a world where every pregnant woman and baby receive quality care throughout\npregnancy, childbirth and the postnatal period (10). WHO recommendations on antenatal care for a positive\npregnancy experience highlight the importance of prov"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_32",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 32,
    "text": "and baby receive quality care throughout\npregnancy, childbirth and the postnatal period (10). WHO recommendations on antenatal care for a positive\npregnancy experience highlight the importance of providing effective communication about physiological,\nbiomedical, behavioural and sociocultural issues, as well as effective social, cultural, emotional and\npsychological support, to pregnant women in a respectful way (10).\n• Although women with diabetes may have complex care needs during pregnancy, it is important to consider\nthe individual woman’s values and preferences and facilitate the most positive pregnancy experience that\nis possible while managing these needs effectively.\n\n• There is potential to improve health outcomes for women and babies by taking a life-course approach\nthat integrate"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_33",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 33,
    "text": "tive pregnancy experience that\nis possible while managing these needs effectively.\n\n• There is potential to improve health outcomes for women and babies by taking a life-course approach\nthat integrates prevention of, and care for, NCDs, such as diabetes, with care that addresses sexual,\nreproductive, maternal, newborn and child health needs (13).\n• A critical aspect of optimal antenatal care is shared decision-making when pharmacological treatments\nare recommended. This involves a collaborative approach where health-care providers and pregnant\nwomen make medication-related decisions together, considering both the best available evidence on\nthe benefits and harms to the woman and the developing baby, as well as the woman’s preferences and\nvalues. It also respects the woman’s right to make d"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_34",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 34,
    "text": "considering both the best available evidence on\nthe benefits and harms to the woman and the developing baby, as well as the woman’s preferences and\nvalues. It also respects the woman’s right to make decisions about her care, including the right to decline\nor discontinue treatment.\n• The aim of glucose-lowering treatment for pregnant women with diabetes is to achieve the best possible\nglycaemic control with the resources available when this cannot be achieved with diet and physical\nactivity alone. Irrespective of the treatment or protocol used, high-quality care prioritizes the wellbeing\nand safety of the woman and baby, ensuring that the treatment provided is likely to be beneficial and\nachieve the desired outcomes, and minimizing risks of harm. Treatments are offered according to the\nwoma"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_35",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 35,
    "text": "fety of the woman and baby, ensuring that the treatment provided is likely to be beneficial and\nachieve the desired outcomes, and minimizing risks of harm. Treatments are offered according to the\nwoman’s preferred approach, affordability, cost–effectiveness and other available resources.\nRecommendations\nThe GDG issued 27 recommendations – four on core practices in caring for women with diabetes during xi\npregnancy; six on glucose monitoring; two on pharmacological treatment for pregnant women with type\n1 diabetes, four on pharmacological treatment for pregnant women with type 2 diabetes and two on\npharmacological treatment for women with GDM; and nine on additional monitoring and assessments. The\nrecommendations are intended for use in addition to routine antenatal care.\nTo ensure that the"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_36",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 36,
    "text": "o on\npharmacological treatment for women with GDM; and nine on additional monitoring and assessments. The\nrecommendations are intended for use in addition to routine antenatal care.\nTo ensure that the recommendations are correctly understood and applied in practice, the GDG provided\nadditional remarks. Users of the recommendations should refer to these remarks, which are presented\ndirectly beneath the recommendations in Section 3.1. The recommendations are given below.\nTopic Recommendation\nCore practices in caring for women with diabetes during pregnancy\nAdvice on diet, 1 For pregnant women with type 1, type 2 or gestational diabetes, provide individualized\nphysical activity advice on diet, physical activity and weight management based on existing WHO guidance,\nand weight including:\nmanage"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_37",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 37,
    "text": "th type 1, type 2 or gestational diabetes, provide individualized\nphysical activity advice on diet, physical activity and weight management based on existing WHO guidance,\nand weight including:\nmanagement • dietary advice for the general adult population;\n• physical activity advice for the general pregnant population;\n• weight management advice based on the above dietary and physical activity advice,\nwith a focus on appropriate gestational weight gain.\n\nTopic Recommendation\nAntenatal 2 For pregnant women with type 1, type 2 or gestational diabetes, provide education on:\neducation • the effects of diabetes in pregnancy on maternal, fetal, newborn and child health\noutcomes;\n• diet and physical activity;\n• appropriate gestational weight gain;\n• managing glycaemia;\n• the need for additional mo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_38",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 38,
    "text": "of diabetes in pregnancy on maternal, fetal, newborn and child health\noutcomes;\n• diet and physical activity;\n• appropriate gestational weight gain;\n• managing glycaemia;\n• the need for additional monitoring of fetal growth and wellbeing.\nSpecialized care 3 For pregnant women with type 1 or type 2 diabetes, deliver multidisciplinary and\nspecialized care provided by health-care providers trained in maternal and diabetes care.\n4 For women with GDM, consider multidisciplinary and specialized care provided by health-\ncare providers trained in maternal and diabetes care, depending on access and availability.\nGlucose monitoring\nMode of glucose 5 For pregnant women with type 1, type 2 or gestational diabetes, recommend self-\nmonitoring monitoring of blood glucose (SMBG) in addition to routine ca"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_39",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 39,
    "text": "ailability.\nGlucose monitoring\nMode of glucose 5 For pregnant women with type 1, type 2 or gestational diabetes, recommend self-\nmonitoring monitoring of blood glucose (SMBG) in addition to routine care, where feasible.\n6 For pregnant women with type 1 diabetes, recommend the use of a continuous glucose\nmonitoring (CGM) system, where feasible.\nxii\n7 For pregnant women with type 2 or gestational diabetes, do not routinely recommend use\nof a CGM system.\nGlycated 8 For pregnant women with type 1 or type 2 diabetes, measure HbA1c in the first trimester\nhaemoglobin or as soon as antenatal care is initiated.\n(HbA1c)\n9 For women with GDM, do not routinely measure HbA1c.\nGlycaemic targets 10 For pregnant women with type 1, type 2 or gestational diabetes, individualize glycaemic\ntargets to optimize"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_40",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 40,
    "text": "nitiated.\n(HbA1c)\n9 For women with GDM, do not routinely measure HbA1c.\nGlycaemic targets 10 For pregnant women with type 1, type 2 or gestational diabetes, individualize glycaemic\ntargets to optimize glycaemic control and improve maternal and neonatal outcomes.\nPharmacological treatment for pregnant women with type 1, type 2 or GDM\nType 1 diabetes 11 For pregnant women with type 1 diabetes, recommend continuation of the same type of\ninsulin used before pregnancy unless a change is considered necessary to optimize blood\nglucose control and outcomes for the woman and baby.\n12 For pregnant women with type 1 diabetes, recommend continuation of the method\nof insulin delivery used before pregnancy unless a change is considered necessary to\noptimize blood glucose control and outcomes for the wom"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_41",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 41,
    "text": "with type 1 diabetes, recommend continuation of the method\nof insulin delivery used before pregnancy unless a change is considered necessary to\noptimize blood glucose control and outcomes for the woman and baby.\n\nTopic Recommendation\nType 2 diabetes 13 For pregnant women with type 2 diabetes who are unable to maintain optimal blood\nglucose levels with diet and physical activity alone, recommend initiation of metformin or\ninsulin to optimize blood glucose control and outcomes for the woman and baby.\n14 For pregnant women with type 2 diabetes who are receiving monotherapy with insulin\nor metformin and who are unable to achieve optimal blood glucose levels, consider\ninitiation of a combination of metformin and insulin to optimize blood glucose control and\noutcomes for the woman and baby.\n15"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_42",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 42,
    "text": "min and who are unable to achieve optimal blood glucose levels, consider\ninitiation of a combination of metformin and insulin to optimize blood glucose control and\noutcomes for the woman and baby.\n15 For pregnant women with type 2 diabetes who are already receiving glucose-lowering\nmedication, recommend that medications with safety concerns during pregnancy be\nreplaced with insulin and/or metformin.\n16 For pregnant women with type 2 diabetes who required insulin to achieve optimal blood\nglucose levels before pregnancy, recommend continuation of the same type of insulin\nunless a change is considered necessary to optimize blood glucose control and outcomes\nfor the woman and baby.\nGDM 17 For women with GDM who are unable to achieve optimal blood glucose levels with diet and\nphysical activity"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_43",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 43,
    "text": "dered necessary to optimize blood glucose control and outcomes\nfor the woman and baby.\nGDM 17 For women with GDM who are unable to achieve optimal blood glucose levels with diet and\nphysical activity alone, recommend initiation of metformin or insulin to optimize blood\nglucose control and outcomes for the woman and baby.\nxiii\n18 For women with GDM who are receiving monotherapy with metformin or insulin and are\nunable to achieve optimal blood glucose levels, consider initiation of a combination of\nmetformin and insulin to optimize blood glucose control and outcomes for the woman\nand baby.\nAdditional monitoring and assessments\nFetal monitoring 19 For pregnant women with type 1, type 2 or gestational diabetes, perform a routine\nultrasound scan before 24 weeks.\n20 For pregnant women with type"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_44",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 44,
    "text": "ional monitoring and assessments\nFetal monitoring 19 For pregnant women with type 1, type 2 or gestational diabetes, perform a routine\nultrasound scan before 24 weeks.\n20 For pregnant women with type 1 or type 2 diabetes, consider performing the routine\nultrasound scan as early as possible in pregnancy, with a follow-up ultrasound to assess\nfetal anatomy and growth in the second trimester.\n21 For pregnant women with type 1, type 2 or gestational diabetes, consider additional\nultrasound growth scans after 24 weeks, as indicated.\n22 For pregnant women with type 1, type 2 or gestational diabetes requiring blood glucose-\nlowering medication, consider additional monitoring of fetal wellbeing, as indicated.\nRetinopathy 23 For pregnant women with type 1 or type 2 diabetes, screen for retinopathy"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_45",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 45,
    "text": "requiring blood glucose-\nlowering medication, consider additional monitoring of fetal wellbeing, as indicated.\nRetinopathy 23 For pregnant women with type 1 or type 2 diabetes, screen for retinopathy when\nscreening antenatal care is initiated and provide follow-up based on the risk of retinopathy\nprogressing.\n24 For women with GDM, do not routinely screen for retinopathy.\n\nTopic Recommendation\nRenal assessment 25 For pregnant women with type 1 or type 2 diabetes, assess renal function when antenatal\ncare is initiated and arrange specialist follow-up for women if impaired renal function is\nidentified.\n26 For women with GDM, do not routinely assess renal function.\n27 For pregnant women with type 1 or type 2 diabetes with impaired renal function,\nemphasize the importance of maintaining blood"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_46",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 46,
    "text": "tified.\n26 For women with GDM, do not routinely assess renal function.\n27 For pregnant women with type 1 or type 2 diabetes with impaired renal function,\nemphasize the importance of maintaining blood pressure levels below 130/80 mmHg\nduring pregnancy and offer antihypertensives known to be safe in pregnancy as indicated.\nAdvise women to modify major risk factors for cardiovascular disease (e.g. smoking,\nunhealthy diet, sedentary behaviour) and to seek specialist postnatal follow-up.\nxiv\n\n1\n1.1\nIntroduction\n1.1 Background\nDiabetes is one of the most prevalent NCDs, with 830 million adults living with diabetes in 2022 (1). The\nprevalence is rising more in low- and middle-income countries than in high-income countries, with 81% of\nadults with diabetes living in low- and middle-income countrie"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_47",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 47,
    "text": "g with diabetes in 2022 (1). The\nprevalence is rising more in low- and middle-income countries than in high-income countries, with 81% of\nadults with diabetes living in low- and middle-income countries in 2022 (1). While more than 95% of people\nwith diabetes have type 2 diabetes (2), in 2017 there were nine million people with type 1 diabetes (3) which is\ncharacterized by deficient insulin production and requires daily administration of insulin. It is estimated that\n1\naround half of all people living with diabetes are undiagnosed (4).\nAbout one in six live births (21 million per year) is affected by diabetes during pregnancy (5). Diabetes in\npregnancy can be pre-existing (type 1 or type 2, also referred to as pre-gestational diabetes) or hyperglycaemia\ncan be first detected during pregnanc"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_48",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 48,
    "text": "ted by diabetes during pregnancy (5). Diabetes in\npregnancy can be pre-existing (type 1 or type 2, also referred to as pre-gestational diabetes) or hyperglycaemia\ncan be first detected during pregnancy, which is classified as either diabetes in pregnancy or GDM (6). Women\nwith a history of GDM have an increased risk of type 2 diabetes after childbirth (7). The risks increase throughout\nthe life span, with a cumulative incidence of type 2 diabetes of up to 70 percent 28 years after a pregnancy (8).\nThe management of type 1 and type 2 diabetes during pregnancy requires intensified treatment and monitoring.\nIn addition, any type of diabetes during pregnancy has effects on the fetus and birth process. Pregnancy-related\ncomplications of diabetes (including GDM), include pre-eclampsia and other"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_49",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 49,
    "text": "monitoring.\nIn addition, any type of diabetes during pregnancy has effects on the fetus and birth process. Pregnancy-related\ncomplications of diabetes (including GDM), include pre-eclampsia and other hypertensive disorders of pregnancy\nfor the woman; and stillbirth, macrosomia, hypoglycaemia, seizures, birth injury and congenital anomalies for\nthe developing baby. Children born after pregnancies complicated by diabetes have increased risks of obesity,\ncardiovascular disease, metabolic syndrome, type 2 diabetes, hypertension, and fatty liver disease (9).\nClinical recommendations for management of diabetes in pregnancy are essential to improve maternal and\nnewborn health. In 2013, WHO published diagnostic criteria and classification of hyperglycaemia in pregnancy,\nbut did not provide recomme"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_50",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 50,
    "text": "of diabetes in pregnancy are essential to improve maternal and\nnewborn health. In 2013, WHO published diagnostic criteria and classification of hyperglycaemia in pregnancy,\nbut did not provide recommendations on diabetes management (6). The WHO 2016 antenatal care guidelines\nidentified this as a priority research area, particularly in low- and middle-income countries (10). In a review\nof pregnancy-specific guidelines, 25 guidelines relating to diabetes in pregnancy were found (25 addressed\nGDM and four addressed type 1 and/or type 2 diabetes) of which 18 were from upper middle- or high-income\ncountries, two were from low- and middle-income countries, and five were from international societies (11).\nGiven that the disease burden of diabetes is global, with most cases in low- and middle-inco"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_51",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 51,
    "text": "countries, two were from low- and middle-income countries, and five were from international societies (11).\nGiven that the disease burden of diabetes is global, with most cases in low- and middle-income countries,\nguidelines applicable to these environments are needed.\n\nWHO recommendations on care for women with diabetes during pregnancy\n1.2 Rationale and objectives\nIn July 2021, the WHO Steering Group convened a scoping meeting – comprising an independent panel of\n15 external experts and relevant stakeholders from the six WHO regions – to explore the scope for a new\nguideline thematic area covering screening for and management of NCDs in pregnancy, childbirth, and the\npostnatal periods.\nTo inform the discussions, the WHO Steering Group developed two evidence syntheses. These described\nthe"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_52",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 52,
    "text": "vering screening for and management of NCDs in pregnancy, childbirth, and the\npostnatal periods.\nTo inform the discussions, the WHO Steering Group developed two evidence syntheses. These described\nthe existing definitions and concepts related to NCDs in pregnancy (14) and mapped the (then) current\nguidelines and recommendations related to maternal health and NCDs (11). The ‘universe’ of thematic areas/\nconditions to be considered for inclusion in guideline development was based upon a review of the indirect\nmaternal conditions. In considering the breadth and depth of potential thematic areas, the scoping group\nwere requested to assess the general prevalence of the conditions, the interaction between the condition and\npregnancy, and the potential for intervention during maternal health cont"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_53",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 53,
    "text": "the scoping group\nwere requested to assess the general prevalence of the conditions, the interaction between the condition and\npregnancy, and the potential for intervention during maternal health contacts.\nThe following topic areas were considered the highest priorities:\n• cardiovascular conditions\n• diabetes\n• respiratory conditions\n2\n• haemoglobinopathies (including sickle cell disease and thalassaemia)\n• mental health disorders and substance use.\nGuidelines on the management of sickle cell disease were published in June 2025. The management of\ndiabetes is the second of these topics to be addressed. Guidelines on screening for diabetes during pregnancy\nare currently under development.\n\nWHO recommendations on care for women with diabetes during pregnancy Introduction\n1.3 Target audience\nW"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_54",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 54,
    "text": "dressed. Guidelines on screening for diabetes during pregnancy\nare currently under development.\n\nWHO recommendations on care for women with diabetes during pregnancy Introduction\n1.3 Target audience\nWHO maternal and perinatal health guidelines are relevant to those providing care and support during\npregnancy, labour, childbirth and postnatal periods, in any health-care setting.\nThe primary audience for this guideline includes policy-makers or service providers who are responsible\nfor developing national and local health-care protocols and policies related to care during pregnancy,\nchildbirth and the postnatal period, and those directly providing care to women during pregnancy, including\nobstetricians, midwives, endocrinologists, nurses, general practitioners, dietitians and diabetes educat"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_55",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 55,
    "text": "nd the postnatal period, and those directly providing care to women during pregnancy, including\nobstetricians, midwives, endocrinologists, nurses, general practitioners, dietitians and diabetes educators,\nand managers of maternal and child health programmes, in all settings. The guideline will also be useful for\ndeveloping clinical tools for pre- and in-service training of health workers and health-system strengthening\nefforts to enhance their delivery of clinical care.\nIt is expected that the guideline will be of interest to professional societies involved in the care of pregnant\nwomen; nongovernmental organizations concerned with the promotion of woman-centered maternal care;\nand implementers of maternal and child health programmes.\n1.4 Scope of the recommendations\nThe recommendations pr"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_56",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 56,
    "text": "vernmental organizations concerned with the promotion of woman-centered maternal care;\nand implementers of maternal and child health programmes.\n1.4 Scope of the recommendations\nThe recommendations provide guidance on both the pharmacological management and the non-\n3\npharmacological management of diabetes during pregnancy. The priority questions that guided evidence\nsynthesis and decision making for these recommendations were developed using the Population (P),\nIntervention (I), Comparison (C), Outcome (O) (PICO) format and are presented in the web annex to this\nGuideline. The priority outcomes used in decision making are listed in Annex 2.\n1.5 Persons affected by the recommendations\nThe population affected by the recommendations is women with type 1, type 2 or GDM who receive antenatal\nc"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_57",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 57,
    "text": "es used in decision making are listed in Annex 2.\n1.5 Persons affected by the recommendations\nThe population affected by the recommendations is women with type 1, type 2 or GDM who receive antenatal\ncare and give birth in low-, middle- and high-resource settings.\n\n2\nMethods\nThe guideline was developed using the process described in the WHO handbook for guideline development (12).\nIn summary, the process included: (i) identification of the priority questions and outcomes; (ii) retrieval of\nthe evidence; (iii) assessment and synthesis of the evidence; (iv) formulation of the recommendations; and\n(v) planning for the dissemination, implementation, impact evaluation and updating of the recommendations.\nSix main groups participated in this process and their specific roles are described below.\n4"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_58",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 58,
    "text": "(v) planning for the dissemination, implementation, impact evaluation and updating of the recommendations.\nSix main groups participated in this process and their specific roles are described below.\n4 2.1 Contributors to the guideline\n2.1.1 WHO Steering Group\nThe WHO Steering Group, comprising WHO staff members from the Department of Sexual and Reproductive\nHealth and Research, the Department of Maternal, Newborn, Child and Adolescent Health and Ageing, the\nDepartment of Nutrition and Food Safety, and the Department of Noncommunicable Diseases and Mental\nHealth, Rehabilitation and Disability managed the process. The WHO Steering Group drafted the key research\nquestions in PICO format, identified the systematic review teams and guideline methodologists, as well as\nmembers of the Guideline D"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_59",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 59,
    "text": "anaged the process. The WHO Steering Group drafted the key research\nquestions in PICO format, identified the systematic review teams and guideline methodologists, as well as\nmembers of the Guideline Development Group and the External Review Group. In addition, the WHO Steering\nGroup supervised the retrieval and syntheses of evidence, organized the GDG meetings, finalized the guideline\ndocument, and managed its dissemination, implementation and impact assessment. The members of the\nWHO Steering Group are listed in Annex 1.\n2.1.2 Guideline Development Group\nFor the development of this guideline, 16 external experts and relevant stakeholders were invited to\nparticipate as members of the GDG. These individuals were drawn from a pool of approximately 50 experts\nand relevant stakeholders that co"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_60",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 60,
    "text": "16 external experts and relevant stakeholders were invited to\nparticipate as members of the GDG. These individuals were drawn from a pool of approximately 50 experts\nand relevant stakeholders that constitute the WHO Maternal and Perinatal Health GDG. Those selected\nwere a diverse group with expertise in research, guideline development methods, and clinical policy and\nprogrammes relating to improving the quality of care and outcomes for women with diabetes during\npregnancy, as well as a representative of the affected population.\nThe GDG members were selected in a way that, as far as possible, represented a geographic and gender balance\nand ensured that there were no important conflicts of interest. The GDG comprised 44% women and 56% men.\n\nMethods\nBased on the documents prepared by the Ste"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_61",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 61,
    "text": "represented a geographic and gender balance\nand ensured that there were no important conflicts of interest. The GDG comprised 44% women and 56% men.\n\nMethods\nBased on the documents prepared by the Steering Group, the GDG appraised and interpreted the evidence,\nand formulated the final recommendations on non-pharmacological management at a meeting convened on\n12–15 May 2025 and on pharmacological management at a meeting convened on 29–31 July 2025. The group\nalso reviewed and approved the final guideline document. The members of this group are listed in Annex 1.\n2.1.3 Evidence Synthesis Group\nWHO convened an Evidence Synthesis Group (ESG) composed of guideline methodologists and systematic\nreview teams for the conduct or updating of systematic reviews, appraisal of evidence, and development"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_62",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 62,
    "text": "HO convened an Evidence Synthesis Group (ESG) composed of guideline methodologists and systematic\nreview teams for the conduct or updating of systematic reviews, appraisal of evidence, and development of\nthe EtD frameworks.\nTwo technical consultants, Jen Ramson and Myfanwy Williams, served as the guideline methodologists. They\noversaw the appraisal of evidence using the GRADE methodology (15).\nTo inform this guideline, systematic reviews of qualitative evidence on diabetes and maternity care from the\nperspectives of health-care providers (16) and women with type 1 or type 2 diabetes (17) were conducted.\nThis work was led by experts from the University of Central Lancashire (United Kingdom of Great Britain and\nNorthern Ireland) with extensive experience in qualitative evidence reviews. In a"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_63",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 63,
    "text": "conducted.\nThis work was led by experts from the University of Central Lancashire (United Kingdom of Great Britain and\nNorthern Ireland) with extensive experience in qualitative evidence reviews. In addition, the ESG initiated a\nnew systematic review of economic evaluations for screening and management of diabetes in pregnancy (18).\nThe guideline methodologists worked closely with the ESG to review the evidence and prepare the GRADE\n5\nEtD frameworks. Members of the ESG attended the GDG meeting to respond to technical queries from the\nGDG. The members of the ESG are listed in Annex 1.\n2.1.4 External partners and observers\nRepresentatives of the International Confederation of Midwives, International Council of Nurses, International\nDiabetes Foundation, International Federation of Gynecology"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_64",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 64,
    "text": "ernal partners and observers\nRepresentatives of the International Confederation of Midwives, International Council of Nurses, International\nDiabetes Foundation, International Federation of Gynecology and Obstetrics, International Pediatric\nAssociation and the Noncommunicable Disease Alliance participated in the GDG meetings as observers.\nThese organizations collaborate with WHO Departments in guideline dissemination and implementation and\nwere identified as significant implementers of the guideline. The list of observers who participated in the\nGDG meetings is included in Annex 1.\n2.1.5 External Review Group\nAn external review group comprised four technical experts with interest and expertise in the provision\nof evidence-based care to improve the quality of care and outcomes for women with"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_65",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 65,
    "text": "al Review Group\nAn external review group comprised four technical experts with interest and expertise in the provision\nof evidence-based care to improve the quality of care and outcomes for women with diabetes during\npregnancy. The members had no important conflicts of interest. The experts reviewed the final document\nto identify any factual errors and commented on the clarity of language, contextual issues and implications\nfor implementation. They ensured that the decision-making processes had considered and incorporated\ncontextual values and the preferences of persons affected by the recommendations, health-care providers\nand policy-makers. It was not within the remit of this group to change the recommendations that were\nformulated by the GDG. Members of the External Review Group are lis"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_66",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 66,
    "text": "ndations, health-care providers\nand policy-makers. It was not within the remit of this group to change the recommendations that were\nformulated by the GDG. Members of the External Review Group are listed in Annex 1.\n\nWHO recommendations on care for women with diabetes during pregnancy\n2.2 Evidence identification and retrieval\nEvidence to support the development of the guideline recommendations was derived from several sources by\nthe systematic review teams working in collaboration with the WHO Steering Group.\n2.2.1 Evidence on effectiveness\nTo inform the development of the recommendations, WHO commissioned a set of three de novo systematic\nreviews on the management of diabetes during pregnancy, one of which covered nine priority questions.\nExternal groups of systematic reviewers were asked"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_67",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 67,
    "text": "commissioned a set of three de novo systematic\nreviews on the management of diabetes during pregnancy, one of which covered nine priority questions.\nExternal groups of systematic reviewers were asked to prepare review protocols with clear PICO questions\nand criteria for identification of studies, including search strategies for different bibliographic databases,\nmethods for assessing risk of bias and a data analysis plan (19–21). The WHO Steering Group and the guideline\nmethodologists reviewed and endorsed the protocols before the systematic reviews were conducted.\nThe search strategies employed to identify the studies and the specific criteria for inclusion and exclusion\nof studies are described in the individual systematic reviews. Studies from low-, middle- and high-\nincome countries w"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_68",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 68,
    "text": "yed to identify the studies and the specific criteria for inclusion and exclusion\nof studies are described in the individual systematic reviews. Studies from low-, middle- and high-\nincome countries were considered and there were no language restrictions. The entire systematic review\ndevelopment process was iterative, with the systematic reviewers and guideline methodologists constantly\ncommunicating with the WHO Steering Group to discuss challenges and agree on solutions.\n6 2.2.2 Evidence on values, resource use and cost–effectiveness, equity and\nhuman rights, acceptability and feasibility\nValues, equity and human rights, acceptability and feasibility\nTwo qualitative evidence syntheses (QES) explored the views and experiences of women with type 1 or\ntype 2 diabetes during their encounters"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_69",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 69,
    "text": "lues, equity and human rights, acceptability and feasibility\nTwo qualitative evidence syntheses (QES) explored the views and experiences of women with type 1 or\ntype 2 diabetes during their encounters with maternity services (17) and those of health-care providers caring\nfor women with diabetes during the maternity phase (16).\nEvidence on the views and experiences of women with GDM was obtained from previously published systematic\nreviews of qualitative evidence. Existing reviews identified by a systematic search were appraised using the\nJoanna Briggs Institute Checklist for Systematic Reviews, and 14 high-quality reviews were referenced.\nThese reviews were the primary source of evidence on values, equity and human rights, acceptability, and\nfeasibility.\nResource use and cost–effectiveness"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_70",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 70,
    "text": ", and 14 high-quality reviews were referenced.\nThese reviews were the primary source of evidence on values, equity and human rights, acceptability, and\nfeasibility.\nResource use and cost–effectiveness\nThe evidence synthesis team initiated a new systematic review of economic evaluations for the screening,\nmanagement and treatment for women with diabetes during pregnancy (18). The review aimed to:\n• synthesize the available evidence from economic evaluations of interventions to screen/diagnose, treat\nand/or manage diabetes during pregnancy;\n• assess the methodological quality of the economic evaluation studies;\n• identify the gaps in the evidence from economic evaluations of interventions to manage diabetes during\npregnancy.\n\nWHO recommendations on care for women with diabetes during pregnan"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_71",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 71,
    "text": "luation studies;\n• identify the gaps in the evidence from economic evaluations of interventions to manage diabetes during\npregnancy.\n\nWHO recommendations on care for women with diabetes during pregnancy Methods\n2.3 Quality assessment and grading of the evidence\n2.3.1 Quality assessment of primary studies included in the reviews\nFor the effectiveness reviews, all eligible randomized controlled trials were assessed using a research integrity\nassessment tool adapted from that described by Weibel et al 2022 (22). The tool aims to detect any potential\nissues related to study retraction, trial registration, ethics approval, author contributions, plausibility of\nmethods (e.g. randomization), and plausibility of study results.\nFor all trials judged to be trustworthy, two reviewers independently as"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_72",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 72,
    "text": "tration, ethics approval, author contributions, plausibility of\nmethods (e.g. randomization), and plausibility of study results.\nFor all trials judged to be trustworthy, two reviewers independently assessed the risk of bias of randomized trials\nusing the revised Cochrane risk-of-bias tool (RoB 2.0). For non-randomized trials, the ROBINS-I tool was used.\nAny disagreement was resolved by discussion or by involving a third assessor.\nFor each included randomized controlled trial (RCT) and each outcome, the domains of bias explored were:\nrandomization process; identification or recruitment of individual participants within clusters; deviations from\nintended interventions; missing outcome data; measurement of the outcome; selection of the reported result;\nand overall bias.\nFor non-randomized stu"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_73",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 73,
    "text": "idual participants within clusters; deviations from\nintended interventions; missing outcome data; measurement of the outcome; selection of the reported result;\nand overall bias.\nFor non-randomized studies, the domains of bias explored were: confounding; selection of participants into\nthe study; classification of interventions; deviations from intended interventions; missing data; measurement\nof outcomes; selection of the reported result; and overall bias.\n7\nThe quality of studies included in the QES was appraised using the GRADE-CERQual tool (23) as outlined below.\nThe cost–effectiveness systematic review used the extended Consensus on Health Economics Criteria list (24)\nfor assessing the quality of studies.\n2.3.2 Assessment of certainty of the effectiveness evidence\nFor the effectiveness"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_74",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 74,
    "text": "matic review used the extended Consensus on Health Economics Criteria list (24)\nfor assessing the quality of studies.\n2.3.2 Assessment of certainty of the effectiveness evidence\nFor the effectiveness evidence, the certainty of evidence for a given outcome was rated using the\nstandard GRADE approach based on consideration of study design limitations (risk of bias), inconsistency\n(heterogeneity or variability in results), indirectness (differences in study populations), imprecision (small\nstudy populations and/or few events; wide confidence intervals) and publication bias (12).\nWhere possible, evidence profile tables were prepared using GRADEpro software (25). These included the\neffect estimates (expressed as relative and absolute risk), explanations of the certainty assessments, and an\nover"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_75",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 75,
    "text": "vidence profile tables were prepared using GRADEpro software (25). These included the\neffect estimates (expressed as relative and absolute risk), explanations of the certainty assessments, and an\noverall certainty rating for each outcome and are included in the web annex to this guideline.\nGRADE certainty of the evidence\nThe certainty of evidence for each outcome was rated as ‘high’, ‘moderate’, ‘low’ or ‘very low’ as defined by the\nGRADE methodology.\n• High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.\n• Moderate certainty: We are moderately confident in the effect estimate. The true effect is likely to be\nclose to the estimate of the effect, but there is a possibility that it is substantially different.\n\nWHO recommendations on car"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_76",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 76,
    "text": "rately confident in the effect estimate. The true effect is likely to be\nclose to the estimate of the effect, but there is a possibility that it is substantially different.\n\nWHO recommendations on care for women with diabetes during pregnancy\n• Low certainty: Our confidence in the effect estimate is limited. The true effect may be substantially\ndifferent from the estimate of the effect.\n• Very low certainty: We have very little confidence in the effect estimate. The true effect is likely to be\nsubstantially different from the estimate of effect.\nSensitivity analyses\nWhen the main analysis included trials for which the reviewer had identified research integrity concerns, and\nauthors had been contacted for clarification but had not yet replied, sensitivity analyses were conducted with\nthese"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_77",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 77,
    "text": "uded trials for which the reviewer had identified research integrity concerns, and\nauthors had been contacted for clarification but had not yet replied, sensitivity analyses were conducted with\nthese trials removed. Other than a probable reduction in risk of neonatal hypoglycaemia with CGM compared\nto SMBG among women with type 1 diabetes, there were no substantial changes in conclusions (i.e. no clear\nshifts in suggestion of benefit / harm / no difference) or certainty.\n2.3.3 Assessment of the certainty of (confidence in) the qualitative evidence\nThe findings of studies included in the QES were appraised using the GRADE-CERQual tool (23). The GRADE-\nCERQual tool, which uses a similar conceptual approach to other GRADE tools, provides a transparent method\nfor assessing and assigning the le"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_78",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 78,
    "text": "re appraised using the GRADE-CERQual tool (23). The GRADE-\nCERQual tool, which uses a similar conceptual approach to other GRADE tools, provides a transparent method\nfor assessing and assigning the level of confidence that can be placed in evidence from reviews of qualitative\nresearch. The systematic review team used the GRADE-CERQual tool to assign a level of confidence to each\nreview finding according to four components: methodological limitations of the individual studies; adequacy of\ndata; coherence; and relevance to the review question of the individual studies contributing to a review finding.\n8\nThe confidence of evidence for each review finding is rated as ‘high’, ‘moderate’, ‘low’ or ‘very low’ (23).\n• High confidence: It is highly likely that the review finding is a reasonable rep"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_79",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 79,
    "text": "nding.\n8\nThe confidence of evidence for each review finding is rated as ‘high’, ‘moderate’, ‘low’ or ‘very low’ (23).\n• High confidence: It is highly likely that the review finding is a reasonable representation of the\nphenomenon of interest.\n• Moderate confidence: It is likely that the review finding is a reasonable representation of the\nphenomenon of interest.\n• Low confidence: It is possible that the review finding is a reasonable representation of the phenomenon\nof interest.\n• Very low confidence: It is not clear whether the review finding is a reasonable representation of the\nphenomenon of interest.\n2.4 Formulation of the recommendations\nThe WHO Steering Group supervised the preparation and finalization of summary of findings tables\nand narrative evidence summaries in collaboration wi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_80",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 80,
    "text": "f interest.\n2.4 Formulation of the recommendations\nThe WHO Steering Group supervised the preparation and finalization of summary of findings tables\nand narrative evidence summaries in collaboration with the guideline methodologists using the GRADE\nEtD framework (26). The EtD framework includes explicit and systematic consideration of evidence on\nthe intervention in terms of specified domains: effectiveness, values, resources, equity and human\nrights, acceptability and feasibility. Using the EtD framework template, the Steering Group and guideline\nmethodologists created summary documents for each priority question covering evidence on each domain.\nFor each priority question, judgements were made on the impact of the intervention on each domain, to\ninform and guide the decision-making proces"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_81",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 81,
    "text": "ch priority question covering evidence on each domain.\nFor each priority question, judgements were made on the impact of the intervention on each domain, to\ninform and guide the decision-making process.\n\nWHO recommendations on care for women with diabetes during pregnancy Methods\nThe WHO Steering Group provided the EtD frameworks for discussion, including evidence summaries and\nsummary of findings tables, to GDG members one week before the GDG meetings. The GDG members were\nasked to review and electronically provide comments on the documents before the GDG meeting. During\nthe online meetings of the GDG (12–15 May 2025 and July 29–31 2025), under the leadership of the GDG\nchairpersons, the GDG members collectively reviewed and discussed the frameworks.\nThe purpose of the meetings was to for"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_82",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 82,
    "text": "f the GDG (12–15 May 2025 and July 29–31 2025), under the leadership of the GDG\nchairpersons, the GDG members collectively reviewed and discussed the frameworks.\nThe purpose of the meetings was to formulate and reach consensus on recommendations, based on explicit\nconsideration of the range of evidence presented in the EtD frameworks and the judgements of the GDG members.\nIn formulating the recommendations, the GDG used the GRADE EtD frameworks and considered separately\nthe synthesized evidence on effectiveness of the intervention, values of stakeholders, resource use and\ncost–effectiveness of the intervention, acceptability and feasibility of the intervention, and the impact of the\nintervention on equity and human rights. For each of these domains, the certainty of evidence was evaluated"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_83",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 83,
    "text": "the intervention, acceptability and feasibility of the intervention, and the impact of the\nintervention on equity and human rights. For each of these domains, the certainty of evidence was evaluated\nusing methods that were appropriate to the available supporting evidence synthesis (such as GRADE or\nGRADE CerQual) and the GDG made judgements on the effects of an intervention across these domains.\nIt was the view of the GDG that, as certainty of evidence was evaluated across several domains to arrive at\nthe recommendation, and not just for evidence on effectiveness of the intervention, this cannot be captured\nwithin a single ‘certainty’ rating. Providing the certainty of evidence for effectiveness alone within the\nrecommendation texts does not adequately demonstrate the consideration of all"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_84",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 84,
    "text": "not be captured\nwithin a single ‘certainty’ rating. Providing the certainty of evidence for effectiveness alone within the\nrecommendation texts does not adequately demonstrate the consideration of all the types of evidence, and\ncould potentially confuse the target audience. 9\nA further step in the GRADE approach is to attribute one of two levels of strength (i.e. strong or weak, strong\nor conditional) to each recommendation. Since 2016, all consolidated WHO maternal and perinatal health\nguidelines and updates of recommendations have not taken this step based on feedback received from users\nabout the challenges of interpreting recommendations coupled with specific evidence ratings. It was the view\nof the GDG that a change in the presentation approach of this set of recommendations could cre"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_85",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 85,
    "text": "ut the challenges of interpreting recommendations coupled with specific evidence ratings. It was the view\nof the GDG that a change in the presentation approach of this set of recommendations could create confusion\nfor the target audience.\n2.5 Management of declaration of interests\nAll GDG members and other external contributors were required to complete a standard WHO declaration\nof interests (DOI) form before engaging in the guideline development process and taking part in any of the\nguideline development meetings. Before finalizing experts’ invitations to participate in the development of\nthe guideline, the WHO Steering Committee reviewed all the DOI forms using the criteria for assessing the\nseverity of a conflict of interest in the WHO handbook for guideline development (12) to determi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_86",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 86,
    "text": "e guideline, the WHO Steering Committee reviewed all the DOI forms using the criteria for assessing the\nseverity of a conflict of interest in the WHO handbook for guideline development (12) to determine whether\nany identified conflict of interest warranted action. Each member was asked to update their DOI form prior\nto the each GDG meeting in case information had changed in the intervening period. None of the meeting\nparticipants declared a conflict of interest that was considered significant enough to pose any risk to the\nguideline development process or to reduce its credibility. A summary of the DOI statements and how\nconflicts of interest were managed is included in Annex 3.\n\nWHO recommendations on care for women with diabetes during pregnancy\n2.6 Decision making during the GDG meeting"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_87",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 87,
    "text": "f the DOI statements and how\nconflicts of interest were managed is included in Annex 3.\n\nWHO recommendations on care for women with diabetes during pregnancy\n2.6 Decision making during the GDG meetings\nThe GDG meetings were designed to allow participants to discuss the supporting evidence and to reach a\nconsensus on the final wording of each recommendation. Consensus was defined as the agreement by three\nquarters or more of the GDG, provided that those who disagreed did not feel strongly about their position.\nNo GDG member expressed opposition to the recommendations.\n2.7 Document preparation and peer review\nThe WHO Steering Group made a draft version of the EtD frameworks available to the participants one week\nbefore the meeting for their comments. During the meeting, the frameworks were m"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_88",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 88,
    "text": "nd peer review\nThe WHO Steering Group made a draft version of the EtD frameworks available to the participants one week\nbefore the meeting for their comments. During the meeting, the frameworks were modified in line with the\nparticipants’ deliberations and remarks. Following the meeting, the WHO Steering Group worked with the\nguideline methodologists to prepare a full guideline document to accurately reflect the deliberations and\ndecisions of the participants. The draft document was sent electronically to GDG members for their final\nreview and approval. The final document was also sent for peer review to four external independent experts\nwho were not involved in the development of the guideline. The WHO Steering Group evaluated the advice\nof the peer reviewers for inclusion in this documen"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_89",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 89,
    "text": "r review to four external independent experts\nwho were not involved in the development of the guideline. The WHO Steering Group evaluated the advice\nof the peer reviewers for inclusion in this document. After the meetings and external peer reviews, the\nmodifications made by the WHO Steering Group to the document consisted only of the correction of factual\nerrors and edits to address any lack of clarity.\n10\n\nWHO recommendations on care for women with diabetes during pregnancy\nRecommendations\n3\nand supporting\nevidence\nThe GDG issued 27 recommendations – four on care for all women with diabetes (type 1, type 2 or gestational)\nduring pregnancy, six on glucose monitoring, two on pharmacological treatment for pregnant women with\ntype 1 diabetes, four on pharmacological treatment for pregnant wom"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_90",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 90,
    "text": "type 1, type 2 or gestational)\nduring pregnancy, six on glucose monitoring, two on pharmacological treatment for pregnant women with\ntype 1 diabetes, four on pharmacological treatment for pregnant women with type 2 diabetes and two on\npharmacological treatment for women with GDM, and nine on additional monitoring and assessments. This\nsection outlines the recommendations corresponding to the priority questions.\nTo ensure that the recommendations are correctly understood and appropriately implemented in\npractice, additional ‘remarks’ reflecting the summary of the discussions by the GDG are included. The 11\nrecommendations should be applied in conjunction with the implementation considerations.\nThe EtD frameworks – presenting the available effectiveness evidence, the balance between the desi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_91",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 91,
    "text": "uded. The 11\nrecommendations should be applied in conjunction with the implementation considerations.\nThe EtD frameworks – presenting the available effectiveness evidence, the balance between the desirable\nand undesirable effects, values of stakeholders, resource requirements, cost–effectiveness, acceptability,\nfeasibility and equity, and human rights that were considered in formulating each recommendation – are\npresented separately in the web annexes to this guideline.\n3.1 Recommendations\n3.1.1 Core practices in caring for women with diabetes during pregnancy\nAdvice on diet, physical activity and weight management\nRecommendation\n1 For pregnant women with type 1, type 2 or gestational diabetes, provide individualized advice on diet, physical\nactivity and weight management based on existing"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_92",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 92,
    "text": "and weight management\nRecommendation\n1 For pregnant women with type 1, type 2 or gestational diabetes, provide individualized advice on diet, physical\nactivity and weight management based on existing WHO guidance, including:\n• dietary advice for the general adult population;\n• physical activity advice for the general pregnant population;\n• weight management advice based on the above dietary and physical activity advice, with a focus on appropriate\ngestational weight gain.\n\nWHO recommendations on care for women with diabetes during pregnancy\nRationale\n• Counselling about healthy eating during pregnancy to prevent excessive gestational weight gain was\nrecommended by the WHO antenatal care guidelines (10). Physical activity during pregnancy to improve\nmaternal and fetal health outcomes was r"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_93",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 93,
    "text": "pregnancy to prevent excessive gestational weight gain was\nrecommended by the WHO antenatal care guidelines (10). Physical activity during pregnancy to improve\nmaternal and fetal health outcomes was recommended by the WHO antenatal care guidelines (10) and the\nWHO 2020 guidelines on physical activity and sedentary behaviour (27). A healthy diet and regular physical\nactivity are also integral to type 2 diabetes management (28).\n• In the context of limited direct empirical evidence on advice on diet, physical activity and weight\nmanagement advice for pregnant women with diabetes, the GDG developed this recommendation based\non existing WHO guidance.\n• The GDG chose to base its recommendation on dietary advice on WHO guidance for the general\npopulation (29–32), as WHO guidance on diet in the g"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_94",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 94,
    "text": "ed this recommendation based\non existing WHO guidance.\n• The GDG chose to base its recommendation on dietary advice on WHO guidance for the general\npopulation (29–32), as WHO guidance on diet in the general pregnant population (10) and the general\npopulation with type 2 diabetes (28) is non-specific, recommending a ‘healthy diet’, while guidance for the\ngeneral adult population provides details on how this might be achieved.\n• The GDG chose to base its recommendation on physical activity advice on the WHO recommendation\nspecific to the general pregnant population (27), noting that the risks for the amounts and types of physical\nactivity recommended for pregnant and postnatal women are low and are outweighed by substantial\nhealth benefits.\n12\nRemarks\nSpecific dietary and physical activity a"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_95",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 95,
    "text": "r the amounts and types of physical\nactivity recommended for pregnant and postnatal women are low and are outweighed by substantial\nhealth benefits.\n12\nRemarks\nSpecific dietary and physical activity advice\n• Dietary advice following WHO recommendations for the general adult population (29–32):\n– carbohydrates primarily from wholegrains, vegetables, fruits and pulses (legumes);\n– at least 400 g vegetables daily; 25 g naturally occurring fibre daily;\n– limitation of total fat intake to 30% of total energy intake, with fat consumed primarily unsaturated\nfatty acids and no more than 10% of total energy from saturated fats and no more than 1% of total\nenergy intake form trans-fatty acids; and\n– reduction of free sugars to less than 5–10% of daily intake.\n• Physical activity advice following WHO"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_96",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 96,
    "text": "nergy from saturated fats and no more than 1% of total\nenergy intake form trans-fatty acids; and\n– reduction of free sugars to less than 5–10% of daily intake.\n• Physical activity advice following WHO recommendations for the general pregnant population (27):\n– regular physical activity throughout pregnancy;\n– 150 minutes per week of moderate-intensity aerobic activity;\n– incorporating resistance (muscle strengthening) exercise and stretching; and\n– continuation of pre-pregnancy physical activity habits for women who, before pregnancy, were\nhabitually engaged in vigorous-intensity aerobic activity, or who were physically active.\nIndividualization of advice\n• Individualizing advice on diet, physical activity and weight management, based on each woman’s weight\nand/or glycaemic control, includ"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_97",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 97,
    "text": "ity, or who were physically active.\nIndividualization of advice\n• Individualizing advice on diet, physical activity and weight management, based on each woman’s weight\nand/or glycaemic control, including specialized advice from a registered dietitian or exercise physiologist\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nwith expertise in diabetes during pregnancy, may be beneficial. Cultural tailoring of both dietary and\nphysical activity advice is likely to improve uptake.\n• Weight management is defined as achieving appropriate gestational weight gain in relation to the mother’s\npre-pregnancy weight. WHO is developing gestational weight gain standards for the general pregnant\npopulation, which may also inform advice for women"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_98",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 98,
    "text": "estational weight gain in relation to the mother’s\npre-pregnancy weight. WHO is developing gestational weight gain standards for the general pregnant\npopulation, which may also inform advice for women with diabetes on appropriate gestational weight gain\nduring pregnancy.\nBenefits and harms\n• The limited evidence identified through the systematic review conducted to inform this guideline\nsuggested a possible reduction in gestational weight gain in women with type 1 or type 2 diabetes\nwith a diabetes-specific high carbohydrate, high fibre, low fat diet versus routine care (n=20 women)\n(low certainty). It also suggested a possible reduction in risk of preterm birth in women with GDM with\nindividualized dietary advice compared to routine care (n=234 women) (low certainty). No harms were\nidenti"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_99",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 99,
    "text": "inty). It also suggested a possible reduction in risk of preterm birth in women with GDM with\nindividualized dietary advice compared to routine care (n=234 women) (low certainty). No harms were\nidentified for any diet.\n• The limited evidence identified in the review of physical activity versus routine care found only very low\ncertainty evidence on the benefits or harms of physical activity advice for women with type 1 diabetes,\nand no evidence on women with type 2 diabetes.\n• Among women with GDM, with any physical activity there was probably little to no difference in gestational\nweight gain (n=595 women) (moderate certainty) and possibly little to no difference in risk of caesarean 13\nbirth (n=1014 women) and instrumental vaginal birth (n=375 women) (low certainty). There was possibly\nli"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_100",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 100,
    "text": "(n=595 women) (moderate certainty) and possibly little to no difference in risk of caesarean 13\nbirth (n=1014 women) and instrumental vaginal birth (n=375 women) (low certainty). There was possibly\nlittle to no difference in gestational weight gain with aerobic activity (n=263 women) or aerobic plus\nresistance activity (n=268 women) (low certainty).\n• There was possibly little to no difference in effect on gestational age at birth with any maternal physical\nactivity (n=301 babies), resistance exercise (n=64 babies), or combined aerobic and resistance activity\n(n=169 babies) (low certainty).There was possibly little to no difference in effect on birthweight with any\nphysical activity (n=651 babies), resistance exercise (n=64 babies) or combined aerobic and resistance\nactivity (n=276 babies)"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_101",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 101,
    "text": "re was possibly little to no difference in effect on birthweight with any\nphysical activity (n=651 babies), resistance exercise (n=64 babies) or combined aerobic and resistance\nactivity (n=276 babies) (low certainty).\n• There was no evidence of other benefits or harms for women with GDM, although the lack of benefits or\nharms is not established as many outcomes were of very low certainty.\nEquity and human rights\n• Evidence from the QES suggests that for some women on low or limited incomes, the extra costs of finding\nor buying ‘healthy food’ may be prohibitive and lead to an inequitable service for these women (moderate\nconfidence) (16).\nAcceptability to women\n• Women with type 1 or type 2 diabetes: The QES found that some women view pregnancy as an opportunity\nfor behavioural change (mode"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_102",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 102,
    "text": "e for these women (moderate\nconfidence) (16).\nAcceptability to women\n• Women with type 1 or type 2 diabetes: The QES found that some women view pregnancy as an opportunity\nfor behavioural change (moderate confidence) and welcome advice on diet and physical activity provided\nit is given in a clear, understandable and culturally appropriate format (including pictures and online\nresources) by health-care providers who are sensitive to their individual needs (high confidence) (17). Some\nwomen may struggle, however, to adapt to dietary changes (low confidence) or find some foods difficult\n\nWHO recommendations on care for women with diabetes during pregnancy\nto tolerate because of digestive problems or morning sickness (low confidence) (17). In certain contexts,\nthe additional cost of recommende"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_103",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 103,
    "text": "mmendations on care for women with diabetes during pregnancy\nto tolerate because of digestive problems or morning sickness (low confidence) (17). In certain contexts,\nthe additional cost of recommended ‘healthy food’ can lead to poor adherence by some women on low\nor limited incomes (low confidence) (17). In addition, some women may be confused by inconsistent or\nconflicting dietary advice from different health-care providers (low confidence) (17). In some contexts\nwhere weight gain during pregnancy is viewed as a cultural norm, women (and their families) may be\nresistant to weight management advice (low confidence). In addition, some women may feel guilty about\ntheir weight (low confidence) and find it difficult to discuss weight management concerns with health-care\nproviders who lack emp"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_104",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 104,
    "text": "advice (low confidence). In addition, some women may feel guilty about\ntheir weight (low confidence) and find it difficult to discuss weight management concerns with health-care\nproviders who lack empathy or sensitivity (moderate confidence).\n• Women with GDM: The systematic reviews referenced in the QES found that some women felt that adapting\nto dietary changes was a steep learning curve, with very limited time to make the changes (33–35)\n(high confidence). Some also found it difficult to accept dietary advice, especially if it conflicted with their\nregular diet or their normative cultural diet (33, 35) (moderate confidence). Authors indicated there was a\nclear need for personalized dietary advice for women from different cultural population groups (35–38)\n(high confidence). For some wom"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_105",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 105,
    "text": "iet (33, 35) (moderate confidence). Authors indicated there was a\nclear need for personalized dietary advice for women from different cultural population groups (35–38)\n(high confidence). For some women, the financial implications of healthy eating, or adapting to advised\ndiets can be a barrier (38) (moderate confidence). Authors also stressed the importance of engaging family\nsupport (especially partners) in helping women adapt to dietary changes (35, 37) (moderate confidence).\nIn addition, some women with GDM hold the belief that recommended dietary changes may not support\nthe optimal wellbeing of the developing baby so may be reluctant to accept dietary advice (34, 37)\n(low confidence). In regard to physical activity advice, some women may be more likely to engage with the\n14\nadvice bec"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_106",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 106,
    "text": "ing of the developing baby so may be reluctant to accept dietary advice (34, 37)\n(low confidence). In regard to physical activity advice, some women may be more likely to engage with the\n14\nadvice because of a desire to avoid pharmacotherapy (low confidence) (36).\n• Women with all types of diabetes: Among women with all types of diabetes, some may struggle to\nincorporate additional physical activity into their routines because of family or work-related commitments\n(high confidence) (16, 33–35, 39). In addition, some women in specific contexts may be reluctant to exercise\nbecause of cultural beliefs around pregnancy or because they feel uncomfortable about exercising in\npublic (moderate confidence) (16, 35, 37, 40).\nAcceptability to implementers\n• The QES found that, from the health-care pr"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_107",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 107,
    "text": "liefs around pregnancy or because they feel uncomfortable about exercising in\npublic (moderate confidence) (16, 35, 37, 40).\nAcceptability to implementers\n• The QES found that, from the health-care provider perspective, women are generally receptive to dietary advice\n(high confidence) provided it is delivered in a clear, understandable format in a sensitive, empathic manner (high\nconfidence) (16). Some providers, however, expressed a sense of frustration when they encountered women\nwho appeared unwilling or unable to adhere to dietary advice (moderate confidence) (16).\n• In some contexts, providers felt dietary information was predominantly focused on a ‘western’ diet and\ndidn’t address the needs of culturally diverse populations (moderate confidence) (16). This left some providers\nfeeling"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_108",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 108,
    "text": "iders felt dietary information was predominantly focused on a ‘western’ diet and\ndidn’t address the needs of culturally diverse populations (moderate confidence) (16). This left some providers\nfeeling poorly prepared and lacking the resources (including dietary information in different languages and/or\ntranslators) to offer appropriate advice to some minority population groups (low confidence) (16).\n• Some health-care providers found conversations about weight to be challenging, especially with\nwomen who became defensive about their weight (low confidence) or with women from specific cultural\nbackgrounds who held different beliefs about weight management during pregnancy (low confidence) (16).\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and support"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_109",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 109,
    "text": "backgrounds who held different beliefs about weight management during pregnancy (low confidence) (16).\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\n• Indirect evidence suggests that some health-care providers found protocols and guidelines about the\nmanagement of diabetes in pregnancy to be confusing and sometimes conflicting and wanted more clarity\nabout the advice and guidance they should be giving to pregnant women (moderate confidence) (16).\nFeasibility\n• The QES found that some health-care providers lack the time to discuss dietary, physical activity and\nweight management advice with women (high confidence) (16). Furthermore, findings also indicate that\na few health-care providers omit dietary advice completely and move"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_110",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 110,
    "text": "dietary, physical activity and\nweight management advice with women (high confidence) (16). Furthermore, findings also indicate that\na few health-care providers omit dietary advice completely and move straight to discussing insulin use\nbecause they don’t feel they have the time to explain information about diet (low confidence). In addition,\nsome health-care providers felt that they lacked knowledge and skills and wanted more training on a\nvariety of issues related to lifestyle advice including nutrition, physical activity and cultural awareness\n(moderate confidence). In some contexts, providers also highlighted a shortage of dieticians as a potential\nbarrier to the provision of appropriate dietary advice for women with diabetes (low confidence).\nAntenatal education\nRecommendation\n2 For pre"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_111",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 111,
    "text": "s also highlighted a shortage of dieticians as a potential\nbarrier to the provision of appropriate dietary advice for women with diabetes (low confidence).\nAntenatal education\nRecommendation\n2 For pregnant women with type 1, type 2 or gestational diabetes, provide education on:\n• the effects of diabetes in pregnancy on maternal, fetal, newborn and child health outcomes;\n• diet and physical activity; 15\n• appropriate gestational weight gain;\n• managing glycaemia;\n• the need for additional monitoring of fetal growth and wellbeing.\nRationale\n• Education and counselling in pregnancy to improve maternal health outcomes was recommended by the\nWHO 2016 antenatal care guidelines (10). The GDG noted the need for education specific to diabetes during\npregnancy in addition to the education and counse"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_112",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 112,
    "text": "ernal health outcomes was recommended by the\nWHO 2016 antenatal care guidelines (10). The GDG noted the need for education specific to diabetes during\npregnancy in addition to the education and counselling provided routinely as part of antenatal care.\nRemarks\nBenefits and harms\n• The limited evidence identified through the systematic review conducted to inform this guideline\nsuggested that education of women with GDM resulted in a possible increase in follow-up for assessment\nfor development of type 2 diabetes in the long term, potentially due to increased understanding of the\nneed for re-assessment (n=107 women) (low certainty). The GDG noted that this lack of evidence does not\nnegate the known positive effects of engaging with women.\nPotential approaches to diabetes-specific antenatal ed"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_113",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 113,
    "text": "ssment (n=107 women) (low certainty). The GDG noted that this lack of evidence does not\nnegate the known positive effects of engaging with women.\nPotential approaches to diabetes-specific antenatal education\n• Culturally relevant resources may be beneficial and promote women’s empowerment, shared decision-\nmaking, and health literacy.\n\nWHO recommendations on care for women with diabetes during pregnancy\nEquity and human rights\n• Evidence from the QES suggests that additional educational sessions may have financial implications for\nsome women which could limit engagement (low confidence) (16). Health-care providers highlighted the\nextra costs associated with attendance for additional clinic visits including transportation, childcare and\ntime off work. They also mentioned the lack of transla"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_114",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 114,
    "text": "Health-care providers highlighted the\nextra costs associated with attendance for additional clinic visits including transportation, childcare and\ntime off work. They also mentioned the lack of translation services in several high-income settings, which\ncould result in an inequitable service for some women from migrant and refugee communities\n(low confidence).\nAcceptability\n• Women with type 1 or type 2 diabetes: The QES found that some women view pregnancy as an opportunity\nfor change and would welcome the opportunity to learn more about how to manage their condition\n(moderate confidence) (17). Women may also want more information about the effects of diabetes on\npregnancy provided it is delivered in a clear, understandable and consistent format (moderate confidence)\nby health-care provide"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_115",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 115,
    "text": ". Women may also want more information about the effects of diabetes on\npregnancy provided it is delivered in a clear, understandable and consistent format (moderate confidence)\nby health-care providers who are sensitive to their specific needs (high confidence). In addition, some\nwomen would like more peer support, so may benefit from antenatal education initiatives that provide this\nopportunity (moderate confidence).\n• Women with GDM: The systematic reviews referenced in the QES found that women had varying\nexperiences with regard to the quality and amount of information provided though there was a general\ndesire for more information (including education), especially individualized information given by health-\n16 care providers with whom they had an existing relationship (high confidence"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_116",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 116,
    "text": "e was a general\ndesire for more information (including education), especially individualized information given by health-\n16 care providers with whom they had an existing relationship (high confidence) (35–38). Some women\nfrom different ethnic minority backgrounds living in high-income countries also found there was a lack\nof culturally appropriate information and/or access to translators (moderate confidence) (37). For some\nwomen, the lack of continuity (seeing different health-care providers at each clinic visit) resulted in\ninconsistent and/or conflicting information (high confidence) (33, 35, 36, 38) and the limited time spent with\nhealth-care providers at each visit sometimes led to women feeling unsatisfied because educational needs\nwere overlooked (moderate confidence) (36, 38). The"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_117",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 117,
    "text": "35, 36, 38) and the limited time spent with\nhealth-care providers at each visit sometimes led to women feeling unsatisfied because educational needs\nwere overlooked (moderate confidence) (36, 38). Therefore, women with GDM often supplemented their\neducational needs by accessing online resources (of varying quality) or online support groups (moderate\nconfidence) (36). While there were different views about the amount of education and information\nprovided, some women with GDM felt that there was too much focus on diabetes and not enough on the\nactual pregnancy (moderate confidence) (41).\n• Health-care providers: The QES of health-care providers’ views on providing maternity care to women with\ndiabetes found that providers recognized the need for more education, information and resources for"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_118",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 118,
    "text": "h-care providers: The QES of health-care providers’ views on providing maternity care to women with\ndiabetes found that providers recognized the need for more education, information and resources for\npregnant women, particularly those with GDM who may not be familiar with the condition (high confidence)\n(16). Some health-care providers also highlighted the importance of using pictures, videos and interactive\nresources to make the information more understandable to a broad cross-section of women from different\neducational backgrounds and ethnicities (low confidence). However, some health-care providers also\nraised the possibility of ‘information overload’, especially for women with GDM, who may already be\nprocessing a significant amount of new information (low confidence).\nFeasibility\n• Evi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_119",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 119,
    "text": "roviders also\nraised the possibility of ‘information overload’, especially for women with GDM, who may already be\nprocessing a significant amount of new information (low confidence).\nFeasibility\n• Evidence from the QES suggests that some health-care providers lacked the knowledge and skills\n(including sociocultural awareness) to support women with diabetes (type 1, type 2, GDM) and required\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nmore training to improve relevant aspects of their practice (high confidence) (16). Indirect evidence\nindicated that diabetes services for pregnant women were often running at full capacity or overloaded\n(high confidence). Health-care providers highlighted a lack of time and the unavailability o"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_120",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 120,
    "text": "dence\nindicated that diabetes services for pregnant women were often running at full capacity or overloaded\n(high confidence). Health-care providers highlighted a lack of time and the unavailability of resources\n(including health-care staff and translators) as key factors in their ability to provide ‘additional’ support\nand services to women with all types of diabetes (high confidence).\nSpecialized care\nRecommendations\n3 For pregnant women with type 1 or type 2 diabetes, deliver multidisciplinary and specialized care provided by\nhealth-care providers trained in maternal and diabetes care.\n4 For women with gestational diabetes, consider multidisciplinary and specialized care provided by health-care\nproviders trained in maternal and diabetes care, depending on access and availability.\nRation"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_121",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 121,
    "text": "r women with gestational diabetes, consider multidisciplinary and specialized care provided by health-care\nproviders trained in maternal and diabetes care, depending on access and availability.\nRationale\n• In light of a lack of direct empirical evidence on specialized care for pregnant women with diabetes, the\nGDG developed this recommendation based on the complex care needs of women with diabetes during\npregnancy, which warrant specialized care.\nRemarks 17\nWhat is specialized care?\n• Specialized services aim to deliver timely, high-quality care that addresses pregnancy and diabetes care\nand their interrelated effects in pregnancy, over and above routine antenatal care. Specialized care may\ninclude a multidisciplinary team that integrates diabetes and antenatal care, with systems establish"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_122",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 122,
    "text": "heir interrelated effects in pregnancy, over and above routine antenatal care. Specialized care may\ninclude a multidisciplinary team that integrates diabetes and antenatal care, with systems established to\nfacilitate communication between team members.\nWho provides specialized care?\n• The team may comprise experts in different aspects of care that are known to be effective for pregnant\nwomen with diabetes (such as an obstetrician, endocrinologist/diabetologist, maternal fetal medicine\nspecialist, pharmacist, midwives, specialist nurses, a nutritionist/dietician, exercise specialist,\npsychologist, counsellor, etc.), and may connect with other local services as needed (e.g. social work). Care\nmay be coordinated through case conferences, digital care platforms or other available mechanisms.\nS"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_123",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 123,
    "text": "st, counsellor, etc.), and may connect with other local services as needed (e.g. social work). Care\nmay be coordinated through case conferences, digital care platforms or other available mechanisms.\nSetting\n• In some settings, specialized care may be provided at a local/regional centre that is not co-located with\nroutine antenatal services. Some provision may be possible via telehealth. In some contexts, standard care\nfor pregnant women with type 1, type 2 or GDM may already be somewhat specialized.\nAims of specialized care\n• Although this list is non-exhaustive, specialized care may aim to:\n– provide education and psychological support to the pregnant woman to manage her diabetes during\npregnancy;\n\nWHO recommendations on care for women with diabetes during pregnancy\n– support the woman in"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_124",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 124,
    "text": "provide education and psychological support to the pregnant woman to manage her diabetes during\npregnancy;\n\nWHO recommendations on care for women with diabetes during pregnancy\n– support the woman in monitoring blood glucose;\n– support the woman in maintaining target glucose levels;\n– effectively manage the use of insulin and/or oral glucose-lowering agents in pregnancy;\n– provide individualized dietary and activity advice, education and support;\n– undertake and respond to appropriate fetal surveillance.\nEquity and human rights\n• Indirect evidence from the QES (16) indicates that specialized services may not be available in all settings,\nparticularly in low-income contexts (low confidence).\n• In addition, where specialized services are available, the additional costs associated with atten"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_125",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 125,
    "text": "services may not be available in all settings,\nparticularly in low-income contexts (low confidence).\n• In addition, where specialized services are available, the additional costs associated with attendance\n(transportation, childcare, time away from work) may be prohibitive for some women, especially those on\nlow incomes and/or those requiring extra clinic visits to support other aspects of their antenatal care and/\nor diabetic management (low confidence).\nFeasibility\n• Indirect evidence from the QES (16) suggests that health-care providers recognize the importance of inter-\nprofessional collaboration and a multidisciplinary team approach to care (moderate confidence).\n• Indirect evidence from the same review (16) suggests that some health-care providers would like more\n18\nspecialized train"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_126",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 126,
    "text": "oration and a multidisciplinary team approach to care (moderate confidence).\n• Indirect evidence from the same review (16) suggests that some health-care providers would like more\n18\nspecialized training to better understand diabetes management during pregnancy (moderate confidence).\n3.1.2 Glucose monitoring\nMode of glucose monitoring\nRecommendations\n5 For pregnant women with type 1, type 2 or gestational diabetes, recommend SMBG in addition to routine care,\nwhere feasible.\n6 For pregnant women with type 1 diabetes, recommend the use of a CGM system, where feasible.\n7 For pregnant women with type 2 or gestational diabetes, do not routinely recommend use of a CGM system.\nRationale\n• Regular monitoring of blood glucose levels, and recognizing when they are low or high, is crucial to\nmanaging"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_127",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 127,
    "text": "ype 2 or gestational diabetes, do not routinely recommend use of a CGM system.\nRationale\n• Regular monitoring of blood glucose levels, and recognizing when they are low or high, is crucial to\nmanaging diabetes during pregnancy and preventing complications. Women using insulin or other\nglucose-lowering agents require more frequent monitoring.\n• The GDG noted that SMBG has been standard care for people with type 1 diabetes since the mid- to late-\n1980s and it is unethical not to offer it in this population.\n• In the context of potential harm to the developing baby from both hypoglycaemia and hyperglycaemia\nand limited empirical evidence on the harms and benefits of different modes of glucose monitoring during\npregnancy, these recommendations provide guidance on the appropriate mode of monito"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_128",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 128,
    "text": "erglycaemia\nand limited empirical evidence on the harms and benefits of different modes of glucose monitoring during\npregnancy, these recommendations provide guidance on the appropriate mode of monitoring for the\ndifferent types of diabetes.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nRemarks\nThese recommendations supersede and extend beyond the previous WHO self-care recommendations, which\nrecommend SMBG for non-pregnant people with type 1 or type 2 diabetes using insulin based on individual\nneed, and for women with GDM (42).\nBenefits and harms\n• Self-monitoring of blood glucose (SMBG): The systematic review conducted to inform this guideline found\nonly very low certainty evidence for women with type 1 diabetes and no evide"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_129",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 129,
    "text": "enefits and harms\n• Self-monitoring of blood glucose (SMBG): The systematic review conducted to inform this guideline found\nonly very low certainty evidence for women with type 1 diabetes and no evidence for women with type\n2 diabetes so conclusions about harms and benefits cannot be drawn. For women with GDM, compared\nto glucose monitoring at antenatal visits, there was evidence of a reduction in gestational weight gain,\nbirthweight, large for gestational age, macrosomia, shoulder dystocia, and birth injury with SMBG (high\ncertainty). No harms were identified for any group.\n• Continuous glucose monitoring: For women with type 1 diabetes, there was a probable increase in third\ntrimester time in target glucose range, and a probable reduction in neonatal intensive care unit admission\nwith CG"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_130",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 130,
    "text": "se monitoring: For women with type 1 diabetes, there was a probable increase in third\ntrimester time in target glucose range, and a probable reduction in neonatal intensive care unit admission\nwith CGM compared to SMBG (moderate certainty). There was also a possible increase in wellbeing (patient\nsatisfaction and perceived quality of life at 34 weeks) (low certainty). For women with GDM, there was a\nreduction in gestational weight gain (high certainty).\nFrequency of monitoring\n19\n• There is insufficient evidence to support a recommendation on the frequency of monitoring in any type\nof diabetes during pregnancy. The frequency of monitoring will depend on the severity of the woman’s\ndiabetes, and availability of health-care services and other resources.\nRoutine use\n• While Recommendation 7 a"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_131",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 131,
    "text": "during pregnancy. The frequency of monitoring will depend on the severity of the woman’s\ndiabetes, and availability of health-care services and other resources.\nRoutine use\n• While Recommendation 7 advises against routinely recommending use of CGM in pregnant women with\ntype 2 diabetes or GDM due to resource implications, this does not preclude its use for some pregnant\nwomen with diabetes (e.g. in women with GDM using insulin) where its use could potentially improve\noutcomes, where available.\nEquity and human rights\n• Evidence from the QES indicates that in some low-income contexts the availability of equipment/devices\nrequired to monitor glucose levels (glucometers, sensors, etc) may be limited or lacking (low confidence)\n(16). In settings where women (or their families) are expected to"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_132",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 132,
    "text": "ability of equipment/devices\nrequired to monitor glucose levels (glucometers, sensors, etc) may be limited or lacking (low confidence)\n(16). In settings where women (or their families) are expected to buy monitoring equipment/devices they\nmay not have the resources to do so (low confidence) (16, 17).\nAcceptability\n• Evidence from the QES suggests that some women with type 1 or type 2 diabetes become more anxious\nabout their blood glucose levels during pregnancy and tend to check/test their levels more frequently\n(sometimes multiple times a day), irrespective of the monitoring system used (high confidence) (17). Losing\ncontrol of their diabetes management (due to pregnancy) can be disconcerting and worrying for women\n(high confidence), some of whom may require additional psychological or em"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_133",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 133,
    "text": "confidence) (17). Losing\ncontrol of their diabetes management (due to pregnancy) can be disconcerting and worrying for women\n(high confidence), some of whom may require additional psychological or emotional support from health-\ncare providers to address their concerns (moderate confidence).\n\nWHO recommendations on care for women with diabetes during pregnancy\n• Although findings vary, some women with GDM find blood glucose monitoring to be a useful way of\nmanaging their condition without the use of insulin (moderate confidence) (37). However, some women\nwith GDM find blood glucose monitoring to be time consuming and socially isolating (moderate confidence)\n(33), with some expressing concern about the associated pain and potential bleeding (moderate\nconfidence) (33, 35). In addition, for w"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_134",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 134,
    "text": "to be time consuming and socially isolating (moderate confidence)\n(33), with some expressing concern about the associated pain and potential bleeding (moderate\nconfidence) (33, 35). In addition, for women unused to the routine of blood glucose monitoring, there was\na tendency to forget to test at regular intervals (moderate confidence) (38). The use of smartphone apps or\nhealth centre reminders sometimes negated this problem (low confidence) (38).\nFeasibility\n• While the QES found no direct evidence regarding the feasibility of different monitoring systems from the\nperspective of health-care providers (16), indirect evidence suggests that some may require additional\ntraining to better understand the management of diabetes during pregnancy (moderate confidence)\nand that some find guidelines"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_135",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 135,
    "text": "roviders (16), indirect evidence suggests that some may require additional\ntraining to better understand the management of diabetes during pregnancy (moderate confidence)\nand that some find guidelines and protocols for diabetes management (including monitoring) during\npregnancy to be inconsistent, confusing and occasionally outdated (moderate confidence).\nGlycated haemoglobin (HbA1c)\nRecommendations\n8 For pregnant women with type 1 or type 2 diabetes, measure HbA1c in the first trimester or as soon as antenatal\ncare is initiated.\n20\n9 For women with gestational diabetes, do not routinely measure HbA1c.\nRationale\n• HbA1c is used to reflect average plasma glucose over the last 8 to 12 weeks and is recommended by\nWHO to establish the diagnosis of type 2 diabetes and monitor glycaemic control"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_136",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 136,
    "text": "re HbA1c.\nRationale\n• HbA1c is used to reflect average plasma glucose over the last 8 to 12 weeks and is recommended by\nWHO to establish the diagnosis of type 2 diabetes and monitor glycaemic control in people with diabetes\noutside of pregnancy (28).\n• In light of a lack of empirical evidence on health benefits of measuring HbA1c for pregnant women with\ndiabetes, the GDG developed recommendations based on the capacity for testing of HbA1c early in\npregnancy for women with type 1 or type 2 diabetes to act as an adjunct to risk stratification (e.g. in\nidentifying risk for serious complications). The GDG acknowledged that HbA1c is not useful in caring for\nwomen with GDM.\nRemarks\nAvailability\n• The availability and affordability of HbA1c testing varies between countries and health-care setting"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_137",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 137,
    "text": "The GDG acknowledged that HbA1c is not useful in caring for\nwomen with GDM.\nRemarks\nAvailability\n• The availability and affordability of HbA1c testing varies between countries and health-care settings (43).\nFollow-up after testing\n• Follow-up after HbA1c testing will depend on the individual woman’s results and available resources.\nRoutine use\n• While Recommendation 9 advises against routinely recommending HbA1c measurement in women with\nGDM, this does not preclude its use in clinical contexts where its use could potentially improve outcomes.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nIn some settings, HbA1c measurement may be used to identify type 1 or type 2 diabetes that was present\nbefore the pregnancy.\nEquity and huma"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_138",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 138,
    "text": "es during pregnancy Recommendations and supporting evidence\nIn some settings, HbA1c measurement may be used to identify type 1 or type 2 diabetes that was present\nbefore the pregnancy.\nEquity and human rights\n• Indirect evidence from the QES suggests that HbA1c monitoring may have financial implications for some\nwomen with low or limited incomes (low confidence) (16). Extra costs associated with attendance for\nadditional clinic visits including transportation, childcare and time off work may be of particular concern\nfor women on low incomes who may already require extra clinic visits to support their antenatal care and/\nor diabetes management (low confidence) (16).\nAcceptability\n• Evidence from the QES suggests that some women with type 1 or type 2 diabetes find HbA1c testing to\nbe benefic"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_139",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 139,
    "text": "t their antenatal care and/\nor diabetes management (low confidence) (16).\nAcceptability\n• Evidence from the QES suggests that some women with type 1 or type 2 diabetes find HbA1c testing to\nbe beneficial and reassuring (low confidence) (17). However, some women may feel guilty or anxious when\ntheir HbA1c levels do not fall within recommended or acceptable levels (high confidence), or frustrated or\nangry when their encounters with health professionals focus disproportionately on the HbA1c reading (and\ndiabetes management) rather than on routine antenatal care (low confidence).\nFeasibility\n• Indirect evidence from the QES suggests that some health-care providers may require additional training\nto better understand the management of diabetes during pregnancy (moderate confidence) and find\ndif"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_140",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 140,
    "text": "irect evidence from the QES suggests that some health-care providers may require additional training\nto better understand the management of diabetes during pregnancy (moderate confidence) and find\ndifferent guidelines and protocols for diabetes management (including screening and monitoring) during 21\npregnancy to be inconsistent, confusing and occasionally outdated (moderate confidence) (16).\n• The GDG noted that convenience and ability to self-monitor may be factors that influence the modes of\ntesting that are implemented.\nGlycaemic targets\nRecommendation\n10 For pregnant women with type 1, type 2 or gestational diabetes, individualize glycaemic targets to optimize\nglycaemic control and improve maternal and neonatal outcomes.\nRationale\n• Glycaemic targets during pregnancy are usually lowe"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_141",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 141,
    "text": "ype 2 or gestational diabetes, individualize glycaemic targets to optimize\nglycaemic control and improve maternal and neonatal outcomes.\nRationale\n• Glycaemic targets during pregnancy are usually lower than outside of pregnancy due to underlying\npathophysiology and treatment risks (44). In type 1 diabetes, the absolute deficiency of insulin predisposes\nwomen to frequent glycaemic variability and a higher risk of severe hypoglycaemia, necessitating a careful\nbalance between tight glucose control and safety. Therefore, glycaemic targets are often individualized\nbased on hypoglycaemic risk. In contrast, individuals with type 2 diabetes typically retain some\nendogenous insulin secretion, leading to more stable glycaemic profiles and enabling more aggressive\nearly control, although targets must"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_142",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 142,
    "text": "ntrast, individuals with type 2 diabetes typically retain some\nendogenous insulin secretion, leading to more stable glycaemic profiles and enabling more aggressive\nearly control, although targets must be moderated in the presence of cardiovascular comorbidities or\nadvanced age.\n• The WHO PEN (Package of Essential Noncommunicable Disease Interventions) protocol recommends\nthat most people with diabetes aim for an HbA1c of 7.0% (53 mmol/mol). If HbA1c measurement is not\n\nWHO recommendations on care for women with diabetes during pregnancy\navailable, a target fasting blood glucose of ≤7 mmol/L (126 mg/dl) and a postprandial plasma glucose of\n≤9 mmol/L (45) can serve as surrogates. However, an individualized approach is encouraged in setting the\npatient’s target level for glycaemic control, ta"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_143",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 143,
    "text": "26 mg/dl) and a postprandial plasma glucose of\n≤9 mmol/L (45) can serve as surrogates. However, an individualized approach is encouraged in setting the\npatient’s target level for glycaemic control, taking into account their comorbidities, risks from medication\nside-effects and likely benefit from tight glycaemic control in view of life expectancy (46).\n• In the context of limited empirical evidence, the GDG developed this recommendation based on the\npotential harm to the developing baby from hypoglycaemia and hyperglycaemia and the importance of\nglucose monitoring as noted in Recommendation 5.\nRemarks\nBenefits and harms\n• The systematic review conducted to inform this guideline found that for women with type 1 diabetes:\n– for very tight glycaemic targets (fasting plasma glucose [FPG] 3.33"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_144",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 144,
    "text": "Remarks\nBenefits and harms\n• The systematic review conducted to inform this guideline found that for women with type 1 diabetes:\n– for very tight glycaemic targets (fasting plasma glucose [FPG] 3.33 to 5.00 mmol/L [60 to 90 mg/dL])\nversus moderately tight glycaemic targets (FPG 5.27 to 6.38 mmol/L [95 to 115 mg/dL]), there was no\nevidence of benefit and possible increases in the percentage of days with maternal hypoglycaemia\n(n=22 women) and increased length of postnatal hospitalization (n=137 women) (low certainty);\n– for tight glycaemic targets (FPG <5.6 mmol/L [<101 mg/dL]) versus moderate (FPG 5.6 to 6.7 mmol/L\nglycaemic targets [101 to 121 mg/dL]) there was no evidence of benefit or harm;\n– for moderate glycaemic targets (FPG target 5.6 to 6.7 mmol/L [101 to 121 mg/dL]) versus loose"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_145",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 145,
    "text": "(FPG 5.6 to 6.7 mmol/L\nglycaemic targets [101 to 121 mg/dL]) there was no evidence of benefit or harm;\n– for moderate glycaemic targets (FPG target 5.6 to 6.7 mmol/L [101 to 121 mg/dL]) versus loose\n22\nglycaemic targets (FPG 6.7 to 8.9 mmol/L [121 mg/dL to 160 mg/dL]), there were possible reductions\nin caesarean birth (n=44 women), large-for-gestational age (n=44 babies) and respiratory distress\nsyndrome (n=44 babies) (low certainty) and no certain evidence of harm.\n• For tight versus moderate glycaemic targets or moderate versus loose glycaemic targets, the lack of harm is\nnot established as many outcomes were of very low certainty.\n• For women with GDM, with tight versus moderate glycaemic targets there was little to no difference in\neffect on induction of labour (n=1097 women), mean bi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_146",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 146,
    "text": "many outcomes were of very low certainty.\n• For women with GDM, with tight versus moderate glycaemic targets there was little to no difference in\neffect on induction of labour (n=1097 women), mean birthweight (n=1202 babies), large-for-gestational\nage (n=1202 babies), length of maternal antenatal hospitalization (n=1097 women), length of neonatal\nhospitalization (n=1097 babies), and length of postnatal hospitalization (n=1097 women) (high certainty),\nsuggesting a lack of harm.\nIndividualized care\n• The low certainty evidence identified through the review challenges the assumption that stricter\nglycaemic control always leads to better outcomes. In type 1 diabetes, tight control may increase harm\n(hypoglycaemia), highlighting the need for individualized targets that balance safety, benefits"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_147",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 147,
    "text": "r\nglycaemic control always leads to better outcomes. In type 1 diabetes, tight control may increase harm\n(hypoglycaemia), highlighting the need for individualized targets that balance safety, benefits and resource\nuse. In addition, the use of an individualized target allows for consistency in approach and ease of use in\nclinical practice. Other considerations include the woman’s values and preferences, her ability to manage a\nhypoglycaemic event, and her access to health care.\nNew technologies\n• Available technologies for glucose monitoring and control differ between high-income and low-income\nsettings. In all contexts, the training that health-care providers can access will influence the technologies\nthey are able to recommend.\n\nWHO recommendations on care for women with diabetes during p"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_148",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 148,
    "text": "settings. In all contexts, the training that health-care providers can access will influence the technologies\nthey are able to recommend.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nEquity and human rights\n• While the QES found no direct evidence, indirect evidence suggests that if women are required to attend\na clinic to monitor glycaemic targets there may be financial implications that could be challenging for\nwomen with low or limited incomes (low confidence) (16). Health-care providers highlighted the extra costs\nassociated with attendance for additional clinic visits including transportation, childcare and time off\nwork. This was of particular concern for women on low incomes who already required extra clinic visits to"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_149",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 149,
    "text": "with attendance for additional clinic visits including transportation, childcare and time off\nwork. This was of particular concern for women on low incomes who already required extra clinic visits to\nsupport their pregnancy care and/or diabetes management (low confidence).\nAcceptability\n• Evidence from the QES indicates that some women find staying within specific glycaemic targets difficult\nto achieve (hard work) (high confidence) (16). Findings also suggest that some women feel under pressure\nto remain within glycaemic targets and feel criticized or judged by health-care providers when they fail to\ndo so (high confidence). Findings from the same review (16) also show that losing control of their diabetes\nmanagement (as a consequence of pregnancy) can be disconcerting and worrying for wo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_150",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 150,
    "text": "fail to\ndo so (high confidence). Findings from the same review (16) also show that losing control of their diabetes\nmanagement (as a consequence of pregnancy) can be disconcerting and worrying for women, some of\nwhom may require additional psychological or emotional support from health-care providers to address\ntheir concerns (high confidence). Evidence also shows that, while some women with type 1 or type 2\ndiabetes feel reassured by visiting clinics for regular monitoring, others wish to continue to self-manage to\nretain a sense of autonomy (moderate confidence) (16).\n• Women with GDM felt they needed time to adjust to the new routine in order to achieve glycaemic\ntargets and often felt there was insufficient time to do so (33, 36) (high confidence). Findings also show 23\nthat concerns"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_151",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 151,
    "text": "they needed time to adjust to the new routine in order to achieve glycaemic\ntargets and often felt there was insufficient time to do so (33, 36) (high confidence). Findings also show 23\nthat concerns about the wellbeing of their baby was a major stimulus for achieving glycaemic targets and\nresulted in feelings of satisfaction and control when they were able to do so (33, 36, 41) (high confidence).\n• The QES found no direct evidence regarding the acceptability of glycaemic targets from the perspective of\nhealth-care providers.\nFeasibility\n• While the QES found no direct evidence, indirect evidence suggests that some health-care providers may\nrequire additional training to better understand the management of diabetes during pregnancy\n(moderate confidence) (16). Indirect evidence from the sam"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_152",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 152,
    "text": "nce suggests that some health-care providers may\nrequire additional training to better understand the management of diabetes during pregnancy\n(moderate confidence) (16). Indirect evidence from the same review also suggests that some health-care\nproviders found different guidelines and protocols for diabetes management (including screening and\nmonitoring) during pregnancy to be inconsistent, confusing and occasionally outdated (moderate confidence).\n3.1.3 Pharmacological treatment\nType 1 diabetes\nRecommendations\n11 For pregnant women with type 1 diabetes, recommend continuation of the same type of insulin used before pregnancy\nunless a change is considered necessary to optimize blood glucose control and outcomes for the woman and baby.\n12 For pregnant women with type 1 diabetes, recommend c"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_153",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 153,
    "text": "of insulin used before pregnancy\nunless a change is considered necessary to optimize blood glucose control and outcomes for the woman and baby.\n12 For pregnant women with type 1 diabetes, recommend continuation of the method of insulin delivery used before\npregnancy unless a change is considered necessary to optimize blood glucose control and outcomes for the woman\nand baby.\n\nWHO recommendations on care for women with diabetes during pregnancy\nRationale\n• The GDG acknowledged that women with type 1 diabetes will likely be using insulin before becoming\npregnant and considered the optimal approach to optimize blood glucose control and outcomes for the\nwoman and baby.\nRemarks\nChoice of insulin\n• The GDG acknowledged that the systematic review of evidence from randomized trials did not identi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_154",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 154,
    "text": "ach to optimize blood glucose control and outcomes for the\nwoman and baby.\nRemarks\nChoice of insulin\n• The GDG acknowledged that the systematic review of evidence from randomized trials did not identify a\nclear difference in benefits and harms between different types of insulin during pregnancy (see Desirable\nand undesirable effects below). The choice of insulin for pregnant women with type 1 diabetes will be\nbased on the woman’s experiences of insulin before becoming pregnant, her glycaemic control during\npregnancy, and local availability and expertise. When treatments previously used are continued into\npregnancy, it is important to monitor glycaemic control and modify the regimen promptly when it is not\nachieving optimal blood glucose control.\nMethod of insulin delivery\n• The GDG acknowl"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_155",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 155,
    "text": "tinued into\npregnancy, it is important to monitor glycaemic control and modify the regimen promptly when it is not\nachieving optimal blood glucose control.\nMethod of insulin delivery\n• The GDG acknowledged that the availability of different methods for insulin delivery varies across\ncountries and in various contexts and settings (e.g. twice daily injections, multiple daily injections,\ncontinuous subcutaneous insulin infusion, automated insulin delivery systems).\n24\nFrequency of insulin injections\n• Based on physiological evidence, insulin resistance increases during the second and third trimesters of\npregnancy (47). The GDG acknowledged that, although the evidence on the frequency of insulin injections\nin pregnant women with type 1 diabetes is limited, increased frequency of insulin inject"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_156",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 156,
    "text": "ters of\npregnancy (47). The GDG acknowledged that, although the evidence on the frequency of insulin injections\nin pregnant women with type 1 diabetes is limited, increased frequency of insulin injections or continuous\nsubcutaneous insulin infusion may be required. Indirect evidence from the systematic review of evidence\nconducted to inform this guideline suggests improved glycaemic control with four times compared to\ntwice daily injections in women with GDM. Automated insulin delivery systems and/or hybrid closed loop\ntherapy may also be a consideration, as available.\nTiming of insulin\n• The GDG acknowledged that the study included in the systematic review that addressed this question did\nnot provide evidence of a clear difference in benefits and harms between different timings of insulin"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_157",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 157,
    "text": "GDG acknowledged that the study included in the systematic review that addressed this question did\nnot provide evidence of a clear difference in benefits and harms between different timings of insulin during\npregnancy (e.g. before or after meals). Indirect evidence (in non-pregnant type 1 diabetes populations)\nsuggests that insulin before meals is advisable (48).\nAdjunctive metformin\n• Although the GDG prioritized this question, the systematic review identified no randomized trials\ninvestigating the use of adjunctive metformin for women with type 1 diabetes in pregnancy.\nDesirable and undesirable effects of insulin types\n• The systematic review conducted to inform this guideline identified the following comparisons and findings.\nThe GDG acknowledged that changes in the market mean that som"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_158",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 158,
    "text": "ble effects of insulin types\n• The systematic review conducted to inform this guideline identified the following comparisons and findings.\nThe GDG acknowledged that changes in the market mean that some medications may become unavailable\nand that new products may become available and trigger review of the guidelines as evidence emerges.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\n– Compared to regular human insulin, treatment with rapid-acting insulin analogues may reduce the\nrisk of preterm birth (<37 weeks) (absolute risk [AR] 110 fewer per 1000, 95% confidence interval [CI]\nfrom 178 fewer to 3 fewer; one trial, 268 babies; low certainty) and there is no clear indication of other\ndesirable or undesirable effects.\n– Compared"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_159",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 159,
    "text": "110 fewer per 1000, 95% confidence interval [CI]\nfrom 178 fewer to 3 fewer; one trial, 268 babies; low certainty) and there is no clear indication of other\ndesirable or undesirable effects.\n– Compared to neutral protamine Hagedorn (NPH) insulin, treatment with insulin detemir may increase\nthe risk of pre-eclampsia (AR 46 more per 1000, 95% CI from 0 more to 409 more; one trial, 310 women;\nlow certainty) but there is no clear indication of other desirable or undesirable effects.\n– For insulin degludec compared to insulin detemir, there is no clear evidence of desirable or undesirable\neffects (one trial, 188 women).\nDesirable and undesirable effects of methods of insulin delivery\n• There is no clear evidence of desirable or undesirable effects for continuous subcutaneous insulin infusion\ncom"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_160",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 160,
    "text": "ne trial, 188 women).\nDesirable and undesirable effects of methods of insulin delivery\n• There is no clear evidence of desirable or undesirable effects for continuous subcutaneous insulin infusion\ncompared to conventional insulin delivery (multiple daily injections) (five trials, 169 women); insulin before\ncompared to after meals (one crossover trial, nine women); or different settings for sensor-augmented\npumps (one crossover trial, 11 women).\nResources\n• The review of economic evaluations (18) identified a 2009 economic evaluation of an RCT included in the\nsystematic review of effectiveness evidence. The evaluation compared regular human insulin with insulin\naspart in 302 pregnant women with type 1 diabetes and reported that insulin aspart resulted in more 25\nlive births ≥37 weeks withou"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_161",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 161,
    "text": "evidence. The evaluation compared regular human insulin with insulin\naspart in 302 pregnant women with type 1 diabetes and reported that insulin aspart resulted in more 25\nlive births ≥37 weeks without increasing total costs of treatment (49). However, the live birth endpoint\nwas retrospectively applied and the treatment costs of human and insulin aspart were found to be\nidentical because it had been assumed that both preparations were administered via cartridge whereas\nadministration via cartridge for human insulin was not available at the time in the National Health Service\nof the United Kingdom of Great Britain and Northern Ireland.\n• Evidence from surveys suggests that human insulins are more affordable than insulin analogues, with\nprices sourced from the public and private sectors in"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_162",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 162,
    "text": "gdom of Great Britain and Northern Ireland.\n• Evidence from surveys suggests that human insulins are more affordable than insulin analogues, with\nprices sourced from the public and private sectors in surveyed countries typically showing a 3- to 5-fold\ndifference between the lowest and highest reported prices per 1000 international units (50).\nAcceptability\n• Evidence from surveys of women participating in an RCT suggests that insulin aspart is acceptable and\nmay lead to slightly higher treatment satisfaction than regular human insulin because of flexibility with\ntiming of injection before a meal (51).\n• Evidence from the QES suggests that some women find it difficult when health-care providers change their\nmedications (as a consequence of pregnancy) (17).\n\nWHO recommendations on care for w"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_163",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 163,
    "text": "al (51).\n• Evidence from the QES suggests that some women find it difficult when health-care providers change their\nmedications (as a consequence of pregnancy) (17).\n\nWHO recommendations on care for women with diabetes during pregnancy\nType 2 diabetes\nRecommendations\n13 For pregnant women with type 2 diabetes who are unable to maintain optimal blood glucose levels with diet\nand physical activity alone, recommend initiation of metformin or insulin to optimize blood glucose control and\noutcomes for the woman and baby.\n14 For pregnant women with type 2 diabetes who are receiving monotherapy with insulin or metformin and who are\nunable to achieve optimal blood glucose levels, consider initiation of a combination of metformin and insulin to\noptimize blood glucose control and outcomes for the wo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_164",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 164,
    "text": "insulin or metformin and who are\nunable to achieve optimal blood glucose levels, consider initiation of a combination of metformin and insulin to\noptimize blood glucose control and outcomes for the woman and baby.\n15 For pregnant women with type 2 diabetes who are already receiving glucose-lowering medication, recommend that\nmedications with safety concerns during pregnancy be replaced with insulin and/or metformin.\n16 For pregnant women with type 2 diabetes who required insulin to achieve optimal blood glucose levels before\npregnancy, recommend continuation of the same type of insulin unless a change is considered necessary to\noptimize blood glucose control and outcomes for the woman and baby.\nRationale\n• The GDG acknowledged that, while some women with type 2 diabetes may maintain optima"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_165",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 165,
    "text": "a change is considered necessary to\noptimize blood glucose control and outcomes for the woman and baby.\nRationale\n• The GDG acknowledged that, while some women with type 2 diabetes may maintain optimal blood glucose\nlevels with diet and physical activity alone before becoming pregnant, a woman’s insulin requirement\n26 increases during the second and third trimesters of pregnancy (47). In this context, some women may need to\ninitiate a glucose-lowering agent to optimize blood glucose control and outcomes for the woman and baby.\nRemarks\nChoice of glucose-lowering agent\n• The GDG acknowledged that there is no clear difference in benefits and harms between metformin and\ninsulin during pregnancy (see below), and clinical practices and availability of medications are highly\nvariable. The choice"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_166",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 166,
    "text": "t there is no clear difference in benefits and harms between metformin and\ninsulin during pregnancy (see below), and clinical practices and availability of medications are highly\nvariable. The choice of glucose-lowering agent for pregnant women with type 2 diabetes will be based\non the woman’s experiences of medication before becoming pregnant, her glycaemic control during\npregnancy, local availability and expertise, and her values and preferences.\n• The GDG noted that many blood-glucose lowering agents are either not recommended for use in\npregnancy or do not have adequate safety data in pregnancy (e.g. glucagon-like peptide-1 receptor\nagonists [GLP-1RA] and sodium-glucose transport protein 2 [SGLT2] Inhibitors).\nDose of glucose-lowering agent\n• The GDG acknowledged that, although the evi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_167",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 167,
    "text": "nancy (e.g. glucagon-like peptide-1 receptor\nagonists [GLP-1RA] and sodium-glucose transport protein 2 [SGLT2] Inhibitors).\nDose of glucose-lowering agent\n• The GDG acknowledged that, although the evidence on type 2 diabetes during pregnancy is limited,\nincreased monitoring and/or intensity of glycaemic management may be required. Continuous\nsubcutaneous insulin infusion may also be a consideration, as available.\nDesirable and undesirable effects\n• The systematic review conducted to inform this guideline identified the following comparisons and findings.\nThe GDG acknowledged that changes in the market mean that some medications may become unavailable\nand new products may become available and trigger review of the guidelines as evidence emerges.\n\nWHO recommendations on care for women with d"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_168",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 168,
    "text": "e market mean that some medications may become unavailable\nand new products may become available and trigger review of the guidelines as evidence emerges.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\n– For metformin compared to insulin, there is no evidence of desirable or undesirable effects as all\noutcomes were of very low certainty (one trial, 25 women). It should be noted that a significant\nproportion of women initially treated only with metformin will require the addition of insulin later in the\npregnancy to achieve optimal glycaemic control\n– Among women already receiving insulin, there is evidence of probable moderate desirable effects\nwith metformin plus insulin compared to placebo plus insulin – reduced risk of caesa"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_169",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 169,
    "text": "glycaemic control\n– Among women already receiving insulin, there is evidence of probable moderate desirable effects\nwith metformin plus insulin compared to placebo plus insulin – reduced risk of caesarean birth\n(AR 94 fewer per 1000, 95% CI from 169 fewer to 6 fewer; one trial, 470 women; moderate certainty) and\nmacrosomia (AR 71 fewer per 1000, 95% CI from 113 fewer to 6 fewer; one trial, 461 babies; moderate\ncertainty) and a reduction in gestational weight gain (mean difference [MD] 1.8 kg lower, 95% CI 2.7 kg\nlower to 0.9 kg lower; one trial 482 women; moderate certainty) with adjunctive metformin. However,\nthere is also evidence of probable moderate undesirable effects – small-for-gestational age\n(AR 64 more per 1000, 95% CI from 6 more to 168 more; one trial, 460 babies; moderate cert"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_170",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 170,
    "text": "tformin. However,\nthere is also evidence of probable moderate undesirable effects – small-for-gestational age\n(AR 64 more per 1000, 95% CI from 6 more to 168 more; one trial, 460 babies; moderate certainty).\n– There may be small differences in the effects of insulin detemir compared with NPH – a possible\ndesirable effect on reduced gestational weight gain (MD 3.62 kg lower, 95% CI 3.99 kg lower to 3.25 kg\nlower; one trial, 103 women; low certainty) but possible small undesirable effects – lower birthweight\n(MD 450.30 g higher, 95% CI 163.63 g higher to 736.97 g higher; one trial, 103 babies; low certainty).\nAcceptability\n• Evidence from studies included in the systematic review of effectiveness evidence comparing metformin\n27\nwith insulin for the treatment of GDM suggests that treatment sa"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_171",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 171,
    "text": "ow certainty).\nAcceptability\n• Evidence from studies included in the systematic review of effectiveness evidence comparing metformin\n27\nwith insulin for the treatment of GDM suggests that treatment satisfaction is higher with metformin than\nwith insulin (52–54), which may be extrapolated to women with type 2 diabetes.\nAvailability\n• The WHO 2021 report on access to insulin suggests that there are a significant number of markets in\nlower-income countries and in the WHO African Region, WHO South-East Asia Region and WHO Eastern\nMediterranean Region where the availability of insulin does not meet demand (50).\nGestational diabetes\nRecommendations\n17 For women with GDM who are unable to achieve optimal blood glucose levels with diet and physical activity\nalone, recommend initiation of metformin"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_172",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 172,
    "text": "demand (50).\nGestational diabetes\nRecommendations\n17 For women with GDM who are unable to achieve optimal blood glucose levels with diet and physical activity\nalone, recommend initiation of metformin or insulin to optimize blood glucose control and outcomes for the\nwoman and baby.\n18 For women with GDM who are receiving monotherapy with metformin or insulin and are unable to achieve optimal\nblood glucose levels, consider initiation of a combination of metformin and insulin to optimize blood glucose\ncontrol and outcomes for the woman and baby.\nRationale\n• The GDG acknowledged that, while some women with GDM may maintain optimal blood glucose levels\nwith diet and physical activity alone, other women may need to initiate a glucose-lowering agent to\noptimize blood glucose control and outcomes"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_173",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 173,
    "text": "women with GDM may maintain optimal blood glucose levels\nwith diet and physical activity alone, other women may need to initiate a glucose-lowering agent to\noptimize blood glucose control and outcomes for the woman and baby.\n\nWHO recommendations on care for women with diabetes during pregnancy\nRemarks\nCommencement of pharmacotherapy\n• The GDG acknowledged that a two-week trial of diet and physical activity to achieve glycaemic control is\ntypically conducted before considering commencement of blood glucose-lowering medication for GDM.\nThe trials comparing different pharmacological agents included in the systematic review used a range\nof lengths of diet/activity (when described this ranged from 3 to 28 days, most commonly seven days).\nHowever, in some settings and for some clinical presentat"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_174",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 174,
    "text": "ed in the systematic review used a range\nof lengths of diet/activity (when described this ranged from 3 to 28 days, most commonly seven days).\nHowever, in some settings and for some clinical presentations (e.g. based on level of glycaemic control or\nmaternal/fetal concerns), medication may be commenced without a trial of diet/activity.\nTrigger for treatment initiation or change\n• In the trials comparing different pharmacological agents included in the systematic review, thresholds\nused for insulin initiation, treatment agent switch and dose escalation were poorly and inconsistently\nreported. In most studies, the trigger for FPG was 5.0 to 5.5 mmol/L (90 to 100 mg/dL), with some using\nstricter (3.4 to 5.0 mmol/L [60 to 90 mg/dL]) or looser (<6.1 mmol/L [<110 mg/dL]) targets. One-hour\npostpr"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_175",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 175,
    "text": "n most studies, the trigger for FPG was 5.0 to 5.5 mmol/L (90 to 100 mg/dL), with some using\nstricter (3.4 to 5.0 mmol/L [60 to 90 mg/dL]) or looser (<6.1 mmol/L [<110 mg/dL]) targets. One-hour\npostprandial targets ranged from <6.5 to <9.0 mmol/L (<117 to <162 mg/dL) and most studies used a two-\nhour postprandial target of <6.7 mmol/L (120 mg/dL), ranging between <5.6 and <7.8 mmol/L (<100 mg/dL\nand <140 mg/dL).\n• In clinical practice, a flexible approach may be appropriate and triggers for treatment initiation or change\nwill likely be based on a woman’s blood glucose control and clinical criteria that reflect local realities\n28\n(e.g. food insecurity, challenges in monitoring or follow-up), aiming to balance safety and feasibility.\nChoice of glucose-lowering agent\n• The GDG acknowledged th"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_176",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 176,
    "text": "eria that reflect local realities\n28\n(e.g. food insecurity, challenges in monitoring or follow-up), aiming to balance safety and feasibility.\nChoice of glucose-lowering agent\n• The GDG acknowledged that although there is some indication of possible benefits of commencing with\nmetformin, overall the evidence does not strongly support metformin over insulin as a first-line medicine.\nMany women who begin pharmacotherapy with metformin will go on to need insulin. Clinical practices\nand the availability of medications are highly variable. The choice of glucose-lowering agent for women\nwith GDM will be based on the woman’s glycaemic control, local availability and expertise, and her values\nand preferences.\n• Many blood-glucose lowering agents are either not recommended for use in pregnancy or do"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_177",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 177,
    "text": "be based on the woman’s glycaemic control, local availability and expertise, and her values\nand preferences.\n• Many blood-glucose lowering agents are either not recommended for use in pregnancy or do not have\nadequate safety data in pregnancy (e.g. GLP-1Ras and SGLT2 inhibitors). However, the GDG acknowledged\nthat there may be situations where a blood-glucose lowering agent other than insulin or metformin needs\nto be considered (e.g. when a woman refuses insulin and metformin is not tolerated or is ineffective in\nachieving the woman’s glycaemic control). In these circumstances other agents, such as a sulfonylurea,\nmay be considered after discussion of potential benefits and harms.\nDosage of glucose-lowering agent\n• Titration of medications for glycaemic control is individualized and guide"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_178",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 178,
    "text": "uch as a sulfonylurea,\nmay be considered after discussion of potential benefits and harms.\nDosage of glucose-lowering agent\n• Titration of medications for glycaemic control is individualized and guided by regular blood glucose monitoring.\nStopping treatment with glucose-lowering agents\n• The GDG acknowledged that usual clinical practice is to stop treatment with glucose-lowering agents soon\nafter the birth of the baby. Due to the increased risk of type 2 diabetes in women who have experienced\nGDM (7), follow-up assessment of glucose tolerance is essential 6 to 12 weeks postnatally.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nDesirable and undesirable effects\n• The systematic review conducted to inform this guideline identifi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_179",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 179,
    "text": "endations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nDesirable and undesirable effects\n• The systematic review conducted to inform this guideline identified the following comparisons and findings.\nThe GDG acknowledged that changes in the market mean that some medications may become unavailable\nand new products may become available and trigger review of the guidelines as evidence emerges.\nComparisons with placebo or no agent\n– When metformin is compared to placebo, there is evidence of moderate desirable effects – lower rates of\nneed for initiation of insulin (AR 108 fewer per 1000, 95% CI from 164 fewer to 39 fewer; two trials,\n622 women; high certainty) and large-for-gestational age (AR 84 fewer, 95% CI from 112 fewer to 37 fewer;\none trial, 5"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_180",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 180,
    "text": "of insulin (AR 108 fewer per 1000, 95% CI from 164 fewer to 39 fewer; two trials,\n622 women; high certainty) and large-for-gestational age (AR 84 fewer, 95% CI from 112 fewer to 37 fewer;\none trial, 522 babies; high certainty) and a slight reduction in gestational weight gain (MD 1.13 kg lower,\n95% CI 1.63 kg lower to 0.64 kg lower; three trials, 705 women; high certainty) and birthweight (MD 137.58 g\nlower, 95% CI 207.23 g lower to 67.92 lower; three trials, 705 babies; high certainty). There is also evidence of\nsmall undesirable effects – an increase in low birthweight (AR 42 more per 1000, 95% CI from 2 more to\n115 more; two trials, 628 babies; high certainty) – affecting a small proportion of those exposed (<5%).\n– When other glucose-lowering agents are compared to placebo, there is no"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_181",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 181,
    "text": "95% CI from 2 more to\n115 more; two trials, 628 babies; high certainty) – affecting a small proportion of those exposed (<5%).\n– When other glucose-lowering agents are compared to placebo, there is no clear indication of desirable\nor undesirable effects for glibenclamide (one trial, 395 women), and effects were not estimable or\nwere assessed to be of very low certainty for sitagliptin (one trial, 263 women). Three small trials\n(151 women), all of which took place before 1991, compared treatment with insulin versus no insulin\namong women with GDM. Diet and exercise interventions varied between groups. The trials did not\nprovide a clear indication of desirable or undesirable effects for insulin versus no insulin. Most reported 29\noutcomes were not estimable or were assessed to be very low ce"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_182",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 182,
    "text": "groups. The trials did not\nprovide a clear indication of desirable or undesirable effects for insulin versus no insulin. Most reported 29\noutcomes were not estimable or were assessed to be very low certainty.\nComparisons of oral glucose-lowering agents and insulin\n– When metformin is compared to insulin as a first-line medication, there is evidence of probable or\npossible moderate desirable effects – induction of labour (AR 78 fewer per 1000, 95% CI from 131 fewer\nto 10 fewer; seven trials, 1703 women; moderate certainty); maternal hypoglycaemia (AR 147 fewer per\n1000, 95% CI from 191 fewer to 75 fewer; four trials, 702 women; low certainty); admission to neonatal\nintensive care (AR 50 fewer per 1000, 95% CI from 80 fewer to 14 fewer; 16 trials, 3184 babies;\nmoderate certainty); macrosomia"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_183",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 183,
    "text": "75 fewer; four trials, 702 women; low certainty); admission to neonatal\nintensive care (AR 50 fewer per 1000, 95% CI from 80 fewer to 14 fewer; 16 trials, 3184 babies;\nmoderate certainty); macrosomia (AR 44 fewer per 1000, 95% CI from 65 fewer to 17 fewer; 14 trials,\n2728 babies; low certainty), shoulder dystocia (AR 16 fewer per 1000, 95% CI from 23 fewer to 0 fewer;\nfive trials, 1290 babies; low certainty), neonatal hypoglycaemia (AR 97 fewer per 1000, 95% CI from\n121 fewer to 69 fewer; 19 trials, 4104 babies; low certainty) and respiratory distress syndrome\n(AR 19 fewer per 1000, 95% CI from 32 fewer to 1 fewer; 10 trials, 2288 babies; low certainty). There is\nno clear indication of undesirable effects. The GDG acknowledged, however, that many women on\nmetformin will progress to requir"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_184",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 184,
    "text": "om 32 fewer to 1 fewer; 10 trials, 2288 babies; low certainty). There is\nno clear indication of undesirable effects. The GDG acknowledged, however, that many women on\nmetformin will progress to requiring insulin to maintain or achieve glycaemic control.\n– For glibenclamide compared to insulin, there is no clear indication of desirable effects, and evidence\nof probable moderate undesirable effects – maternal hypoglycaemia (AR 24 more per 1000, 95% CI\nfrom 3 more to 88 more; three trials, 988 women; moderate certainty) and neonatal hypoglycaemia\n(AR 28 more per 1000, 95% CI from 4 more to 62 more; nine trials, 1967 babies; moderate certainty)\naffecting a small proportion of those exposed (<3% for both outcomes).\n– There is no clear indication of desirable or undesirable effects for acarbose"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_185",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 185,
    "text": "e; nine trials, 1967 babies; moderate certainty)\naffecting a small proportion of those exposed (<3% for both outcomes).\n– There is no clear indication of desirable or undesirable effects for acarbose versus insulin (most\noutcomes very low certainty) (two trials, 150 women).\n\nWHO recommendations on care for women with diabetes during pregnancy\nComparisons of one oral glucose-lowering agent with another\n– For metformin versus glibenclamide, there is evidence of possible moderate desirable effects – lower\ngestational weight gain (mean 7.78 kg versus 9.84 kg; MD 2.06 kg lower, 95% CI 3.98 kg lower to 0.14 kg\nlower; one trial, 200 women; low certainty) and reduced risk of large-for-gestational age (AR 111 fewer\nper 1000, 95% CI from 156 fewer to 16 fewer; one trial, 200 babies; low certainty) f"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_186",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 186,
    "text": "to 0.14 kg\nlower; one trial, 200 women; low certainty) and reduced risk of large-for-gestational age (AR 111 fewer\nper 1000, 95% CI from 156 fewer to 16 fewer; one trial, 200 babies; low certainty) for >10% of exposed\npopulation, and no clear indication of undesirable effects. There is no clear indication of desirable or\nundesirable effects for glibenclamide versus acarbose (one trial, 43 women).\nComparisons of protocols\n– When glibenclamide is compared to insulin as a second-line treatment to metformin, there is no clear\nindication of desirable effects and evidence of possible moderate undesirable effects – increase in\nbirthweight (mean 3706 g versus 3262 g; MD 444 g higher, 95% CI 16.62 higher to 871.38 higher; one\ntrial, 23 babies; low certainty). There is no clear indication of desira"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_187",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 187,
    "text": "irable effects – increase in\nbirthweight (mean 3706 g versus 3262 g; MD 444 g higher, 95% CI 16.62 higher to 871.38 higher; one\ntrial, 23 babies; low certainty). There is no clear indication of desirable or undesirable effects when\nglibenclamide (first line), metformin (second line), insulin (third line) is compared to metformin\n(first line), glibenclamide (second line), insulin (third line) (one trial, 108 women).\nComparisons of types of insulin\n– There is no clear indication of desirable or undesirable effects for premixed insulin analogue versus\npremixed human insulin (one trial, 323 women), rapid-acting insulin analogue versus regular human\ninsulin (five trials, 330 women), or intermediate-acting human insulin versus regular human insulin\n30\n(one trial, 23 women).\nComparison of frequen"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_188",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 188,
    "text": ", rapid-acting insulin analogue versus regular human\ninsulin (five trials, 330 women), or intermediate-acting human insulin versus regular human insulin\n30\n(one trial, 23 women).\nComparison of frequency of insulin\n– When twice daily insulin is compared with insulin four times daily, there is evidence of possible\nmoderate undesirable effects – neonatal hypoglycaemia (AR 500 more per 1000, 95% CI from 282 more\nto 855 more; one trial, 480 babies; low certainty) and hyperbilirubinaemia (AR 400 more per 1000,\n95% CI from 252 more to 602 more; one trial 480 babies; low certainty). The systematic review analysis\nfound a possible reduction in maternal hypoglycaemia in the twice daily compared to the four times\ndaily group (AR 296 fewer per 1000, 95% CI from 332 fewer to 250 fewer; two trials, 754"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_189",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 189,
    "text": "iew analysis\nfound a possible reduction in maternal hypoglycaemia in the twice daily compared to the four times\ndaily group (AR 296 fewer per 1000, 95% CI from 332 fewer to 250 fewer; two trials, 754 women;\nlow certainty). However, when the GDG requested further information, the systematic review team\nprovided data that showed that ‘glycaemic control’ (an outcome not prioritized for the review) was\nimproved in the four times daily group in both trials reporting the comparison.\nAcceptability\n• Evidence from studies included in the systematic review of effectiveness evidence comparing metformin\nwith insulin for the treatment of GDM suggests that treatment satisfaction is higher with metformin than\nwith insulin (52–54).\nLimitations of the evidence\n• The GDG acknowledged that the available evi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_190",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 190,
    "text": "with insulin for the treatment of GDM suggests that treatment satisfaction is higher with metformin than\nwith insulin (52–54).\nLimitations of the evidence\n• The GDG acknowledged that the available evidence on pharmacotherapy for women with GDM is highly\nheterogeneous. Gestational age at trial commencement and the length of any initial trial of diet and/or\nexercise is variable, it is often unclear how many women received insulin in addition to the agent being\ntrialled, and reporting of outcomes for women receiving ‘rescue’ insulin is poor.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\n3.1.4 Additional monitoring\nAdditional fetal monitoring\nRecommendations\n19 For pregnant women with type 1, type 2 or gestational diabetes, perfor"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_191",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 191,
    "text": "ring pregnancy Recommendations and supporting evidence\n3.1.4 Additional monitoring\nAdditional fetal monitoring\nRecommendations\n19 For pregnant women with type 1, type 2 or gestational diabetes, perform a routine ultrasound scan before 24 weeks.\n20 For pregnant women with type 1 or type 2 diabetes, consider performing the routine ultrasound scan as early as\npossible in pregnancy with a follow-up ultrasound to assess fetal anatomy and growth in the second trimester.\n21 For pregnant women with type 1, type 2 or gestational diabetes, consider additional ultrasound growth scans after\n24 weeks, as indicated.\n22 For pregnant women with type 1, type 2 or gestational diabetes requiring blood glucose-lowering medication,\nconsider additional monitoring of fetal wellbeing, as indicated.\nRationale\n• Mo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_192",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 192,
    "text": "ndicated.\n22 For pregnant women with type 1, type 2 or gestational diabetes requiring blood glucose-lowering medication,\nconsider additional monitoring of fetal wellbeing, as indicated.\nRationale\n• Monitoring to assess growth and wellbeing of the developing baby is a routine part of antenatal care,\nparticularly in high-income countries. WHO recommends ultrasound before 24 weeks to estimate\ngestational age, improve detection of fetal anomalies and multiple pregnancies, reduce induction of\nlabour for post-term pregnancy, and improve a woman’s pregnancy experience (10). It also recommends\nthat healthy pregnant women be made aware of the importance of fetal movements in the third trimester 31\nand of reporting reduced fetal movements, and that clinical enquiry about maternal perception of fetal"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_193",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 193,
    "text": "althy pregnant women be made aware of the importance of fetal movements in the third trimester 31\nand of reporting reduced fetal movements, and that clinical enquiry about maternal perception of fetal\nmovements occur at each antenatal care visit as part of good clinical practice (10).\n• Given the potential for congenital anomalies and other adverse perinatal outcomes among women with\ndiabetes of any type during pregnancy, the GDG considered that earlier and additional fetal monitoring is\noptimal.\nRemarks\n• There is little empirical evidence on fetal monitoring for pregnant women with type 1, type 2, or GDM. The\nGDG considered an approach that is woman-centred, based on the ethical principle of autonomy including\nthe importance of informed decision making, and physiological evidence on how"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_194",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 194,
    "text": "ype 2, or GDM. The\nGDG considered an approach that is woman-centred, based on the ethical principle of autonomy including\nthe importance of informed decision making, and physiological evidence on how diabetes might impact\npregnancy outcomes. In pregnant women with diabetes, the GDG acknowledged that antenatal fetal\nmonitoring may help to inform the timing of childbirth.\nBenefits and harms\n• Based on limited evidence identified through the systematic review conducted to inform this guideline,\nthere was no suggestion of benefits or harms with increased frequency of ultrasound scans (scans at\n28 and 32 weeks compared to at 32 weeks only) in women with GDM (n=154 women). There was also no\nevidence of benefit or harm with computerized compared to visual interpretation of the nonstress test in\nw"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_195",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 195,
    "text": "and 32 weeks compared to at 32 weeks only) in women with GDM (n=154 women). There was also no\nevidence of benefit or harm with computerized compared to visual interpretation of the nonstress test in\nwomen with unspecified diabetes and an indication for fetal heart assessment (n=85 women), although\nthe lack of benefit or harm is not established as the limited outcomes reported were of very low certainty.\nFor ultrasound growth scan compared to no ultrasound growth scan among women with ‘pregestational\nand gestational diabetes’, there was a probable reduction in small-for-gestational age (n=304 babies)\n\nWHO recommendations on care for women with diabetes during pregnancy\n(moderate certainty), a probable increase in risk of caesarean section (n=3994 women) (moderate certainty)\nand a possible i"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_196",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 196,
    "text": "abies)\n\nWHO recommendations on care for women with diabetes during pregnancy\n(moderate certainty), a probable increase in risk of caesarean section (n=3994 women) (moderate certainty)\nand a possible increase in risk of induction of labour (n=304 women) (low certainty).\nIndications for additional ultrasound scans after 24 weeks\n• Additional ultrasound scans after 24 weeks aim to identify growth restriction and accelerated growth\nand help in planning for the birth. Their use may be indicated when restricted or accelerated growth is\nsuggested by fundal height measurement or in the context of complicated diabetes (i.e. insulin treated or\nwhen glycaemic control is poor) and will likely be based on availability of resources.\n• Modelling to estimate the effect of the interval between examinations"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_197",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 197,
    "text": "licated diabetes (i.e. insulin treated or\nwhen glycaemic control is poor) and will likely be based on availability of resources.\n• Modelling to estimate the effect of the interval between examinations on fetal growth in the general\npregnant population suggests that taking measurements at least three weeks apart may minimize\nfalse positive rates (55). False positive rates were higher when the first scan was performed at 36 weeks\n(compared to first scan at 32 weeks) (55).\nWomen’s values\n• Evidence from the 2016 WHO recommendations on antenatal care for a positive pregnancy experience\n(10) showed that within the context of maternal and fetal assessment, women valued the opportunity to\nreceive screening and tests to optimize their health and that of their developing baby as long as individual"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_198",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 198,
    "text": "that within the context of maternal and fetal assessment, women valued the opportunity to\nreceive screening and tests to optimize their health and that of their developing baby as long as individual\nprocedures were explained to them clearly and administered by knowledgeable, supportive and respectful\nhealth-care providers (high confidence).\n32\nEquity and human rights\n• Indirect evidence from the QES suggests that additional fetal monitoring may have financial implications\nfor some women with low or limited incomes (low confidence) (16). Health-care providers highlighted the\nextra costs associated with attendance for additional clinic visits including transportation, childcare and\ntime off work. This was of particular concern for women on low incomes who may already require extra\nclinic vi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_199",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 199,
    "text": "ated with attendance for additional clinic visits including transportation, childcare and\ntime off work. This was of particular concern for women on low incomes who may already require extra\nclinic visits to support their antenatal care and/or diabetic management (low confidence).\nAcceptability\n• Evidence from the QES suggests that some women with type 1 and type 2 diabetes found additional fetal\nmonitoring to be beneficial and reassuring (low confidence) (17). Some women also indicated they would\nlike more ultrasounds during the antenatal phase to curb feelings of anxiety (low confidence). However,\nevidence also suggests that some women may find it difficult to attend extra clinic visits because of work,\nfamily or financial considerations (low confidence) (17).\n• For women with GDM, indir"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_200",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 200,
    "text": "wever,\nevidence also suggests that some women may find it difficult to attend extra clinic visits because of work,\nfamily or financial considerations (low confidence) (17).\n• For women with GDM, indirect evidence suggests that women with GDM may struggle to attend extra clinic\nvisits because of work, family or financial considerations (40).\nFeasibility\n• Indirect evidence from the QES suggests that some health systems may struggle to cope with enhanced\nservices for pregnant women with diabetes given the extra demands (staff and equipment) required to\nsupport these services in already overstretched health systems (high confidence) (16).\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nRetinopathy screening and care\nRecommendations"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_201",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 201,
    "text": "ched health systems (high confidence) (16).\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nRetinopathy screening and care\nRecommendations\n23 For pregnant women with type 1 or type 2 diabetes, screen for retinopathy when antenatal care is initiated and\nprovide follow-up based on the risk of retinopathy progressing.\n24 For women with gestational diabetes, do not routinely screen for retinopathy.\nRationale\n• Maintaining strict glycaemic control plays a vital role in reducing the risk of developing and worsening diabetic\nretinopathy. Persistent hyperglycaemia damages the small blood vessels of the retina, contributing to both\nnon-proliferative and proliferative stages of diabetic retinopathy. Research indicates that not only averag"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_202",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 202,
    "text": "ersistent hyperglycaemia damages the small blood vessels of the retina, contributing to both\nnon-proliferative and proliferative stages of diabetic retinopathy. Research indicates that not only average\nglucose levels but also fluctuations in blood glucose significantly influence the progression of diabetic\nretinopathy (56). Additionally, higher HbA1c levels correlate with increased retinopathy severity, although\ndifferences in disease progression are observed even among individuals with similar HbA1c readings (57).\nRecent studies further emphasize that initiating and maintaining good glycaemic control early can effectively\ndelay the onset of diabetic macular oedema and the transition to proliferative disease stages (58).\n• In the light of a lack of empirical evidence on screening for retin"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_203",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 203,
    "text": "control early can effectively\ndelay the onset of diabetic macular oedema and the transition to proliferative disease stages (58).\n• In the light of a lack of empirical evidence on screening for retinopathy, the GDG based its\nrecommendations on the increased risk of retinopathy and its consequences associated with type 1 or\ntype 2 diabetes (59), and a lack of risk for retinopathy in women with GDM. 33\nRemarks\nFollow-up after screening\n• The GDG acknowledged that in some settings, it is common to re-screen pregnant women with type 1 or\ntype 2 diabetes later in pregnancy but there is no standard timeframe for repeat screening. The GDG also\nacknowledged, that this practice may not be feasible or available in all settings.\nRoutine screening\n• While Recommendation 24 advises against routinely r"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_204",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 204,
    "text": "timeframe for repeat screening. The GDG also\nacknowledged, that this practice may not be feasible or available in all settings.\nRoutine screening\n• While Recommendation 24 advises against routinely recommending retinopathy screening for women with\nGDM, this does not preclude its use in clinical contexts where its use would potentially improve outcomes\nfor the individual woman.\nEquity and human rights\n• Indirect evidence from the QES suggests that enhanced retinopathy care may have financial implications\nfor some women with low or limited incomes (low confidence) (16). Health-care providers highlighted the\nextra costs associated with attendance for additional clinic visits including transportation, childcare and\ntime off work. This was of particular concern for women on low incomes who alr"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_205",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 205,
    "text": "ghlighted the\nextra costs associated with attendance for additional clinic visits including transportation, childcare and\ntime off work. This was of particular concern for women on low incomes who already required extra clinic\nvisits to support their antenatal care and/or diabetes management (low confidence).\nAcceptability\n• Indirect evidence from the QES suggests that some women find additional diabetes screening and\nmonitoring services to be beneficial and reassuring (low confidence) (17). However, some women may find\nit difficult to attend extra clinic visits because of work, family or financial considerations (low confidence).\n\nWHO recommendations on care for women with diabetes during pregnancy\n• Indirect evidence highlights the importance of teamwork, especially for women receiving a"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_206",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 206,
    "text": "ncial considerations (low confidence).\n\nWHO recommendations on care for women with diabetes during pregnancy\n• Indirect evidence highlights the importance of teamwork, especially for women receiving additional (or\nenhanced) services (16). Some health-care providers felt there were gaps in the system caused by poor\ncommunication between different disciplines and/or departments and stressed the importance of ‘joined\nup’ care and efficient, multidisciplinary teamworking (moderate confidence).\nFeasibility\n• Indirect evidence from the QES suggests that some health systems may struggle to cope with enhanced\nservices for pregnant diabetic women given the extra demands (in terms of resources, staff training and\nequipment) required to support these services in already overstretched health systems ("
  },
  {
    "id": "diabetes  of woman.pdf::chunk_207",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 207,
    "text": "enhanced\nservices for pregnant diabetic women given the extra demands (in terms of resources, staff training and\nequipment) required to support these services in already overstretched health systems (high confidence) (16).\nRenal assessment\nRecommendations\n25 For pregnant women with type 1 or type 2 diabetes, assess renal function when antenatal care is initiated and\narrange specialist follow-up for women if impaired renal function is identified.\n26 For women with GDM, do not routinely assess renal function.\n27 For pregnant women with type 1 or type 2 diabetes with impaired renal function, emphasize the importance of\nmaintaining blood pressure levels below 130/80 mmHg during pregnancy and offer antihypertensives known to be\nsafe in pregnancy as indicated. Advise women to modify major risk f"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_208",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 208,
    "text": "asize the importance of\nmaintaining blood pressure levels below 130/80 mmHg during pregnancy and offer antihypertensives known to be\nsafe in pregnancy as indicated. Advise women to modify major risk factors for cardiovascular disease (e.g. smoking,\n34\nunhealthy diet, sedentary behaviour) and to seek specialist postnatal follow-up.\nRationale\n• Diabetic nephropathy is the most common cause of chronic kidney disease and end-stage renal disease\nworldwide. It arises as a microvascular complication of chronic hyperglycaemia, leading to structural\ndamage within the glomeruli and progressive loss of kidney function (60). The early stages of diabetic\nnephropathy, characterized by microalbuminuria, signal systemic endothelial dysfunction and serve as\na critical marker of poor metabolic control. Impo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_209",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 209,
    "text": "idney function (60). The early stages of diabetic\nnephropathy, characterized by microalbuminuria, signal systemic endothelial dysfunction and serve as\na critical marker of poor metabolic control. Importantly, the progression of renal disease often mirrors\nthe overall status of diabetes management – individuals with worsening nephropathy typically exhibit\npersistent hyperglycaemia, hypertension and dyslipidaemia (61).\n• Laboratory assessment for renal function during pregnancy includes measurement of serum creatinine\nand protein in urine. Tests for proteinuria include spot albumin, protein/creatinine ratio, and 24-hour urine\ncollection for albumin/protein. While estimated glomerular filtration rate (eGFR) is used in assessing renal\nfunction outside of pregnancy, its accuracy is reduced duri"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_210",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 210,
    "text": "tinine ratio, and 24-hour urine\ncollection for albumin/protein. While estimated glomerular filtration rate (eGFR) is used in assessing renal\nfunction outside of pregnancy, its accuracy is reduced during pregnancy (62, 63). The GDG acknowledged\nthat the different tests may not be available in all settings.\n• Early and aggressive interventions targeting hyperglycaemia, blood pressure control, and renin-\nangiotensin-aldosterone system inhibition are now the foundation of management (64).\n• In the light of a lack of empirical evidence on renal assessment for women with diabetes, the GDG based\nits recommendations on the increased risk of impaired renal function associated with type 1 and type 2\ndiabetes, and a lack of risk for impaired renal function in women with GDM.\n\nWHO recommendations on c"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_211",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 211,
    "text": "recommendations on the increased risk of impaired renal function associated with type 1 and type 2\ndiabetes, and a lack of risk for impaired renal function in women with GDM.\n\nWHO recommendations on care for women with diabetes during pregnancy Recommendations and supporting evidence\nRemarks\nAssessing pre-eclampsia risk\n• The urinary albumin/creatinine ratio or protein/creatinine ratio early in pregnancy may be used as a\nbaseline when evaluating the risk of pre-eclampsia later in pregnancy.\nRoutine assessment\n• While Recommendation 26 advises against routine renal assessment for women with GDM, this does not\npreclude its use in clinical contexts where its use would potentially improve outcomes, such as providing a\nbaseline for comparison later in pregnancy during an evaluation for pre-ecla"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_212",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 212,
    "text": ", this does not\npreclude its use in clinical contexts where its use would potentially improve outcomes, such as providing a\nbaseline for comparison later in pregnancy during an evaluation for pre-eclampsia.\nBlood pressure management\n• Recommendation 27 has been adapted from advice for the management of type 2 diabetes, using\nmedications that are used for blood pressure management during pregnancy. The WHO guideline on\nthe treatment of non-severe hypertension in pregnancy suggests consideration of oral alpha-agonist\n(methyldopa) and beta-blockers as effective treatment options (65).\nEquity and human rights\n• Indirect evidence from the QES suggests that renal assessment at initiation of antenatal care may have\nfinancial implications for some women with low or limited incomes (low confidence)"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_213",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 213,
    "text": "human rights\n• Indirect evidence from the QES suggests that renal assessment at initiation of antenatal care may have\nfinancial implications for some women with low or limited incomes (low confidence) (16). Health-care\nproviders highlighted the extra costs associated with attendance for additional clinic visits including\n35\ntransportation, childcare and time off work. This was of particular concern for women on low incomes\nwho already required extra clinic visits to support their antenatal care and/or diabetes management\n(low confidence).\nAcceptability\n• Indirect evidence from the QES suggests that some women with type 1 or type 2 diabetes find additional\nassessment and monitoring services to be beneficial and reassuring (low confidence) (17). However,\nindirect evidence from this review al"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_214",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 214,
    "text": "that some women with type 1 or type 2 diabetes find additional\nassessment and monitoring services to be beneficial and reassuring (low confidence) (17). However,\nindirect evidence from this review also suggests that some women find it difficult to attend extra clinic\nvisits because of work, family or financial considerations (low confidence)\n• Indirect evidence highlights the importance of teamwork, especially for women receiving additional (or\nenhanced) services (16). Some health-care providers felt there were gaps in the system caused by poor\ncommunication between different disciplines and/or departments and stressed the importance of ‘joined\nup’ care and efficient, multidisciplinary teamworking (moderate confidence).\nFeasibility\n• Indirect evidence from the QES suggests that some healt"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_215",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 215,
    "text": "or departments and stressed the importance of ‘joined\nup’ care and efficient, multidisciplinary teamworking (moderate confidence).\nFeasibility\n• Indirect evidence from the QES suggests that some health systems may struggle to cope with enhanced\nservices for pregnant women with diabetes given the extra demands (in terms of resources, staff training\nand equipment) required to support these services in already overstretched health systems (high\nconfidence) (16).\n\nDissemination and\n4\nimplementation\nof the guideline\nThe dissemination and implementation of this guideline is to be considered by all stakeholders involved in\nthe provision of care for pregnant women at the international, national and local levels. There is a vital need\nto increase women’s access to maternal health care and strengthe"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_216",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 216,
    "text": "takeholders involved in\nthe provision of care for pregnant women at the international, national and local levels. There is a vital need\nto increase women’s access to maternal health care and strengthen the capacity at health-care facilities of\nall levels to ensure they can provide high-quality services to all women giving birth. It is therefore crucial that\nthe guideline recommendations be translated into care packages and programmes at country and health-\ncare facility levels, where appropriate. In particular, the recommendations will need to be incorporated into\nexisting programmes and policies on the management of diabetes in pregnancy and childbirth. The guideline\n36\nmay also inform the care of women with diabetes who are planning a pregnancy.\n4.1 Dissemination and evaluation\nDissemina"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_217",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 217,
    "text": "ies on the management of diabetes in pregnancy and childbirth. The guideline\n36\nmay also inform the care of women with diabetes who are planning a pregnancy.\n4.1 Dissemination and evaluation\nDissemination of an executive summary containing the recommendations, remarks, implementation\nconsiderations and research priorities will increase public awareness of the recommendations. Derivative\ntools developed by the WHO Steering Group will also aid understanding and adaptation of these\nrecommendations to local contexts.\nThe recommendations and derivative tools will be disseminated through WHO regional and country offices,\nministries of health, professional organizations, WHO collaborating centres, other United Nations agencies\nand nongovernmental organizations, among others. The recommendations w"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_218",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 218,
    "text": "l and country offices,\nministries of health, professional organizations, WHO collaborating centres, other United Nations agencies\nand nongovernmental organizations, among others. The recommendations will be published on the\nWHO website and promoted in the quarterly HRP News disseminated to over 8000 subscribers, including\nclinicians, health programme managers, policy-makers, researchers and service users working in sexual and\nreproductive health from all around the world. The recommendations will also be promoted in the monthly\nglobal diabetes compact newsletter disseminated to 3000 stakeholders, shared with the Global Diabetes\nCompact Forum, established by WHO to foster advocacy, collaboration, and the sharing of ideas to reduce\ndiabetes risk and improve care for people with the condition"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_219",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 219,
    "text": "rs, shared with the Global Diabetes\nCompact Forum, established by WHO to foster advocacy, collaboration, and the sharing of ideas to reduce\ndiabetes risk and improve care for people with the condition (150 stakeholders) and be highlighted on World\nDiabetes Day.\nThe executive summary and recommendations from this publication will be translated into the six official\nUnited Nations languages for dissemination through the WHO regional and country offices and during\nmeetings and scientific conferences organized by, or attended by, staff of the WHO Department of Sexual and\n\nDissemination and implementation of the guideline\nReproductive Health and Research, the Department of Maternal, Newborn, Child and Adolescent Health and\nthe Department of Noncommunicable Diseases and Mental Health. Technical"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_220",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 220,
    "text": "ntation of the guideline\nReproductive Health and Research, the Department of Maternal, Newborn, Child and Adolescent Health and\nthe Department of Noncommunicable Diseases and Mental Health. Technical assistance will be provided to\nany WHO regional office willing to translate these recommendations into any language used in that region.\nIn addition, the publication of journal articles presenting the recommendations and key implementation\nconsiderations will be considered in compliance with WHO’s open access and copyright policies. Relevant\nWHO clusters, departments and partnerships, such as the Partnership for Maternal, Newborn and Child\nHealth, the Global Diabetes Compact Forum, and the Technical Advisory Group for Diabetes will also be part\nof this dissemination process.\nTo ensure that the"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_221",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 221,
    "text": "Partnership for Maternal, Newborn and Child\nHealth, the Global Diabetes Compact Forum, and the Technical Advisory Group for Diabetes will also be part\nof this dissemination process.\nTo ensure that these recommendations have a positive impact on maternal and perinatal health at the country\nlevel, coordinated action between international agencies, national departments of health and key maternal\nand perinatal health stakeholders is needed. National and subnational working groups should assess current\nnational guidelines and protocols and determine whether development of new guidelines or updating of existing\nguidelines is required in line with these new WHO recommendations. WHO staff at the headquarters, regional\nand country levels, as well as international agency partners and international p"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_222",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 222,
    "text": "of existing\nguidelines is required in line with these new WHO recommendations. WHO staff at the headquarters, regional\nand country levels, as well as international agency partners and international professional societies (such as the\nInternational Federation of Gynaecology and Obstetrics and the International Confederation of Midwives), and\nnational professional associations, can support national stakeholders in developing or revising existing national\nguidelines or protocols, and optimizing their implementation.\nIn the context of humanitarian emergencies, the adaptation of the current recommendations should consider\n37\ntheir integration and alignment with other response strategies. Additional consideration of the unique needs\nof women in emergency settings, including women’s values and p"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_223",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 223,
    "text": "endations should consider\n37\ntheir integration and alignment with other response strategies. Additional consideration of the unique needs\nof women in emergency settings, including women’s values and preferences, should be made. Context-\nspecific tools and toolkits may be required in addition to standard tools to support the implementation of the\nrecommendation in humanitarian emergencies.\n4.2 Implementation considerations\nAs part of the recommendation development process, implementation considerations were developed. These\nmay assist policy-makers, clinicians and other stakeholders to better prepare for implementation.\n• The successful introduction of evidence-based policies related to the management of chronic medical\nconditions such as diabetes into the antenatal care model will depend o"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_224",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 224,
    "text": "repare for implementation.\n• The successful introduction of evidence-based policies related to the management of chronic medical\nconditions such as diabetes into the antenatal care model will depend on well-planned, participatory\nand consensus-driven processes of integration and implementation. These processes may include the\ndevelopment or revision of national guidelines or protocols based on these recommendations, and\nengagement with all relevant stakeholder groups, including skilled health-care providers. Modifications\nto the recommendations, if necessary, should be made with justification and documented in an explicit\nand transparent manner. The WHO Department of Sexual and Reproductive Health and Research and the\nWHO Department of Maternal, Newborn, Child and Adolescent Health and Age"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_225",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 225,
    "text": "and documented in an explicit\nand transparent manner. The WHO Department of Sexual and Reproductive Health and Research and the\nWHO Department of Maternal, Newborn, Child and Adolescent Health and Ageing will support national and\nsubnational groups to adapt and implement the recommendations based on existing strategies.\n• Implementation of the recommendations for managing diabetes in pregnancy must be considered within\nthe broader context of ensuring that all women have access to respectful, woman-centred care throughout\ntheir life course.\n\nWHO recommendations on care for women with diabetes during pregnancy\n• National health systems must support an enabling environment for the implementation of these\nrecommendations, including education to support behaviour change among skilled health per"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_226",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 226,
    "text": "uring pregnancy\n• National health systems must support an enabling environment for the implementation of these\nrecommendations, including education to support behaviour change among skilled health personnel\nteams to facilitate the use of evidence-based practices. Clear and up-to-date clinical protocols should be\navailable to skilled health-care providers regarding the care of medical conditions in pregnancy.\n• Local professional societies and training institutions can have an important role in implementation. An all-\ninclusive and participatory process should be encouraged.\n• National health systems must ensure that supplies of medicines and commodities are available in health-\ncare facilities where antenatal care services are provided. These resources must be safe, legitimate and\nmanufact"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_227",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 227,
    "text": "ystems must ensure that supplies of medicines and commodities are available in health-\ncare facilities where antenatal care services are provided. These resources must be safe, legitimate and\nmanufactured according to good manufacturing practices. To ensure that the resources are of high quality,\nrobust and sustainable regulatory, procurement and logistics processes must be established, ensuring\nthat good-quality products are obtained, transported and stored correctly.\n• Skilled health-care providers working in settings where women receive antenatal care will require training\nand supportive supervision on how to integrate the care of chronic medical conditions into routine\nantenatal care, and how to inform and counsel women, as appropriate. In settings where a new practice\nis introduced (o"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_228",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 228,
    "text": "pervision on how to integrate the care of chronic medical conditions into routine\nantenatal care, and how to inform and counsel women, as appropriate. In settings where a new practice\nis introduced (or where recommended practices are changed), additional training and monitoring may be\nrequired. In contexts with high rates of personnel turnover, pre-service training and regular opportunities\nfor ongoing training and competency assessment are particularly important.\n38\n4.3 Anticipated impact on the organization of care\nand resources\nEffective implementation of the recommendations in this guideline may require reorganization of care and\nredistribution of health-care resources, particularly in low- and middle-income countries. The GDG noted that\nupdating training curricula and providing traini"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_229",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 229,
    "text": "ne may require reorganization of care and\nredistribution of health-care resources, particularly in low- and middle-income countries. The GDG noted that\nupdating training curricula and providing training on the recommendations would increase their impact and\nfacilitate their implementation.\nAs part of efforts to implement these recommendations, health-system stakeholders may wish to consider the\nfollowing potential barriers to their application:\n• feasibility of components of the recommendations, barriers and facilitators to their implementation;\n• lack of human resources with the requisite expertise and skills to implement, supervise and support\nrecommended practices;\n• lack of infrastructure and multidisciplinary teams to support interventions;\n• lack of resources for active implementatio"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_230",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 230,
    "text": "ertise and skills to implement, supervise and support\nrecommended practices;\n• lack of infrastructure and multidisciplinary teams to support interventions;\n• lack of resources for active implementation strategies;\n• lack of essential equipment, supplies (e.g. insulin) and consumables (e.g. syringes for injection of insulin);\n• lack of health information management systems designed to document and monitor recommended\npractices (e.g. patient records, registers);\n\nWHO recommendations on care for women with diabetes during pregnancy Dissemination and implementation of the guideline\n• lack of consistent staffing from high provider turnover impacting the sustainability and scalability of\ninterventions; and\n• limited access to health services during emergencies and crises.\n4.4 Monitoring and eval"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_231",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 231,
    "text": "stent staffing from high provider turnover impacting the sustainability and scalability of\ninterventions; and\n• limited access to health services during emergencies and crises.\n4.4 Monitoring and evaluating guideline\nimplementation\nThe implementation and impact of these recommendations will be monitored at the health service, country\nand regional levels, as part of broader efforts to monitor and improve the quality of maternal and newborn\ncare. The WHO document Standards for improving quality of maternal and newborn care in health facilities\n(66) provides a list of prioritized input, output and outcome measures that can be used to define quality of\ncare criteria and indicators and that should be aligned with locally agreed targets. In collaboration with the\nmonitoring and evaluation teams"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_232",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 232,
    "text": "d outcome measures that can be used to define quality of\ncare criteria and indicators and that should be aligned with locally agreed targets. In collaboration with the\nmonitoring and evaluation teams of the WHO Department of Sexual and Reproductive Health and Research\nand the WHO Department of Maternal, Newborn, Child, Adolescent Health and Ageing, data on country-\nand regional-level implementation of the recommendations will be collected and evaluated in the short to\nmedium term to assess their impact on national policies of individual WHO Member States. Interrupted time\nseries could be used to obtain the relevant data on the use of interventions contained in this guideline.\n39\n\n5\nResearch\nimplications\nThe GDG identified important knowledge gaps directly related to the PICO questions, or"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_233",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 233,
    "text": "to obtain the relevant data on the use of interventions contained in this guideline.\n39\n\n5\nResearch\nimplications\nThe GDG identified important knowledge gaps directly related to the PICO questions, or which may have\na direct impact on the implementation of these recommendations. The following areas were identified as\npriority questions for high-quality evidence generation.\n5.1 Core practices in caring for women with diabetes\nduring pregnancy\n40\n• What are women’s preferences and values regarding diabetes education during pregnancy, and how do\nthese affect engagement and outcomes?\n• What is the effectiveness of culturally sensitive, woman-centred education interventions in improving\nmaternal and neonatal outcomes in women with diabetes?\n• What is the appropriate gestational weight gain range"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_234",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 234,
    "text": "effectiveness of culturally sensitive, woman-centred education interventions in improving\nmaternal and neonatal outcomes in women with diabetes?\n• What is the appropriate gestational weight gain range for women with diabetes, and how does it differ from\ngeneral pregnancy recommendations?\n• What training or task-sharing models effectively support non-specialist providers to deliver diabetes care\nand education during pregnancy in low-resource settings?\n• How can self-care be supported and which services and support can be provided via telehealth\n(e.g. antenatal education, check-ins to assess glycaemic control)?\n• Can a risk prediction tool or scoring system be developed and validated to identify pregnant women with\ndiabetes at higher risk of adverse outcomes?\n• What is the availability and u"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_235",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 235,
    "text": "caemic control)?\n• Can a risk prediction tool or scoring system be developed and validated to identify pregnant women with\ndiabetes at higher risk of adverse outcomes?\n• What is the availability and utility of epidemiological outcome data disaggregated by diabetes status\n(type 1, type 2, GDM) versus general ‘high-risk pregnancy’ categories?\n5.2 Glucose monitoring\n• What are the optimal glycaemic targets in pregnancy for women with type 1, type 2 diabetes, or GDM to\nbalance maternal and neonatal outcomes while minimizing hypoglycaemia?\n\nResearch implications\n• How should HbA1c and CGM targets be defined and used for different types of diabetes during pregnancy,\nespecially in type 2 diabetes and GDM?\n• What is the effectiveness and cost-effectiveness of CGM in pregnant women with type 2 or G"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_236",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 236,
    "text": "e defined and used for different types of diabetes during pregnancy,\nespecially in type 2 diabetes and GDM?\n• What is the effectiveness and cost-effectiveness of CGM in pregnant women with type 2 or GDM,\nparticularly women on insulin?\n• How do serial HbA1c measurements and their trajectory across pregnancy relate to maternal and neonatal\noutcomes in women with type 1 or type 2 diabetes?\n• What maternal and neonatal outcomes are associated with different glycaemic thresholds (e.g. fasting,\n1 hour, 2 hour) based on Hyperglycemia and Adverse Pregnancy Outcome study (HAPO)-derived odds\nratios, and how should they inform diagnostic criteria?\n5.3 Pharmacotherapy\n5.3.1 Type 1 diabetes in pregnancy\n• What is the effectiveness of different insulin types (short- and long-acting human and analogue, a"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_237",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 237,
    "text": "how should they inform diagnostic criteria?\n5.3 Pharmacotherapy\n5.3.1 Type 1 diabetes in pregnancy\n• What is the effectiveness of different insulin types (short- and long-acting human and analogue, and\npremixed), regimens (twice daily and basal-bolus) and delivery methods (syringe and vials, pens, insulin\npumps, automated insulin delivery systems) on glycaemic control and maternal and neonatal outcomes\nfor women with type 1 diabetes?\n41\n• Does the addition of metformin to insulin improve glycaemic control and maternal and neonatal outcomes\ncompared to insulin alone?\n• Can automated insulin delivery systems, with algorithms tailored to the physiological needs of pregnancy,\nbe safely, effectively, and equitably implemented in low- and middle-income countries?\n• What is the cost-effectivenes"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_238",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 238,
    "text": "livery systems, with algorithms tailored to the physiological needs of pregnancy,\nbe safely, effectively, and equitably implemented in low- and middle-income countries?\n• What is the cost-effectiveness, and what are the barriers to, and facilitators of, implementing advanced\ninsulin technologies (pumps, automated insulin delivery systems) in low-resource settings?\n• How does the availability of insulin and monitoring resources and the quality and accessibility of the care\nin low- and middle-income countries influence maternal and neonatal outcomes?\n5.3.2 Type 2 diabetes in pregnancy\n• How do metformin and insulin compare as first-line treatment for type 2 diabetes in terms of glycaemic\ncontrol and maternal and neonatal outcomes?\n• What is the effect of continuing metformin alone versus swi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_239",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 239,
    "text": "etformin and insulin compare as first-line treatment for type 2 diabetes in terms of glycaemic\ncontrol and maternal and neonatal outcomes?\n• What is the effect of continuing metformin alone versus switching to insulin during pregnancy on glycaemic\ncontrol and maternal and neonatal outcomes?\n• What is the effectiveness and safety of oral glucose-lowering agents during pregnancy in terms of\nglycaemic control and maternal and neonatal outcomes?\n• How does combining metformin and insulin compare to monotherapy with either agent alone for women\nwith type 2 diabetes?\n• What are the impacts of in utero exposure to metformin on child growth, adiposity, and metabolic\noutcomes compared with children of women with type 2 diabetes in pregnancy not exposed to metformin?\n\nWHO recommendations on care for"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_240",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 240,
    "text": "ro exposure to metformin on child growth, adiposity, and metabolic\noutcomes compared with children of women with type 2 diabetes in pregnancy not exposed to metformin?\n\nWHO recommendations on care for women with diabetes during pregnancy\n• How do twice-daily, basal bolus and premixed insulin regimens compare in terms of efficacy, safety, and\nfeasibility in low-resource settings?\n• What are the barriers, facilitators, and cost-effectiveness implications of scaling up insulin and metformin\naccess, including advanced insulin delivery methods, in low- and middle-income countries?\n5.3.3 Gestational diabetes mellitus\n• How do metformin and insulin compare as first-line treatment for GDM in terms of glycaemic control and\nmaternal and neonatal outcomes?\n• How does combining metformin and insulin c"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_241",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 241,
    "text": "diabetes mellitus\n• How do metformin and insulin compare as first-line treatment for GDM in terms of glycaemic control and\nmaternal and neonatal outcomes?\n• How does combining metformin and insulin compare to monotherapy with either agent alone for women\nwith GDM?\n• Which women with GDM require escalation to insulin, and what criteria best predict treatment failure with\nmetformin or diet alone?\n• What are the impacts of in utero exposure to metformin on child growth, adiposity, and metabolic\noutcomes compared with children of women with GDM in pregnancy not exposed to metformin?\n• What are the short-term and long-term maternal and neonatal outcomes, acceptability, adherence,\nand cost-effectiveness of GDM treatments (metformin, insulin, combination) in low- and middle-income\ncountries?\n42"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_242",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 242,
    "text": "e short-term and long-term maternal and neonatal outcomes, acceptability, adherence,\nand cost-effectiveness of GDM treatments (metformin, insulin, combination) in low- and middle-income\ncountries?\n42\n5.4 Additional monitoring and assessments\n• For which subgroups of women with GDM is multidisciplinary or intensified care beneficial, and how should\n‘specialized care’ be defined?\n• What is the comparative effectiveness of different fetal monitoring strategies (e.g. ultrasound, Doppler,\ncardiotocography, fundal height) in improving outcomes among pregnant women with diabetes?\n• How acceptable and feasible are various fetal monitoring strategies for women with diabetes across\ndifferent health system settings?\n• What is the optimal timing and frequency of retinopathy screening during pregnancy"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_243",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 243,
    "text": "feasible are various fetal monitoring strategies for women with diabetes across\ndifferent health system settings?\n• What is the optimal timing and frequency of retinopathy screening during pregnancy for women with pre-\nexisting diabetes?\n• Is serum creatinine or eGFR a more accurate marker for assessing renal function during pregnancy in\nwomen with diabetes?\n\nWHO recommendations on care for women with diabetes during pregnancy\n6\nUpdating the\nrecommendations\nThe Maternal and Perinatal Health Guideline Technical Advisory Group convenes regularly to review WHO’s\ncurrent portfolio of maternal and perinatal health recommendations and to help WHO prioritize new and\nexisting questions for recommendation development and updating. These recommendations will be included\nin those reviews. In the eve"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_244",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 244,
    "text": "perinatal health recommendations and to help WHO prioritize new and\nexisting questions for recommendation development and updating. These recommendations will be included\nin those reviews. In the event that new evidence that could potentially impact the current evidence base\nis identified, these recommendations may be updated. If no new reports or information is identified, the\nrecommendations may be revalidated.\nWHO welcomes suggestions regarding additional questions for inclusion in the updated recommendations. 43\nPlease email your suggestions to srhmph@who.int.\n\nReferences\n1. NCD Risk Factor Collaboration. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis\nof 1108 population-representative studies with 141 million participants. Lancet. 2024;404(1"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_245",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 245,
    "text": "or Collaboration. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis\nof 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077–93. doi: https://doi.\norg/10.1016/S0140-6736(24)02317-1.\n2. Diabetes. Key facts. [website]. World Health Organization; 2021 [updated November 10, 2021]. (https://www.who.int/news-room/\nfact-sheets/detail/diabetes, accessed 18 September 2025).\n3. Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, et al. Type 1 diabetes in 2017: global estimates of incident and\nprevalent cases in children and adults. Diabetologia. 2021;64(12):2741–50. doi:https://doi.org/10.1007/s00125-021-05571-8.\n4. Proportion of people with undiagnosed diabetes, % [website]. 2025 International Diabete"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_246",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 246,
    "text": "es in children and adults. Diabetologia. 2021;64(12):2741–50. doi:https://doi.org/10.1007/s00125-021-05571-8.\n4. Proportion of people with undiagnosed diabetes, % [website]. 2025 International Diabetes Federation; 2025\n(https://diabetesatlas.org/data-by-indicator/diabetes-estimates-20-79-y/proportion-of-people-with-undiagnosed-diabetes,\naccessed 18 September 2025).\n5. Diabetes Facts & Figures. Brussels, Belgium: International Diabetes Federation; 2022 [updated September 12, 2021]. (https://idf.\norg/about-diabetes/diabetes-facts-figures, accessed 18 September 2025).\n6. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva: World Health Organization; 2013.\n(https://iris.who.int/handle/10665/85975, accessed 18 September 2025).\n7. Waters TP, Kim SY, Werne"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_247",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 247,
    "text": "lassification of hyperglycaemia first detected in pregnancy. Geneva: World Health Organization; 2013.\n(https://iris.who.int/handle/10665/85975, accessed 18 September 2025).\n7. Waters TP, Kim SY, Werner E, Dinglas C, Carter EB, Patel R, et al. Should women with gestational diabetes be screened at delivery\nhospitalization for type 2 diabetes? Am J Obstet Gynecol. 2020;222(1):73.e1–.e11. doi: https://doi.org/10.1016/j.ajog.2019.07.035.\n8. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care.\n2002;25(10):1862–8. doi: https://doi.org/10.2337/diacare.25.10.1862.\n44\n9. Bianco ME, Josefson JL. Hyperglycemia during pregnancy and long-term offspring outcomes. Curr Diab Rep. 2019;19(12):143. doi:\nhttps://doi.org/10.1007/s11892-019-1"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_248",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 248,
    "text": "org/10.2337/diacare.25.10.1862.\n44\n9. Bianco ME, Josefson JL. Hyperglycemia during pregnancy and long-term offspring outcomes. Curr Diab Rep. 2019;19(12):143. doi:\nhttps://doi.org/10.1007/s11892-019-1267-6.\n10. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016. (https://\niris.who.int/handle/10665/250796, accessed 18 September 2025).\n11. Jung J, Karwal EK, McDonald S, Turner T, Chou D, Vogel JP. Prevention and control of non-communicable diseases in antenatal,\nintrapartum, and postnatal care: a systematic scoping review of clinical practice guidelines since 2011. BMC Med. 2022;20(1):305.\ndoi: https://doi.org/10.1186/s12916-022-02508-9.\n12. WHO handbook for guideline development, second edition. Geneva: World Health Organizatio"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_249",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 249,
    "text": "l practice guidelines since 2011. BMC Med. 2022;20(1):305.\ndoi: https://doi.org/10.1186/s12916-022-02508-9.\n12. WHO handbook for guideline development, second edition. Geneva: World Health Organization; 2014. (https://iris.who.int/\nhandle/10665/145714, accessed 18 September 2025).\n13. Ramson JA, Williams MJ, Afolabi BB, Colagiuri S, Finlayson KW, Hemmingsen B, et al. Pregnancy, childbirth and the postpartum\nperiod: opportunities to improve lifetime outcomes for women with non-communicable diseases. Med J Aust. 2024;221(7):350–3.\ndoi: https://doi.org/10.5694/mja2.52452.\n14. Firoz T, Pineles B, Navrange N, Grimshaw A, Oladapo O, Chou D. Non-communicable diseases and maternal health: a scoping\nreview. BMC Pregnancy Childbirth. 2022;22(1):787. doi: https://doi.org/10.1186/s12884-022-05047-6.\n1"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_250",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 250,
    "text": "Navrange N, Grimshaw A, Oladapo O, Chou D. Non-communicable diseases and maternal health: a scoping\nreview. BMC Pregnancy Childbirth. 2022;22(1):787. doi: https://doi.org/10.1186/s12884-022-05047-6.\n15. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence.\nJ Clin Epidemiol. 2011;64(4):401–6. doi: https://doi.org/10.1016/j.jclinepi.2010.07.015.\n16. Finlayson K, Moncrieff G, Downe S. The views and experiences of health providers caring for women with diabetes during the\nmaternity phase: A qualitative evidence synthesis. In progress.\n17. Finlayson K, Moncrieff G, Downe S. The views and experiences of women with pre-existing diabetes during their encounters with\nmaternity services: A qualitative evidence synthesis. In progr"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_251",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 251,
    "text": "ogress.\n17. Finlayson K, Moncrieff G, Downe S. The views and experiences of women with pre-existing diabetes during their encounters with\nmaternity services: A qualitative evidence synthesis. In progress.\n18. Jung J, Aziz S, Allen C, Ginnane J, Eddy K, Makama M, et al. An economic evaluation of interventions for the screening, treatment,\nand management of diabetes mellitus during pregnancy: a systematic review. PROSPERO. 2024;https://www.crd.york.ac.uk/\nPROSPERO/view/CRD42024511742.\n\n19. Burk J, Sweeting A. The impact of self-monitoring of blood glucose and continuous glucose monitoring on perinatal and health\nsystem outcomes in individuals with diabetes in pregnancy: a systematic review and meta-analysis. PROSPERO. 2024;https://\nwww.crd.york.ac.uk/PROSPERO/view/CRD42024594987.\n20. Hurley"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_252",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 252,
    "text": "inatal and health\nsystem outcomes in individuals with diabetes in pregnancy: a systematic review and meta-analysis. PROSPERO. 2024;https://\nwww.crd.york.ac.uk/PROSPERO/view/CRD42024594987.\n20. Hurley A, Makama M, Vogel J, Sultana S. Antepartum fetal monitoring in diabetic and high-risk women: A systematic review.\nPROSPERO. 2024;https://www.crd.york.ac.uk/PROSPERO/view/CRD42024557435.\n21. Villanueva G, Cogo E, Sguassero Y, Buckley B, Probyn K, Bergman H, et al. Diabetes management during pregnancy. PROSPERO.\n2025;https://www.crd.york.ac.uk/PROSPERO/view/CRD42025630036.\n22. Weibel S, Popp M, Reis S, Skoetz N, Garner P, Sydenham E. Identifying and managing problematic trials: A research integrity\nassessment tool for randomized controlled trials in evidence synthesis. Res Synth Methods. 2023;1"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_253",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 253,
    "text": "s S, Skoetz N, Garner P, Sydenham E. Identifying and managing problematic trials: A research integrity\nassessment tool for randomized controlled trials in evidence synthesis. Res Synth Methods. 2023;14(3):357–69. doi: https://doi.\norg/10.1002/jrsm.1599.\n23. Lewin S, Booth A, Glenton C, Munthe-Kaas H, Rashidian A, Wainwright M, et al. Applying GRADE-CERQual to qualitative evidence\nsynthesis findings: introduction to the series. Implement Sci. 2018;13(Suppl 1):2. doi: https://doi.org/10.1186/s13012-017-0688-3.\n24. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic\nevaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240–5. doi: PMID: https://\npubmed.ncbi.nlm.nih.gov/15921065/.\n25"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_254",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 254,
    "text": "of methodological quality of economic\nevaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240–5. doi: PMID: https://\npubmed.ncbi.nlm.nih.gov/15921065/.\n25. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2024. Available from:\ngradepro.org.\n26. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. [GRADE Evidence to Decision (EtD)\nframeworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. Gac Sanit.\n2018;32(2):166.e1–.e10. doi: https://doi.org/10.1016/j.gaceta.2017.02.010.\n27. WHO guideline on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. (https://iris.who.int/\nhand"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_255",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 255,
    "text": "(2):166.e1–.e10. doi: https://doi.org/10.1016/j.gaceta.2017.02.010.\n27. WHO guideline on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. (https://iris.who.int/\nhandle/10665/336656, accessed 18 September 2025).\n45\n28. Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva: World Health Organization; 2020. (https://iris.who.int/\nhandle/10665/331710, accessed 18 September 2025).\n29. Saturated fatty acid and trans-fatty acid intake for adults and children: WHO guideline. Geneva: World Health Organization; 2023.\n(https://iris.who.int/handle/10665/370419, accessed 18 September 2025).\n30. Total fat intake for prevention of unhealthy weight gain in adults and children: WHO guideline. Geneva: World Health Organization;\n2023. (https://iris.who.int/handle/1"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_256",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 256,
    "text": "accessed 18 September 2025).\n30. Total fat intake for prevention of unhealthy weight gain in adults and children: WHO guideline. Geneva: World Health Organization;\n2023. (https://iris.who.int/handle/10665/370421, accessed 18 September 2025).\n31. Carbohydrate intake for adults and children: WHO guideline. Geneva: World Health Organization; 2023. (https://iris.who.int/\nhandle/10665/370420, accessed 18 September 2025).\n32. Guideline: Sugars intake for adults and children. Geneva: World Health Organization; 2015. (https://iris.who.int/\nhandle/10665/149782, accessed 18 September 2025).\n33. Costi L. Women’s experience of diabetes and diabetes management in pregnancy: A systematic review of qualitative evidence.\nJBI Libr Syst Rev. 2012;10(56 Suppl):1–9. doi: https://doi.org/10.11124/01938924-2012"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_257",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 257,
    "text": "Women’s experience of diabetes and diabetes management in pregnancy: A systematic review of qualitative evidence.\nJBI Libr Syst Rev. 2012;10(56 Suppl):1–9. doi: https://doi.org/10.11124/01938924-201210561-00025.\n34. Craig L, Sims R, Glasziou P, Thomas R. Women’s experiences of a diagnosis of gestational diabetes mellitus: a systematic review.\nBMC Pregnancy Childbirth. 2020;20(1):76. doi: https://doi.org/10.1186/s12884-020-2745-1.\n35. Xu N, Han X, Chen S, Zhang J, Gu P. Self-reported barriers in self-management of women with gestational diabetes: A systematic\nreview of qualitative studies. Nurs Open. 2023;10(11):7130–43. doi: https://doi.org/10.1002/nop2.1988.\n36. Davis D, Kurz E, Hooper ME, Atchan M, Spiller S, Blackburn J, et al. The holistic maternity care needs of women with gestationa"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_258",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 258,
    "text": "s Open. 2023;10(11):7130–43. doi: https://doi.org/10.1002/nop2.1988.\n36. Davis D, Kurz E, Hooper ME, Atchan M, Spiller S, Blackburn J, et al. The holistic maternity care needs of women with gestational\ndiabetes mellitus: A systematic review with thematic synthesis. Women Birth. 2024;37(1):166–76. doi: https://doi.org/10.1016/j.\nwombi.2023.08.005.\n37. Tzotzis L, Hooper ME, Douglas A, Kurz E, Atchan M, Spiller S, et al. The needs and experiences of women with gestational diabetes\nmellitus from minority ethnic backgrounds in high-income nations: A systematic integrative review. Women Birth. 2023;36(2):\n205–16. doi: https://doi.org/10.1016/j.wombi.2022.08.006.\n38. Faal Siahkal S, Javadifar N, Najafian M, Iravani M, Zakerkish M, Heshmati R. The psychosocial challenges associated with\ngestationa"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_259",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 259,
    "text": "36(2):\n205–16. doi: https://doi.org/10.1016/j.wombi.2022.08.006.\n38. Faal Siahkal S, Javadifar N, Najafian M, Iravani M, Zakerkish M, Heshmati R. The psychosocial challenges associated with\ngestational diabetes mellitus: A systematic review of qualitative studies. Prim Care Diabetes. 2022;16(1):11–26. doi: https://doi.\norg/10.1016/j.pcd.2021.09.003.\n\n39. Guo S, Liu D, Bi X, Feng Y, Zhang K, Jiang J, et al. Barriers and facilitators to self-management among women with\ngestational diabetes: A systematic review using the COM-B model. Midwifery. 2024;138:104141. doi: https://doi.org/10.1016/j.\nmidw.2024.104141.\n40. Haigh C, Lau HWR, Weir T, Glastras S. The experiences of women from culturally and linguistically diverse backgrounds with\ngestational diabetes mellitus: A mixed methods systematic"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_260",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 260,
    "text": "w.2024.104141.\n40. Haigh C, Lau HWR, Weir T, Glastras S. The experiences of women from culturally and linguistically diverse backgrounds with\ngestational diabetes mellitus: A mixed methods systematic review. Endocrinol Diabetes Metab. 2023;6(4):e421. doi: https://doi.\norg/10.1002/edm2.421.\n41. Parsons J, Ismail K, Amiel S, Forbes A. Perceptions among women with gestational diabetes. Qual Health Res. 2014;24(4):575–85.\ndoi: https://doi.org/10.1177/1049732314524636.\n42. WHO guideline on self-care interventions for health and well-being, 2022 revision. Geneva: World Health Organization; 2022.\n(https://iris.who.int/handle/10665/357828, accessed 18 September 2025).\n43. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey.\nGenev"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_261",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 261,
    "text": "tps://iris.who.int/handle/10665/357828, accessed 18 September 2025).\n43. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey.\nGeneva: World Health Organization; 2020. (https://iris.who.int/handle/10665/331452, accessed 18 September 2025).\n44. Murphy HR, Howgate C, O’Keefe J, Myers J, Morgan M, Coleman MA, et al. Characteristics and outcomes of pregnant women with\ntype 1 or type 2 diabetes: a 5-year national population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(3):153–64.\ndoi: https://doi.org/10.1016/S2213-8587(20)30406-X.\n45. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva: World Health\nOrganization; 2020. (https://iris.who.int/handle/10665/334186, accessed"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_262",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 262,
    "text": "30406-X.\n45. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva: World Health\nOrganization; 2020. (https://iris.who.int/handle/10665/334186, accessed 18 September 2025).\n46. Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults\nwith diabetes mellitus. Geneva: World Health Organization; 2018. (https://iris.who.int/handle/10665/272433, accessed\n18 September 2025).\n47. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of maternal insulin resistance during pregnancy: an updated overview.\nJ Diabetes Res. 2019;2019:5320156. doi: https://doi.org/10.1155/2019/5320156.\n46\n48. Slattery D, Amiel SA, Choudhary P. Optimal prandial timing of bolus insulin in diabetes managem"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_263",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 263,
    "text": "n updated overview.\nJ Diabetes Res. 2019;2019:5320156. doi: https://doi.org/10.1155/2019/5320156.\n46\n48. Slattery D, Amiel SA, Choudhary P. Optimal prandial timing of bolus insulin in diabetes management: a review. Diabet Med.\n2018;35(3):306–16. doi: https:/doi.org/10.1111/dme.13525.\n49. Lloyd A, Townsend C, Munro V, Twena N, Nielsen S, Holman A. Cost-effectiveness of insulin aspart compared to human\ninsulin in pregnant women with type 1 diabetes in the UK. Curr Med Res Opin. 2009;25(3):599–605. doi: https://doi.\norg/10.1185/03007990802668208.\n50. Keeping the 100-year-old promise: making insulin access universal. Geneva: World Health Organization; 2021. (https://iris.who.int/\nhandle/10665/348384, accessed 18 September 2025).\n51. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_264",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 264,
    "text": "in access universal. Geneva: World Health Organization; 2021. (https://iris.who.int/\nhandle/10665/348384, accessed 18 September 2025).\n51. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al. Maternal glycemic control and hypoglycemia in type\n1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care.\n2007;30(4):771–6. doi: https://doi.org/10.2337/dc06-1887.\n52. Dasari P, Gundagurti B, Karthikeyan K. Comparison of metformin and insulin therapy for the treatment of gestational diabetes\nmellitus—a randomised controlled trial. Int J Diabetes Dev Ctries. 2023;43(4):523–28. doi: https://doi.org/10.1007/s13410-022-\n01048-5.\n53. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_265",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 265,
    "text": "trial. Int J Diabetes Dev Ctries. 2023;43(4):523–28. doi: https://doi.org/10.1007/s13410-022-\n01048-5.\n53. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J\nMed. 2008;358(19):2003–15. doi: https://doi.org/10.1056/NEJMoa0707193.\n54. Picón-César MJ, Molina-Vega M, Suárez-Arana M, González-Mesa E, Sola-Moyano AP, Roldan-López R, et al. Metformin for\ngestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes:\nrandomized prospective trial. Am J Obstet Gynecol. 2021;225(5):517.e1–.e17. doi: https://doi.org/10.1016/j.ajog.2021.04.229.\n55. Mongelli M, Ek S, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time i"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_266",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 266,
    "text": "ecol. 2021;225(5):517.e1–.e17. doi: https://doi.org/10.1016/j.ajog.2021.04.229.\n55. Mongelli M, Ek S, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time interval and\nultrasound error. Obstet Gynecol. 1998;92(6):908–12. doi: https://doi.org/10.1016/s0029-7844(98)00349-4.\n56. Chatziralli IP. The role of glycemic control and variability in diabetic retinopathy. Diabetes Ther. 2018;9(1):431–4. doi: https://doi.\norg/10.1007/s13300-017-0345-5.\n57. Lam CS, Benzie IF, Choi SW, Chan LY, Yeung VT, Woo GC. Relationships among diabetic retinopathy, antioxidants, and glycemic\ncontrol. Optom Vis Sci. 2011;88(2):251–6. doi: https://doi.org/10.1097/OPX.0b013e318208494a.\n\n58. Tecce N, Cennamo G, Rinaldi M, Costagliola C, Colao A. Exploring the impact of glycemi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_267",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 267,
    "text": "s, and glycemic\ncontrol. Optom Vis Sci. 2011;88(2):251–6. doi: https://doi.org/10.1097/OPX.0b013e318208494a.\n\n58. Tecce N, Cennamo G, Rinaldi M, Costagliola C, Colao A. Exploring the impact of glycemic control on diabetic retinopathy:\nemerging models and prognostic implications. J Clin Med. 2024;13(3). doi: https://doi.org/10.3390/jcm13030831.\n59. Widyaputri F, Rogers SL, Kandasamy R, Shub A, Symons RCA, Lim LL. Global estimates of diabetic retinopathy prevalence\nand progression in pregnant women with preexisting diabetes: A systematic review and meta-analysis. JAMA Ophthalmol.\n2022;140(5):486–94. doi: https://doi.org/10.1001/jamaophthalmol.2022.0050.\n60. Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab Syndr. 2015;9(4):343–58.\ndoi: https:"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_268",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 268,
    "text": "–94. doi: https://doi.org/10.1001/jamaophthalmol.2022.0050.\n60. Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab Syndr. 2015;9(4):343–58.\ndoi: https://doi.org/10.1016/j.dsx.2015.02.008.\n61. Martinez-Castelao A, Navarro-Gonzalez JF, Gorriz JL, de Alvaro F. The concept and the epidemiology of diabetic nephropathy have\nchanged in recent years. J Clin Med. 2015;4(6):1207–16. doi: https://doi.org/10.3390/jcm4061207.\n62. Koetje PM, Spaan JJ, Kooman JP, Spaanderman ME, Peeters LL. Pregnancy reduces the accuracy of the estimated\nglomerular filtration rate based on Cockroft-Gault and MDRD formulas. Reprod Sci. 2011;18(5):456–62. doi: https://doi.\norg/10.1177/1933719110387831.\n63. Smith MC, Moran P, Ward MK, Davison JM. Assessment of glomerular filt"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_269",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 269,
    "text": "rate based on Cockroft-Gault and MDRD formulas. Reprod Sci. 2011;18(5):456–62. doi: https://doi.\norg/10.1177/1933719110387831.\n63. Smith MC, Moran P, Ward MK, Davison JM. Assessment of glomerular filtration rate during pregnancy using the MDRD formula.\nBJOG. 2008;115(1):109–12. doi: https://doi.org/10.1111/j.1471-0528.2007.01529.x.\n64. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines.\nDiabetes Obes Metab. 2020;22 Suppl 1:3–15. doi: https://doi.org/10.1111/dom.14007.\n65. WHO recommendations on drug treatment for non-severe hypertension in pregnancy. Geneva: World Health Organization; 2020.\n(https://iris.who.int/handle/10665/333816, accessed 18 September 2025).\n66. Standards for improving quality of maternal and newbo"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_270",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 270,
    "text": "re hypertension in pregnancy. Geneva: World Health Organization; 2020.\n(https://iris.who.int/handle/10665/333816, accessed 18 September 2025).\n66. Standards for improving quality of maternal and newborn care in health facilities. Geneva: World Health Organization; 2016.\n(https://iris.who.int/handle/10665/249155, accessed 18 September 2025).\n47\n\nAnnex 1.\nContributors to the guideline\nGuideline development group Shabina ARIFF\nAssociate Professor\nSumaiya ADAM\nDepartment of Paediatrics and Child Health\nProfessor\nAga Khan University\nObstetrics and Gynaecology\nPakistan\nUniversity of Pretoria\nSouth Africa Stephen COLAGIURI\n48 Professor Emeritus of Metabolic Health\nAmanda ADLER\nThe Boden Collaboration,\nProfessor\nFaculty of Medicine and Health\nDiabetic Medicine and Health Policy\nUniversity of Sydne"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_271",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 271,
    "text": "frica Stephen COLAGIURI\n48 Professor Emeritus of Metabolic Health\nAmanda ADLER\nThe Boden Collaboration,\nProfessor\nFaculty of Medicine and Health\nDiabetic Medicine and Health Policy\nUniversity of Sydney\nUniversity of Oxford\nAustralia\nUnited Kingdom of Great Britain and Northern\nIreland Margie DAVENPORT\nProfessor\nFatima AL-SLAIL\nFaculty of Kinesiology, Sport, and Recreation\nDirector\nUniversity of Alberta\nDiabetes Prevention and Control Programme and\nCanada\nCardiovascular Prevention and Control Programme\nMinistry of Health Mohamed HASSANEIN\nSaudi Arabia Senior Consultant in Endocrinology and Diabetes\nDubai Hospital\nEmmanuel Ogbada AMEH\nUnited Arab Emirates\nConsultant\nObstetrics and Gynecology, Reproductive Health Shane A NORRIS\nand Family Planning Professor\nDepartment of Obstetrics and Gynaec"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_272",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 272,
    "text": "etes\nDubai Hospital\nEmmanuel Ogbada AMEH\nUnited Arab Emirates\nConsultant\nObstetrics and Gynecology, Reproductive Health Shane A NORRIS\nand Family Planning Professor\nDepartment of Obstetrics and Gynaecology University of Southampton\nGreater Accra Regional Hospital United Kingdom of Great Britain and Northern\nGhana Ireland, and\nUniversity of the Witwatersrand\nSouth Africa\n\nRajalakshmi RAM PRAKASH Partner organizations/observers\nIndependent consultant on Gender and Rights\nElizabeth FRANKLIN\nIndia\nInternational Confederation of Midwives\nProf João Filipe RAPOSO\nHoward CATTON\nMedical Director, Associação Protectora dos\nInternational Council Nurses\nDiabéticos de Portugal\nPresident, Portuguese Society of Diabetology\nBeatriz Yáñez JIMÉNEZ\nPortugal\nInternational Diabetes Foundation\nSofia SACCONE\nLio"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_273",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 273,
    "text": "iação Protectora dos\nInternational Council Nurses\nDiabéticos de Portugal\nPresident, Portuguese Society of Diabetology\nBeatriz Yáñez JIMÉNEZ\nPortugal\nInternational Diabetes Foundation\nSofia SACCONE\nLiona POON\nProfesora Adjunta\nInternational Federation of Gynecology and\nClínica de Endocrinología y metabolismo\nObstetrics\nHospital de Clínicas Dr Manuel Quintela Facultad\nde Medicina Hilary HOEY\nUruguay International Pediatric Association\nPlacxedes SOSA Christopher NOLAN\nPatient representative NCD Alliance\nZimbabwe\n49\nNikhil TANDON Guideline methodologists\nProfessor and Chair\nJen RAMSON\nDepartment of Endocrinology and Metabolism\nConsultant\nAll India Institute of Medical Sciences\nIndia\nMyfanwy WILLIAMS\nConsultant\nHoang Thi TRAN\nAssociate Professor\nEvidence synthesis group\nNeonatal Unit\nDa Nang Ho"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_274",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 274,
    "text": "f Endocrinology and Metabolism\nConsultant\nAll India Institute of Medical Sciences\nIndia\nMyfanwy WILLIAMS\nConsultant\nHoang Thi TRAN\nAssociate Professor\nEvidence synthesis group\nNeonatal Unit\nDa Nang Hospital for Women and Children Jessica BURK\nDepartment of Pediatrics Research Dietitian\nSchool of Medicine and Pharmacy University of Sydney\nThe University of Da Nang Australia\nViet Nam\nSoo DOWNE\nKartik VENKATESH Professor\nAssociate Professor THRIVE Centre\nObstetrics and Gynecology and Epidemiology University of Central Lancashire\nThe Ohio State University College of Medicine School of Community Health and Midwifery United\nUnited States of America Kingdom of Great Britain and Northern Ireland\n\nKenneth FINLAYSON Who regional office representatives\nResearch Associate\nRegional Office for Africa\nUn"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_275",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 275,
    "text": "alth and Midwifery United\nUnited States of America Kingdom of Great Britain and Northern Ireland\n\nKenneth FINLAYSON Who regional office representatives\nResearch Associate\nRegional Office for Africa\nUniversity of Central Lancashire\nSchool of Community Health and Midwifery United Kouamivi AGBOYIBOR\nKingdom of Great Britain and Northern Ireland Technical Officer Noncommunicable Diseases\nAoife HURLEY Adeniyi ADEROBA\nPublic Health Registrar Team Lead Reproductive and Maternal Health\nBurnet Institute\nRegional Office for the Americas/Pan American\nAustralia\nHealth Organization\nJenny JUNG\nCarmen ANTINI\nResearch Assistant\nAdvisor, Diabetes Prevention and Control\nBurnet Institute\nNoncommunicable Diseases and Mental Health\nAustralia\nRodolfo GOMEZ PONCE DE LEÓN\nMaureen MAKAMA\nRegional Advisor on Sexual"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_276",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 276,
    "text": "Research Assistant\nAdvisor, Diabetes Prevention and Control\nBurnet Institute\nNoncommunicable Diseases and Mental Health\nAustralia\nRodolfo GOMEZ PONCE DE LEÓN\nMaureen MAKAMA\nRegional Advisor on Sexual and Reproductive Health\nResearch officer\nBurnet Institute Regional Office for Europe\nAustralia\nJill FARRINGTON\n50\nRegional Medical Officer, Cardiovascular Diseases\nGill MONCRIEFF\nand Diabetes\nResearch Fellow\nUniversity of Stirling\nOleg KUZMENKO\nUnited Kingdom of Great Britain and Northern\nTechnical Officer Reproductive and Maternal Health\nIreland\nRegional Office for the Eastern Mediterranean\nArianne SWEETING\nKarima GHOLBZOURI\nSenior Lecturer\nRegional Advisor Sexual and Reproductive Health\nUniversity of Sydney\nand Research\nAustralia\nLamia MAHMOUD\nGemma VILLANUEVA\nRegional Advisor Noncommunicab"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_277",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 277,
    "text": "nne SWEETING\nKarima GHOLBZOURI\nSenior Lecturer\nRegional Advisor Sexual and Reproductive Health\nUniversity of Sydney\nand Research\nAustralia\nLamia MAHMOUD\nGemma VILLANUEVA\nRegional Advisor Noncommunicable Disease\nSenior Systematic Reviewer\nPrevention\nCochrane Response\nUnited Kingdom of Great Britain and Northern\nRegional Office for South-East Asia\nIreland\nManjulaa DANANSURIYA\nJoshua VOGEL Technical Officer Reproductive Health\nCo-Program Director, Maternal, Child and\nPradeep JOSHI\nAdolescent Health Program\nTechnical Officer Noncommunicable Disease\nBurnet Institute\nPrevention\nAustralia\n\nRegional Office for the Western Pacific Ashish KRISHNA\nConsultant\nRolando Enrique DOMINGO\nDepartment of Noncommunicable Diseases and\nCoordinator, Management of Noncommunicable\nMental Health\nDiseases\nOlufemi T O"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_278",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 278,
    "text": "ffice for the Western Pacific Ashish KRISHNA\nConsultant\nRolando Enrique DOMINGO\nDepartment of Noncommunicable Diseases and\nCoordinator, Management of Noncommunicable\nMental Health\nDiseases\nOlufemi T OLADAPO\nDelgermaa (Degy) VANYA\nUnit Head\nTechnical Officer, Maternal Child Health and\nDepartment of Sexual and Reproductive Health\nQuality Safety\nand Research\nWHO steering group\nUlrika REHNSTRÖM LOI\nMaria BARREIX Technical Officer (Midwifery)\nTechnical Officer Department of Maternal, Newborn, Child and\nDepartment of Sexual and Reproductive Health Adolescent Health and Ageing\nand Research\nLisa ROGERS\nDaria BERLINA Technical Officer\nTechnical Officer Department of Nutrition and Food Safety\nDepartment of Noncommunicable Diseases and\nMental Health External review group\n51\nBosede AFOLABI\nDoris CHOU"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_279",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 279,
    "text": "S\nDaria BERLINA Technical Officer\nTechnical Officer Department of Nutrition and Food Safety\nDepartment of Noncommunicable Diseases and\nMental Health External review group\n51\nBosede AFOLABI\nDoris CHOU\nProfessor\nMedical officer\nLagos University Teaching Hospital\nDepartment of Sexual and Reproductive Health\nUniversity of Lagos\nand Research\nNigeria\nMaría Nieves GARCIA CASAL\nHadil ALI-MASRI\nScientist\nHead of Women’s Health and Development Unit\nDepartment of Nutrition and Food Safety\nMinistry of Health\nAlarcos CIEZA occupied Palestinian territory, including east\nUnit Head Jerusalem\nDepartment of Noncommunicable Diseases and\nViswanathan MOHAN\nMental Health\nChairman,\nTea COLLINS Madras Diabetes Research Foundation, India\nCross cutting lead\nJeremy OATS\nDepartment of Noncommunicable Diseases and\nPro"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_280",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 280,
    "text": "communicable Diseases and\nViswanathan MOHAN\nMental Health\nChairman,\nTea COLLINS Madras Diabetes Research Foundation, India\nCross cutting lead\nJeremy OATS\nDepartment of Noncommunicable Diseases and\nProfessorial Fellow\nMental Health\nMelbourne School of Population and Global Health\nBianca HEMMINGSEN University of Melbourne\nMedical Officer Australia\nDepartment of Noncommunicable Diseases and\nMental Health\n\nAnnex 2.\nPriority outcomes used in\ndecision making\nPriority outcomes included for all PICOs\nCritical maternal outcomes • Small-for-gestational age (<10th centile for\ngestational age)\n• Maternal death\n• Apgar score of less than seven at five minutes\n• Maternal functioning and well-being\n• Neurodevelopmental outcomes (into infancy\n• Women’s views and experiences\nand childhood)\n52\nImportant mat"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_281",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 281,
    "text": "death\n• Apgar score of less than seven at five minutes\n• Maternal functioning and well-being\n• Neurodevelopmental outcomes (into infancy\n• Women’s views and experiences\nand childhood)\n52\nImportant maternal outcomes\nHealth service outcomes\n• Antenatal hospitalization\n• Antenatal admissions to hospital for the woman\n• Admission to intensive care\nand length of stay\n• Mode of birth\n• Emergency department visits for the woman\nCritical newborn outcomes • Admission to intensive care unit for the woman\n• Stillbirth/fetal death • Length of postnatal hospitalization for the\nwoman\n• Neonatal death\n• Length of neonatal hospitalization\n• Perinatal death\n• Costs of care for the woman or baby or both\nImportant newborn outcomes\n• Admission to neonatal intensive care\n• Gestational age at birth\n• Preterm bi"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_282",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 282,
    "text": "th of neonatal hospitalization\n• Perinatal death\n• Costs of care for the woman or baby or both\nImportant newborn outcomes\n• Admission to neonatal intensive care\n• Gestational age at birth\n• Preterm birth (<32 weeks; <37 weeks)\n• Birthweight\n• Intrauterine growth restriction\n• Low birthweight (<2500 g)\n\nPriority outcomes for individual PICOs\nMaternal outcomes Newborn outcomes\n• Early pregnancy loss • Amniotic fluid abnormalities (polyhydramnios\n(spontaneous or elective) and oligohydramnios)\n• Induction of labour • Macrosomia\n• Gestational weight change • Large-for-gestational age\n• Glycaemia (time in range, hypoglycaemia) • Birth injury\n• Hypertensive disorders of pregnancy (pre- • Shoulder dystocia\neclampsia; any hypertensive disorder of\n• Neonatal hypoglycaemia\npregnancy)\n• Hyperbilirubin"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_283",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 283,
    "text": "ime in range, hypoglycaemia) • Birth injury\n• Hypertensive disorders of pregnancy (pre- • Shoulder dystocia\neclampsia; any hypertensive disorder of\n• Neonatal hypoglycaemia\npregnancy)\n• Hyperbilirubinaemia\n• Postpartum haemorrhage\n• Respiratory distress syndrome\n• Childbirth-related injuries (e.g. perineal\n• Transient tachypnoea of the newborn\ninjuries etc)\n• Neonatal seizures\n• Diabetes later in life (maternal)\n• Congenital anomalies (among women who\n• Diabetes in the longer term (for GDM population)\nmay have had poor glycaemic control prior to\n53\n• Diabetes-specific patient-reported outcomes\npregnancy)\n• Chronic kidney disease\n• Breastfeeding\n• Long-term cardiometabolic outcomes\n• Long term cardiometabolic outcomes\n• Obesity in the longer term\n• Visual loss or blindness\n• Worsening retin"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_284",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 284,
    "text": "pregnancy)\n• Chronic kidney disease\n• Breastfeeding\n• Long-term cardiometabolic outcomes\n• Long term cardiometabolic outcomes\n• Obesity in the longer term\n• Visual loss or blindness\n• Worsening retinopathy\n\nAnnex 3.\nSummary and management\nof declared interests from\nGDG members\nName and title Expertise Declared Interest Management of declared interest\ncontributed\nto guideline\ndevelopment\nGuideline development group\nSumaiya ADAMS Obstetrics, Vice chair of the Committee This declared conflict of interest was not\n54\ngynaecology, on the Impact of Pregnancy considered significant enough to pose\ncontent expert, and on Long-Term Health. any risk to the guideline development\nend-user process or to reduce its credibility. The\nconflict constitutes intellectual bias that\ndoes not pose major risk.\nAma"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_285",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 285,
    "text": "tent expert, and on Long-Term Health. any risk to the guideline development\nend-user process or to reduce its credibility. The\nconflict constitutes intellectual bias that\ndoes not pose major risk.\nAmanda ADLER Endocrinology, Research funding from This declared conflict of interest was not\ncontent expert, and National Institute for Health considered significant enough to pose\nend-user and Care Research (NIHR) for any risk to the guideline development\nclinical trial on diabetes in process or to reduce its credibility. The\npregnancy (£4000 per year). conflict constitutes intellectual bias that\ndoes not pose major risk.\nFatima AL-SLAIL Cardiology, content None declared Not applicable\nexpert, and end-\nuser\nEmmanuel AMEH Obstetrics, None declared Not applicable\ngynaecology,\ncontent expert, and\ne"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_286",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 286,
    "text": "es not pose major risk.\nFatima AL-SLAIL Cardiology, content None declared Not applicable\nexpert, and end-\nuser\nEmmanuel AMEH Obstetrics, None declared Not applicable\ngynaecology,\ncontent expert, and\nend-user\nShabina ARIFF Neonatology, None declared Not applicable\ncontent expert,\nend-user\n\nName and title Expertise Declared Interest Management of declared interest\ncontributed\nto guideline\ndevelopment\nStephen Endocrinology, None declared Not applicable\nCOLAGIURI content expert, and\nend-user\nMargie Exercise Consultant (e.g. regarding This declared conflict of interest was not\nDAVENPORT physiology, content policies on exercise for considered significant enough to pose\nexpert, and end- pregnant athletes) to any risk to the guideline development\nuser Fédération Internationale process or to reduce"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_287",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 287,
    "text": "content policies on exercise for considered significant enough to pose\nexpert, and end- pregnant athletes) to any risk to the guideline development\nuser Fédération Internationale process or to reduce its credibility. The\nde Football Association GDG member participated in discussions\n(FIFA) and Women’s Tennis but recused during development of\nAssociation (~20 000 CAD). recommendations related to exercise.\nChair of the 2025 Canadian\nGuideline for Physical\nActivity, Sedentary Behaviour\nand Sleep throughout the\nFirst Year Postpartum. 55\nCo-Chair of the upcoming\n2026 International Olympic\nCommittee (IOC) Guideline\non Recreational and Elite\nAthletes during and following\npregnancy.\nMohamed Endocrinology, None declared Not applicable\nHASSANEIN content expert, and\nend-user\nShane A NORRIS Paediatri"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_288",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 288,
    "text": "e (IOC) Guideline\non Recreational and Elite\nAthletes during and following\npregnancy.\nMohamed Endocrinology, None declared Not applicable\nHASSANEIN content expert, and\nend-user\nShane A NORRIS Paediatrics, Research grant from This declared conflict of interest was not\ncontent expert, and Canadian Institutes of considered significant enough to pose\nend-user Health to explore the impact any risk to the guideline development\nof preconception health process or to reduce its credibility. The\nintervention of gestational conflict constitutes intellectual bias that\ndiabetes incidence in does not pose major risk.\nwomen living in South Africa\n(CAD$ 500 000).\nRajalakshmi RAM Gender and Rights None declared Not applicable\nPRAKASH Expert\n\nWHO recommendations on care for women with diabetes during pregnan"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_289",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 289,
    "text": "jor risk.\nwomen living in South Africa\n(CAD$ 500 000).\nRajalakshmi RAM Gender and Rights None declared Not applicable\nPRAKASH Expert\n\nWHO recommendations on care for women with diabetes during pregnancy\nName and title Expertise Declared Interest Management of declared interest\ncontributed\nto guideline\ndevelopment\nJoão Filipe Endocrinology, None declared Not applicable\nRAPOSO content expert, and\nend-user\nSofia SACCONE Endocrinology, None declared Not applicable\ncontent expert, and\nend-user\nPlacxedes SOSA Patient None declared Not applicable\nrepresentative\nNikhil TANDON Endocrinology Research grant from Indian This declared conflict of interest was not\ncontent expert, and Council of Medical Research considered significant enough to pose\nend-user (ICMR) for €657 200. any risk to the guideline"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_290",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 290,
    "text": "ant from Indian This declared conflict of interest was not\ncontent expert, and Council of Medical Research considered significant enough to pose\nend-user (ICMR) for €657 200. any risk to the guideline development\nprocess or to reduce its credibility. The\nconflict constitutes intellectual bias that\ndoes not pose major risk.\n56\nHoang TRAN Neonatology, None declared Not applicable\ncontent expert,\nand end-user\nKartik Obstetrics, Grant funding for diabetes This declared conflict of interest was not\nVENKATESH gynaecology, research from the considered significant enough to pose\nepidemiology, government of the United any risk to the guideline development\ncontent expert, and States of America for the process or to reduce its credibility. The\nend-user following studies: GDG member participated in di"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_291",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 291,
    "text": "nt of the United any risk to the guideline development\ncontent expert, and States of America for the process or to reduce its credibility. The\nend-user following studies: GDG member participated in discussions\nbut recused during development of\nACHIEVE: Successfully\nrecommendations related to glucose\nachieving and Maintaining\nmonitoring.\nEuglycemia During Pregnancy\nfor Type 2 Diabetes Through The DECIDE trial is ongoing, this was\nTechnology and Coaching acknowledged during discussions.\n$1.5m The participant’s contributions to\nthe discussions on the options of\nDECIDE trial, $12.4m from\npharmacotherapy were restricted to\nPatient-Centred Outcomes\npublished evidence as presented in\nResearch Institute (PCORI)\nthe ETDs.\n\nWHO recommendations on care for women with diabetes during pregnancy Summary"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_292",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 292,
    "text": "herapy were restricted to\nPatient-Centred Outcomes\npublished evidence as presented in\nResearch Institute (PCORI)\nthe ETDs.\n\nWHO recommendations on care for women with diabetes during pregnancy Summary and management of declared interests from GDG members\nName and title Expertise Declared Interest Management of declared interest\ncontributed\nto guideline\ndevelopment\nExternal Review group\nBosede AFOLABI Obstetrics, None declared Not applicable\ngynaecology,\nepidemiology,\ncontent expert, and\nend-user\nHadil ALI-MASRI Obstetrics, None declared Not applicable\ngynaecology,\nepidemiology,\ncontent expert, and\nend-user\nViswanathan Endocrinology None declared Not applicable\nMOHAN content expert, and\nend-user\n57\nJeremy OATS Obstetrics, None declared Not applicable\ngynaecology,\ncontent expert, and\nend-use"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_293",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 293,
    "text": "and\nend-user\nViswanathan Endocrinology None declared Not applicable\nMOHAN content expert, and\nend-user\n57\nJeremy OATS Obstetrics, None declared Not applicable\ngynaecology,\ncontent expert, and\nend-user\n\nWHO recommendations on care for women with diabetes during pregnancy\nWeb annex A. Evidence-to-decision frameworks for\nnon-pharmacological care\nWHO recommendations on care for women with diabetes during pregnancy: Evidence-to-decision frameworks\non non-pharmacological care https://doi.org/10.2471/B09615\nWeb annex B. Evidence-to-decision frameworks for\npharmacological care\nWHO recommendations on care for women with diabetes during pregnancy: Evidence-to-decision framework\non pharmacological care https://doi.org/10.2471/B09616\n58\n\nWHO recommendations on care for women with diabetes during preg"
  },
  {
    "id": "diabetes  of woman.pdf::chunk_294",
    "source": "diabetes  of woman.pdf",
    "chunk_index": 294,
    "text": "care for women with diabetes during pregnancy: Evidence-to-decision framework\non pharmacological care https://doi.org/10.2471/B09616\n58\n\nWHO recommendations on care for women with diabetes during pregnancy\n\nWorld Health Organization\nDepartment of Sexual and Reproductive Health and Research\n20 Avenue Appia\n1211 Geneva 27\nSwitzerland\nEmail: srhhrp@who.int\nWebsite: https://www.who.int/teams/sexual-and-reproductivehealth-and-research-(srh)/\nwww.who.int"
  }
]